Cirrhosis

On this page

Quick Reference

RxDrug of choiceFor primary prevention of decompensation in CSPH: carvedilol 6.25-12.5 mg daily. For acute variceal hemorrhage: terlipressin 2 mg IV bolus then 1-2 mg q4-6h + ceftriaxone 1 g IV daily + endoscopic band ligation.

AltAlternativesPropranolol 20-160 mg BID for NSBB; octreotide 50 mcg bolus then 50 mcg/h for variceal hemorrhage; norepinephrine 0.5-3 mg/h for HRS-AKI; rifaximin 550 mg BID for HE; norfloxacin 400 mg daily for SBP prophylaxis (if available).

⊘AvoidAvoid NSAIDs, non-dihydropyridine CCBs, and aggressive diuresis in decompensated cirrhosis. Avoid terlipressin in HRS-AKI with ACLF grade 3 or baseline SpO₂ <90%.

DxTest of choiceFirst-line: FIB-4 (calculate from age, AST, ALT, platelets). If ≥1.3, follow with VCTE (>12.1 kPa cirrhosis). For etiologic workup: HBsAg, anti-HCV, alcohol history with PEth, TSAT/ferritin, AMA, ANA/anti-smooth muscle, IgG.

ScKey scoreMELD-Na (bilirubin, INR, creatinine, sodium) predicts 90-day mortality and drives transplant allocation. CTP (bilirubin, albumin, INR, ascites, encephalopathy) for surgical risk and variceal bleeding.

→When to referRefer to hepatology at first decompensation event (ascites, variceal bleed, HE, jaundice) or when MELD-Na >15. Refer for liver transplantation evaluation at first decompensation; early LT evaluation improves access.

Cirrhosis is a staged disease: prevent first decompensation with NSBB in CSPH; treat underlying etiology (antivirals, abstinence, MASH therapy); manage complications with targeted protocols (vasoactive drugs, antibiotics, lactulose, terlipressin); refer early for transplantation.

Cirrhosis is the end-stage of chronic liver disease, defined by advanced fibrosis, architectural distortion, and regenerative nodules. It is the 11th leading cause of death globally, with a pooled prevalence of 1.3%. The natural history is dichotomized into compensated (median survival >15 years) and decompensated (median survival ~2 years) phases. Prevention of first decompensation, primarily with non-selective beta-blockers in patients with clinically significant portal hypertension, is the central therapeutic goal. Management focuses on etiologic therapy, complication control, and early transplant referral.

Overview and Recommendations

Background

•Cirrhosis is the common end-stage of any chronic liver disease, characterized by diffuse fibrosis, architectural distortion, and regenerative nodules that replace functional parenchyma. It affects approximately 1.3% of the global population, with advanced fibrosis affecting 3.3%, and accounts for two million deaths annually, 4% of all deaths worldwide.
•The natural history bifurcates into compensated cirrhosis (asymptomatic, median survival >15 years) and decompensated cirrhosis (defined by ascites, variceal hemorrhage, hepatic encephalopathy, or jaundice; median survival ~2 years). This transition is the single most powerful prognostic milestone and drives all management decisions.
•Clinically significant portal hypertension (CSPH), defined by a hepatic venous pressure gradient ≥10 mmHg, is the key hemodynamic milestone in compensated disease that predicts decompensation. Non-selective beta-blockers (NSBB) reduce the risk of first decompensation by 49% (PREDESCI trial; NNT=9).
•Etiologically, cirrhosis is driven by chronic viral hepatitis (HBV, HCV), alcohol-associated liver disease (ALD), and metabolic dysfunction-associated steatotic liver disease (MASLD), the latter now the leading cause in high-income countries. Other causes include cholestatic diseases (PBC, PSC), autoimmune hepatitis, and genetic disorders (hemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency).
•Recompensation, resolution of ascites, encephalopathy, and jaundice with stable liver function off specific therapy, occurs in approximately 35% of decompensated patients who achieve sustained etiologic control, highest in HBV (49%) and lowest in ALD (19%). Recompensation is associated with significantly reduced HCC (OR 0.55) and mortality (OR 0.33).

Evaluation

•Suspect cirrhosis in any patient with exertional dyspnea, unexplained fatigue, abdominal distension, or confusion, especially with a history of chronic liver disease risk factors (viral hepatitis, alcohol use, metabolic syndrome, family history of liver disease).
•Ask about alcohol consumption (quantity, frequency, pattern) and corroborate with serum phosphatidylethanol (PEth), a sensitive biomarker for recent alcohol use. In cryptogenic cases, screen for metabolic risk factors (diabetes, obesity, dyslipidemia) and consider MASLD.
•Examine for physical stigmata of chronic liver disease: spider angiomata (>5 on upper trunk), palmar erythema, gynecomastia, testicular atrophy, Dupuytren contracture, splenomegaly, and abdominal wall collaterals. In decompensated disease, look for ascites (bulging flanks, shifting dullness), hepatic encephalopathy (asterixis, disorientation), and jaundice.
•Order first-line non-invasive testing with the Fibrosis-4 Index (FIB-4), calculated from age, AST, ALT, and platelet count. A FIB-4 <1.3 rules out advanced fibrosis with NPV >90%; a score ≥2.67 rules in cirrhosis with 80% PPV and 96% specificity. Intermediate values (1.3-2.67) require further testing.
•Perform vibration-controlled transient elastography (VCTE) if FIB-4 is ≥1.3. Liver stiffness measurement (LSM) >12.1 kPa confirms cirrhosis with 90% specificity and AUROC 0.93. A cutoff of 6.5 kPa excludes advanced fibrosis with NPV 0.91. Magnetic resonance elastography (MRE) is the most accurate non-invasive method (AUROC 0.96) and may be used when VCTE is unavailable or discordant.
•In patients with intermediate FIB-4 (1.3-2.67) and VCTE 8-12 kPa, consider enhanced liver fibrosis (ELF) testing or proceed directly to MRE. If still indeterminate or if autoimmune/cholestatic disease is suspected, perform liver biopsy (gold standard, invasive with 0.5% major bleeding risk).
•Order etiologic serologies in all patients with established cirrhosis: HBsAg and anti-HCV (with HCV RNA if positive), transferrin saturation and ferritin for hemochromatosis (TSAT >45% women, >50% men), antimitochondrial antibody (AMA) for PBC, ANA/anti-smooth muscle antibody and IgG for autoimmune hepatitis, and tissue transglutaminase IgA for celiac disease in cryptogenic cases (pooled prevalence 4.6%).
•Calculate severity scores at diagnosis: Child-Turcotte-Pugh (CTP) class A (5-6), B (7-9), C (10-15) predicts 1-year survival (95%, 80%, 50% respectively). The MELD score (bilirubin, INR, creatinine) and MELD-Na (adding sodium) predict 90-day mortality and drive transplant allocation. MELD >20 defines severe alcohol-associated hepatitis.
•Screen for complications at baseline: esophagogastroduodenoscopy for varices (if LSM <20 kPa and platelets >150,000/mm³, varices can be safely excluded per Baveno VII criteria), abdominal ultrasound with alpha-fetoprotein (AFP) every 6 months for HCC surveillance, and diagnostic paracentesis in any patient with new or worsening ascites to rule out spontaneous bacterial peritonitis (SBP; neutrophil count >250 cells/mm³).
•Also consider evaluating for extrahepatic manifestations: hepatopulmonary syndrome (orthodeoxia, platypnea), portopulmonary hypertension (dyspnea, elevated right heart pressures on echo), cirrhotic cardiomyopathy (prolonged QT, diastolic dysfunction), and sarcopenia/frailty (grip strength, chair stands, balance). Assess nutritional status, as malnutrition affects >60% of patients.

Management

•Initiate etiology-directed therapy as the foundation of management. For HBV with detectable DNA, start entecavir 0.5 mg daily or tenofovir disoproxil fumarate 300 mg daily indefinitely. For HCV, prescribe pangenotypic direct-acting antiviral (DAA) therapy (e.g., sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks) achieving SVR >95% even in decompensated disease.
•For alcohol-associated liver disease, recommend complete abstinence. Offer multidisciplinary integrated care including hepatology, addiction medicine, and social work. Consider pharmacotherapy for alcohol use disorder (e.g., baclofen 5-10 mg TID, naltrexone 50 mg daily). Abstinence halves decompensation risk (HR 0.61) and improves survival.
•For MASLD with F2-F3 fibrosis, start resmetirom 80 mg PO daily (FDA-approved) or semaglutide 2.4 mg SC weekly (accelerated approval August 2025). Both agents improve NASH resolution and fibrosis but are not approved for compensated cirrhosis (F4). For nondiabetic MASH, vitamin E 800 IU daily may be used.
•In compensated cirrhosis with clinically significant portal hypertension (HVPG ≥10 mmHg), initiate non-selective beta-blocker (NSBB) therapy to prevent first decompensation regardless of variceal status. Start carvedilol 6.25 mg once daily, titrate to 12.5 mg once daily (target HR 55-65 bpm). Alternatively, propranolol 20 mg BID, up to 160 mg BID. Avoid in asthma, bradycardia <50 bpm, or SBP <90 mmHg.
•For primary prophylaxis of variceal bleeding in patients with high-risk varices (medium/large, red signs, or Child C), combine carvedilol with variceal band ligation (VBL), the CAVARLY trial showed combination therapy reduced first bleed by 62.9% vs VBL alone (HR 0.37) and 69.3% vs carvedilol alone (HR 0.31), with 6.3% 1-year mortality in the combination arm.
•Manage acute variceal hemorrhage with immediate vasoactive therapy: terlipressin 2 mg IV bolus then 1-2 mg IV q4-6h (or octreotide 50 mcg IV bolus then 50 mcg/h infusion). Perform endoscopic band ligation within 12 hours. Give antibiotic prophylaxis: ceftriaxone 1 g IV daily for 5-7 days. Consider pre-emptive TIPS within 72 hours in high-risk patients (Child-Pugh 10-13 or Child B 8-9 with active bleeding) to improve 1-year survival (86% vs 61%).
•For spontaneous bacterial peritonitis (SBP), perform diagnostic paracentesis in any cirrhotic patient with new ascites or clinical deterioration. Start empiric antibiotics: cefotaxime 2 g IV q8h or ceftriaxone 2 g IV daily. Give intravenous albumin: 1.5 g/kg at diagnosis, then 1 g/kg on day 3. After resolution, start secondary prophylaxis with norfloxacin 400 mg PO daily or trimethoprim-sulfamethoxazole 1 DS tab PO daily.
•For hepatic encephalopathy (HE), identify and treat precipitants (infection, GI bleed, electrolyte disturbance). Start lactulose 25 mL PO q1-2h until 2-3 soft stools, then titrate to 2-3 bowel movements daily. If no improvement after 24-48 hours, add rifaximin 550 mg PO BID. For severe HE, consider L-ornithine L-aspartate (LOLA) 30 g/day continuous IV added to lactulose+rifaximin. For secondary prophylaxis, maintain lactulose plus rifaximin (HR 0.42 for recurrence; NNT=4).
•For hepatorenal syndrome-AKI (HRS-AKI), first exclude other causes: discontinue diuretics, hold nephrotoxins, volume expand with albumin 1 g/kg/day IV for 2 days. If creatinine does not decrease by ≥0.3 mg/dL, start vasoconstrictor: terlipressin 0.5-1 mg IV q4-6h (or continuous infusion 2 mg/day) plus albumin 20-40 g/day. Alternative: norepinephrine 0.5-3 mg/h IV. Monitor for respiratory failure with terlipressin (11% vs 2% placebo). Definitive therapy is liver transplantation.
•Provide nutritional support: small frequent meals with a nighttime snack, protein intake 1.2-1.5 g/kg/day (do not restrict protein in HE), two or more cups of coffee daily. For sarcopenia, encourage exercise and ensure adequate caloric intake. Avoid NSAIDs, excessive diuresis, and large-volume paracentesis without albumin replacement (6-8 g of 20-25% albumin per liter removed for volumes >5 L).
•Refer for liver transplantation evaluation at the first decompensation event (ascites, bleeding, encephalopathy, jaundice) or when MELD-Na >15. One-year survival post-transplant is ~90%. Patients who achieve recompensation may be considered for delisting if stable off specific therapy for ascites and HE with improved liver function.

Board Review — High Yield

•Compensated vs decompensated survival, Median survival >15 years in compensated cirrhosis, ~2 years after first decompensation, ~9 months with further decompensation.
•CSPH threshold, HVPG ≥10 mmHg defines clinically significant portal hypertension; predicts decompensation and guides NSBB therapy.
•PREDESCI trial, NSBB (carvedilol/propranolol) reduced first decompensation or death by 49% (HR 0.51) in compensated CSPH; NNT=9.
•CAVARLY trial, Carvedilol + VBL reduced first variceal bleed by 62.9% vs VBL alone in Child B/C; 1-year mortality 6.3% in combination arm.
•Terlipressin caution, Avoid in HRS-AKI with ACLF grade 3 or SpO₂ <90% due to respiratory failure risk (11% vs 2%).
•Recompensation rates, Occurs in ~35% overall; highest in HBV (49%) and lowest in ALD (19%); associated with reduced HCC (OR 0.55) and death (OR 0.33).
•FIB-4 cutoffs, <1.3 rules out advanced fibrosis; ≥2.67 rules in cirrhosis (PPV 80%, specificity 96%). Intermediate values require VCTE or MRE.
•HCC surveillance, Ultrasound + AFP every 6 months in all cirrhosis; ultrasound alone sensitivity 47%, adding AFP improves to 63%.
•MELD-Na ≤28 in AIH decompensation, Identifies patients likely to benefit from immunosuppression; 4-week MELD-Na drop ≥11 has 100% NPV for death/transplant.
•Variceal screening, Endoscopy at cirrhosis diagnosis; Baveno VII: if LSM <20 kPa and platelets >150,000, endoscopy can be safely avoided.

Deep Dive — Evidence Details

Definition, Classification & Nomenclature

▸Cirrhosis is defined histologically by advanced fibrosis and regenerative nodules; clinical staging (compensated vs decompensated) determines prognosis and management.
▸Decompensation is marked by ascites, variceal hemorrhage, hepatic encephalopathy, or jaundice, and may present non-acutely or as acute decompensation with risk of ACLF.
▸The new steatotic liver disease nomenclature (MASLD, MetALD, ALD) classifies the most common etiologies, replacing NALFD terminology.

Cirrhosis, also known as liver cirrhosis, hepatic cirrhosis, chronic liver failure, chronic hepatic failure, and end-stage liver disease, is a chronic condition of the liver in which the normal functioning tissue, or par — Cirrhosis — Cirrhosis, also known as liver cirrhosis, hepatic cirrhosis, chronic liver failure, chronic hepatic failure, and end-stage liver disease, is a chronic...Wikipedia ↗

Cirrhosis is a diffuse process of advanced hepatic fibrosis with architectural distortion and regenerative nodule formation, representing the common end-stage of any chronic liver disease ^[2]^A1c.

Synonyms

Also called: end-stage liver disease (when decompensated); historically, Laennec's cirrhosis (alcoholic, obsolete).

Staging and Clinical Phases

The natural history of cirrhosis is dichotomized into a compensated phase, during which patients are asymptomatic, and a decompensated phase, defined by the development of clinically overt complications: , variceal hemorrhage, , or jaundice ^[2]^A1c^[31]^D5. Decompensation may occur via a non-acute pathway (slow development of ascites or mild encephalopathy) or an acute decompensation that often requires hospitalization and may evolve into acute-on-chronic liver failure (ACLF) ^[31]^D5. Recompensated cirrhosis, in which decompensating events resolve, is now recognized in consensus definitions ^[10]^D5.

Clinically significant (CSPH) - hepatic venous pressure gradient ≥10 mmHg - is a key milestone in compensated disease that predicts decompensation risk ^[28]^D5. ACLF is a syndrome of acute decompensation accompanied by extrahepatic organ failures; its definition varies across EASL, APASL, and NACSELD criteria, leading to heterogeneity in reported phenotypes and outcomes ^[25]^A1a.

Etiologic Classification

Category	Examples	Notes
Viral	HBV, HCV, HDV	HBV remains a leading cause globally, with an estimated 250 million individuals affected ^[1]^A1c
Alcohol-related	ALD	Alcohol use is a dominant cause, especially in combination with metabolic risk factors ^[16]^B2b^[42]^B2b
Metabolic dysfunction-associated	MASLD (formerly NAFLD), MetALD	MASLD now the leading cause of cirrhosis in high-income countries ^[46]^D5^[33]^D5
Cholestatic	Primary biliary cholangitis, primary sclerosing cholangitis, cystic fibrosis liver disease ^[26]^D5	Distinct pathophysiology with bile duct injury ^[43]^D5
Autoimmune		May present with cholestatic phenotypes ^[54]^D5
Genetic	Hemochromatosis , , alpha-1 antitrypsin deficiency ^[6]^A1c	Often present at younger ages
Cryptogenic	No identifiable cause	Becoming less common as MASLD criteria are applied ^[46]^D5

Histologic Classification

The P-I-R classification (predominantly progressive, indeterminate, predominantly regressive) captures the dynamic balance of fibrogenesis and fibrolysis on and predicts incident liver-related events independent of fibrosis stage ^[3]^B2b^[7]^D5.

Clinical Significance

Cirrhosis is globally the 11th leading cause of death, and steatotic liver disease (MASLD and ALD) has become the leading cause in the EU and USA ^[46]^D5.

Pearl: The transition from compensated to decompensated cirrhosis is the single most powerful prognostic milestone; strategies - including surveillance, prevention of variceal hemorrhage, and transplantation evaluation - differ fundamentally between these stages ^[2]^A1c^[31]^D5.

Pathophysiology & Mechanism

▸Hepatic stellate cell transdifferentiation to myofibroblasts is the central fibrogenic event, driven by TGF-β from activated Kupffer cells and injured hepatocytes [93].
▸Portal hypertension arises from both increased intrahepatic resistance (fibrosis, sinusoidal remodeling) and increased portal inflow (splanchnic vasodilation) [28].
▸The gut-liver axis, bacterial translocation, endotoxemia, and systemic inflammation, amplifies fibrosis progression and drives decompensation and cirrhosis-associated immune dysfunction [82,112].

HY High Yield: The hepatic venous pressure gradient (HVPG) ≥10 mm Hg defines **clinically significant portal hypertension (CSPH)**, a threshold at which decompensation risk sharply rises [28,70].

From the classification of injury patterns, the narrative moves to the common effector pathway: persistent hepatocellular damage, regardless of cause, triggers a wound-healing response that, when unremitting, replaces functional parenchyma with fibrous scar and regenerative nodules, distorting hepatic architecture and driving ^[96]^D5.

Pearl: The gut-liver axis, bacterial translocation, endotoxemia, and systemic inflammation, amplifies fibrosis progression and drives decompensation and cirrhosis-associated immune dysfunction ^[82]^D5^[112]^D5.

Key Molecular Mediators in Cirrhosis Pathogenesis

Mediator	Source	Effect
TGF-β	Kupffer cells, injured hepatocytes	HSC activation, collagen synthesis ^[93]^D5
PDGF	Kupffer cells, platelets	HSC proliferation, migration ^[93]^D5
Galectin-3 (Gal-3)	Macrophages, HSCs	Profibrotic signaling, HSC activation ^[67]^A1b
RUNX3	LSECs	Maintains LSEC homeostasis; deficiency → LRG1 secretion → HSC activation ^[78]^D5
FGF12	Hepatic macrophages	Promotes proinflammatory macrophage activation, HSC activation via MCP-1/CCR2 ^[79]^D5
Suv39h1	HSCs	Histone methyltransferase; represses HMOX1 → promotes HSC-myofibroblast transition ^[90]^D5
IL-1β, IL-18	Inflammasome-activated macrophages	Pyroptosis, inflammation, fibrosis ^[83]^D5
Endothelin-1	LSECs, HSCs	Vasoconstriction, increased intrahepatic resistance ^[116]^D5
Nitric Oxide (NO)	eNOS in LSECs (deficient), iNOS in inflammation (excess)	Imbalance → sinusoidal vasoconstriction, splanchnic vasodilation ^[121]^D5

Epidemiology, Etiology & Risk Factors

▸Cirrhosis affects 1.3% of the global general population, with advanced fibrosis present in 3.3%; both have been rising since 2016.
▸Alcohol consumption is the strongest modifiable risk factor, with an exponential dose-response relationship and a markedly lower threshold for harm in women.
▸MASLD is the fastest-growing cause of cirrhosis, projected to increase 63% by 2030, and now accounts for up to 14.5% of cirrhosis in select populations.

HY High Yield: Alcohol-associated cirrhosis shows a striking sex dimorphism: women develop cirrhosis at lower lifetime alcohol exposures and progress faster to decompensation [148]. Always counsel women on the lower safe limit (≤1 drink/day).

From the fibrotic and nodular remodelling of the hepatic parenchyma emerges a disease with profound global impact. Liver disease accounts for two million deaths annually, representing 4% of all deaths worldwide, with approximately two-thirds occurring in men ^[167]^D5. The age-standardized incidence of chronic liver disease and cirrhosis is 20.7 per 100,000, a figure that has increased 13% since 2000 ^[189]^D5. In the general population, the pooled prevalence of cirrhosis is 1.3% (95% CI 0.9%-1.7%), with advanced liver fibrosis affecting 3.3% (95% CI 2.4%-4.2%) ^[162]^B2c. These prevalence estimates have shown a statistically significant upward trend after 2016 for both advanced fibrosis (p=0.004) and cirrhosis ^[162]^B2c.

Etiologic Drivers

The most common causes of cirrhosis globally are chronic viral hepatitis, alcohol-associated liver disease (ALD), and metabolic dysfunction-associated steatotic liver disease (MASLD) ^[167]^D5. Over the past decade, the proportion of cirrhosis attributable to viral hepatitis has declined in high-income regions due to vaccination and antiviral therapy, while MASLD and ALD have risen sharply ^[189]^D5^[59]^A1c. In a 2023 analysis, ALD was the most frequent indication for emergency admission for chronic liver disease in England, accounting for 65.3% of first emergency admissions ^[187]^B3b. MASLD, defined by hepatic steatosis plus cardiometabolic risk factors, now affects an estimated 25.24% of the global adult population ^[141]^B2a. Among patients with MASLD, cirrhosis prevalence ranges from 3.26% in general practice settings to 14.51% among those referred for biopsy ^[159]^B2c.

Risk Factors

Factor	Odds Ratio / Relative Risk	Evidence Level
Diabetes (any cause)	OR not pooled; associated with cirrhosis	Meta-analysis ^[162]^B2c
Obesity (BMI ≥30 kg/m²)	OR not pooled; independent risk factor	Meta-analysis ^[162]^B2c
Male sex	OR not pooled; consistent association	Meta-analysis ^[162]^B2c
Hepatitis B virus (chronic)	OR not pooled; strong association	Meta-analysis ^[162]^B2c
MASLD (vs no steatosis)	All-cause mortality RR 1.93 (95% CI 1.86-2.00)	Cohort ^[171]^B3b

The dose-response relationship between alcohol and cirrhosis is exponential: consumption of one drink per day raises risk only in women, while five or more drinks daily elevates risk in both sexes, women carrying a substantially higher relative risk than men at every level ^[148]^B2a.

Temporal Trends

The burden of cirrhosis is shifting. MASLD-related cirrhosis is projected to increase 63% in prevalence by 2030 (from 16.52 million to 27.00 million cases), driven by rising obesity and type 2 diabetes ^[165]^B2c. Conversely, hepatitis C-related cirrhosis is declining in regions with high coverage of direct-acting antiviral therapy ^[186]^B3b. Despite these advances, the number of first emergency admissions for chronic liver disease in England rose in parallel with population growth, and 1-year all-cause mortality remained at 37.3% ^[187]^B3b. Globally, the fastest increases in cirrhosis prevalence are occurring in the Middle East and in countries with middle-high and high sociodemographic index ^[188]^D5.

Pearl: The single most actionable intervention to reduce cirrhosis burden is prevention, through HBV vaccination, HCV eradication, alcohol moderation, and aggressive of metabolic risk factors, because each modifiable driver has a large and dose-dependent effect on cirrhosis incidence.

Key Risk Factors for Cirrhosis and Associated Effect Sizes

Factor	Odds Ratio / Relative Risk (95% CI)	Evidence Level	Source
Alcohol ≥5 drinks/day (women)	RR 12.44 (6.65-23.27)	Systematic review & meta-analysis	^[148]^B2a
Alcohol ≥7 drinks/day (women)	RR 24.58 (14.77-40.90)	Systematic review & meta-analysis	^[148]^B2a
Alcohol ≥5 drinks/day (men)	RR 3.80 (0.85-17.02)	Systematic review & meta-analysis	^[148]^B2a
Alcohol ≥7 drinks/day (men)	RR 6.93 (1.07-44.99)	Systematic review & meta-analysis	^[148]^B2a
Type 2 diabetes (MASLD population)	OR not pooled; strong association	Systematic review & meta-analysis	^[162]^B2c
Obesity (MASLD population)	OR not pooled; strong association	Systematic review & meta-analysis	^[162]^B2c
Male sex	OR not pooled; consistent independent risk	Systematic review & meta-analysis	^[162]^B2c
Chronic hepatitis B infection	OR not pooled; high risk	Systematic review & meta-analysis	^[162]^B2c^[1]^A1c
MASLD (all-cause mortality vs general population)	aHR 1.93 (1.86-2.00)	Nationwide cohort	^[171]^B3b

Clinical Presentation

▸Cirrhosis progresses from an asymptomatic compensated phase to a decompensated stage defined by ascites, variceal hemorrhage, encephalopathy, or jaundice.
▸Ascites is the most common first decompensation event; acute decompensation (high-grade ascites, SBP, or AKI) portends worse transplant-free mortality than non-acute ascites.
▸ACLF is a distinct syndrome with organ failures and 58% 90-day mortality, driven by systemic inflammation and requiring urgent recognition.

HY High Yield: Covert/minimal hepatic encephalopathy affects 40.9% of cirrhotic patients and can impair driving ability and quality of life without overt symptoms [11].

! Warning: Severe alcohol-associated hepatitis carries a 1-month mortality of 20% to 50% and requires immediate risk stratification [59].

From population-level the clinician must turn to the bedside: cirrhosis declares itself silently in the compensated phase or catastrophically at decompensation.

Silent Progression: Compensated Phase

Many patients are asymptomatic; the diagnosis emerges incidentally from thrombocytopenia, elevated transaminases, or a nodular liver on imaging. Non-specific symptoms - fatigue, anorexia, weight loss, muscle cramps - may be present. Physical stigmata: spider angiomata (more than five on the upper trunk), palmar erythema, , testicular atrophy, Dupuytren contracture, and splenomegaly. is signaled by abdominal wall collaterals. Laboratory clues include thrombocytopenia, elevated INR, low albumin, and hyperbilirubinemia ^[2]^A1c^[118]^D5.

The Transition to Decompensation

Decompensation is defined by , variceal hemorrhage, , or jaundice ^[2]^A1c. Ascites is the most common first event, presenting as increasing abdominal girth and early satiety. Among patients with new-onset ascites, those meeting acute decompensation criteria (grade 3 ascites, SBP, or AKI) have a higher hazard of transplant-free mortality (HR 1.43) than those with non-acute ascites ^[223]^B2b. Variceal hemorrhage produces hematemesis or melena. Hepatic encephalopathy spans disorientation and asterixis to coma; covert/minimal encephalopathy is detectable in 40.9% of patients (95% CI 38.3% to) ^[11]^A1a. Jaundice reflects severe hepatocellular dysfunction.

Acute-on-Chronic Liver Failure (ACLF)

ACLF is a distinct syndrome of acute decompensation with organ failure(s) and high short-term mortality ^[216]^A1b. It complicates 35% of admissions for decompensated cirrhosis and carries a 90-day mortality of 58% ^[151]^A1a. Systemic inflammation - driven by bacterial translocation, alcohol, or infection - precipitates rapid jaundice, coagulopathy, encephalopathy, and extrahepatic failures (kidney, circulation, lung) ^[211]^B3b^[112]^D5.

Etiology-Specific Patterns

Alcohol-associated hepatitis presents with rapid jaundice, tender hepatomegaly, and fever; severe forms have a 1-month mortality of 20% to 50% ^[59]^A1c. Primary biliary cholangitis features fatigue and pruritus ^[193]^A1c. Primary sclerosing cholangitis manifests with jaundice, pruritus, and cholangitis episodes ^[101]^D5.

Urgent Presentations

Hematemesis (variceal hemorrhage), confusion (HE), fever with abdominal pain (SBP), and oliguria (HRS) are red flags requiring immediate hospitalisation.

Pearl: Compensated cirrhosis is often silent; unexplained thrombocytopenia, splenomegaly, or multiple spider angiomata should trigger an evaluation for chronic liver disease before first decompensation occurs.

Diagnosis & Workup

▸Cirrhosis can be diagnosed non-invasively in most patients using a sequential algorithm: FIB-4 as first-line, followed by VCTE or MRE for confirmation.
▸FIB-4 <1.3 effectively excludes advanced fibrosis (NPV >90%); VCTE >12.1 kPa is highly specific for cirrhosis (90%).
▸Etiologic serologies (viral hepatitis, iron studies, autoimmune markers, AMA) are mandatory in all newly diagnosed cirrhosis.
▸Liver biopsy remains the gold standard but is reserved for cases where non-invasive tests are discordant or specific histology is needed.

Dx Diagnostic Essentials: Liver biopsy remains the gold standard for cirrhosis diagnosis, but non-invasive tests (FIB-4 + VCTE/MRE) can establish the diagnosis in most patients without the need for tissue sampling.

From the clinical suspicion raised by symptoms and signs in the preceding section, a systematic diagnostic workup now confirms cirrhosis, establishes its etiology, and stages the severity of fibrosis and . The approach follows a stepwise algorithm integrating serum biomarkers, non-invasive liver stiffness measurement (LSM), and, when necessary, .

Non-invasive Liver Stiffness Measurement and Serum Biomarkers

The Fibrosis-4 Index (FIB-4), calculated from age, AST, ALT, and platelet count, serves as the recommended first-line test. A FIB-4 score <1.3 effectively rules out advanced fibrosis (negative predictive value >90%), while a score ≥2.67 rules in advanced fibrosis with an 80% positive predictive value ^[250]^A1a^[292]^B2b. The jackknife-validated area under the receiver operating characteristic curve (AUROC) for FIB-4 in detecting advanced fibrosis is 0.84, outperforming the NAFLD Fibrosis Score (0.77), AST-to-Platelet Ratio Index (0.73), and AST:ALT ratio (0.74) ^[242]^A1a^[292]^B2b.

Vibration-controlled transient elastography (VCTE) measures liver stiffness (LSM) with high diagnostic accuracy. An LSM >12.1 kPa identifies cirrhosis with 90% specificity and an AUROC of 0.93; a cut-off of 6.5 kPa excludes advanced fibrosis with an NPV of 0.91 ^[295]^B2b. In a large individual patient data meta-analysis, sequential combination of FIB-4 (<1.3 then ≥2.67) followed by VCTE (<8.0 then ≥10.0 kPa) achieved 66% sensitivity and 86% specificity for advanced fibrosis while avoiding liver biopsy in 33% of patients ^[250]^A1a. Magnetic resonance elastography (MRE) is the most accurate non-invasive method, with an AUROC up to 0.96 for advanced fibrosis ^[242]^A1a, and demonstrates superior repeatability compared with VCTE (within-case coefficient of variation 8% vs 14%) ^[257]^C4. Two-dimensional shear wave elastography (2D-SWE) yields an AUROC of 0.89 for cirrhosis at an optimal cut-off of 11.5 kPa ^[243]^A1a.

Non-invasive Test	Threshold for Cirrhosis	AUROC (F4)	Sensitivity	Specificity
FIB-4	≥2.67	0.84 ^[242]^A1a	32% ^[242]^A1a	96% ^[242]^A1a
VCTE	>12.1 kPa	0.93 ^[295]^B2b	87% ^[242]^A1a	90% ^[295]^B2b
MRE	>5.0 kPa (stage F4)	0.96 ^[242]^A1a	84% ^[242]^A1a	90% ^[242]^A1a
2D-SWE	11.5 kPa	0.89 ^[243]^A1a	85% ^[243]^A1a	88% ^[243]^A1a

Etiologic Workup

Every patient requires a serologic panel to identify the underlying cause: HBsAg and anti-HCV (with HCV RNA if positive), alcohol history corroborated by the biomarker phosphatidylethanol (PEth) ^[289]^B2b, transferrin saturation (TSAT >45% in women, >50% in men) and ferritin for ^[235]^A1c, antimitochondrial antibody (AMA) for primary biliary cholangitis ^[193]^A1c, antinuclear antibody (ANA), anti-smooth muscle antibody, and serum IgG for ^[256]^D5^[236]^A1c. In patients with cryptogenic cirrhosis after a negative standard workup, screening for celiac disease with tissue transglutaminase IgA is warranted, as the pooled prevalence of biopsy-confirmed celiac disease in cryptogenic cirrhosis is 4.6% ^[247]^A1a.

Liver Biopsy

Liver biopsy remains the gold standard for diagnosis, particularly when non-invasive tests are discordant, when autoimmune or cholestatic liver disease is suspected, or when additional etiologies (e.g., porto-sinusoidal vascular disorder, ) require histologic evaluation ^[241]^C4^[80]^D5. Automated cutting needles produce superior specimens with significantly less fragmentation (4.7% vs 39.2% for aspiration needles) ^[241]^C4. Biopsy is invasive, with a 0.5% risk of major bleeding, and is increasingly reserved for cases where non-invasive assessment is inconclusive.

Imaging for HCC Surveillance and Portal

Abdominal ultrasound every 6 months is standard for hepatocellular carcinoma (HCC) surveillance. Ultrasound alone detects early-stage HCC with only 47% sensitivity; adding alpha-fetoprotein (AFP) improves sensitivity to 63% ^[251]^B2a. Annual dynamic abbreviated MRI demonstrates a higher diagnostic yield (6.4% vs 2.2% for biannual ultrasound) without increasing false-referral rates, and its use is expanding in high-risk populations ^[290]^B2b. Cross-sectional imaging (CT or MRI) is indicated to confirm portal vein thrombosis when Doppler ultrasound is positive ^[62]^D5.

Diagnostic Algorithm

Step 1: Clinical suspicion (symptoms, signs, abnormal liver tests) plus calculation of FIB-4. If FIB-4 <1.3, advanced fibrosis is unlikely; no further workup needed. Step 2: If FIB-4 ≥1.3, perform VCTE (or MRE if available). LSM >12.1 kPa (VCTE) or >5.0 kPa (MRE) confirms cirrhosis. Step 3: If FIB-4 is intermediate (1.3-2.67) and VCTE is 8-12 kPa, consider enhanced liver fibrosis (ELF) testing or proceed directly to MRE to clarify. Step 4: Obtain etiologic serologies in all patients with established cirrhosis. Step 5: If non-invasive tests are discordant or unable to rule out cirrhosis, perform liver biopsy.

Once the diagnosis of cirrhosis is established, the next step is to stratify severity and risk using the and scores, detailed in the following section.

Pearl: Liver biopsy remains the gold standard but is reserved for cases where non-invasive tests are discordant or specific histology is needed.

Severity, Staging & Risk Stratification

▸CTP and MELD/MELD-Na are the foundational severity scores, each with specific thresholds for prognosis and transplant candidacy.
▸Noninvasive tests (FIB-4, LSM) and novel biomarkers (IL-6, uNGAL, copeptin) improve risk stratification beyond conventional scores.
▸Recompensation occurs in about one-third of patients with decompensated cirrhosis, most frequently in HBV-related disease, and markedly improves survival.

HY High Yield: A MELD-Na ≤28 with no grade 3-4 hepatic encephalopathy identifies patients likely to benefit from intensive medical therapy; a 4-week MELD-Na drop ≥11 has 100% negative predictive value for death/transplant in AIH-related decompensated cirrhosis [293].

The diagnostic workup completed, the next step is to translate the clinical, laboratory, and imaging data into a validated severity score that governs prognosis, surveillance intensity, and transplant candidacy. Two complementary systems, Child-Turcotte-Pugh (CTP) and Model for End-Stage Liver Disease ( ), form the backbone of this stratification.

Child-Turcotte-Pugh (CTP) Score

The CTP score (class A 5-6, B 7-9, C 10-15) combines bilirubin, albumin, INR, , and encephalopathy. One-year survival is approximately 95% for class A, 80% for class B, and 50% for class C ^[63]^D5. It is used for surgical risk assessment, HCC staging, and predicting decompensation ^[60]^A1c. In alcohol-associated hepatitis, CTP B with active bleeding or CTP C <14 defines high-risk variceal bleeding candidates for pre-emptive TIPS ^[298]^A1a.

MELD and

The MELD score (bilirubin, INR, creatinine) and MELD-Na (adding serum sodium) predict 90-day mortality and drive liver allocation. A MELD >20 defines severe alcohol-associated hepatitis, with a 28-day mortality of 26.8% (95% CI 21.0%-) ^[156]^B2a^[59]^A1c. MELD-Na ≤28 and absence of high-grade encephalopathy identify patients with -related decompensated cirrhosis likely to benefit from immunosuppression ^[293]^B3b. MELD 3.0 further incorporates sex and albumin, improving discrimination ^[319]^D5.

Beyond Conventional Scores

Noninvasive tests add prognostic granularity. FIB-4 <1.3 excludes advanced fibrosis with high negative predictive value, while >2.67 or >3.48 rules in cirrhosis ^[5]^D5^[250]^A1a. LSM by transient elastography at cutoffs of 8.0 kPa and 10.0 kPa sequentially stratify risk, reducing need for biopsy ^[250]^A1a. In NAFLD, fibrosis stage F3-F4 carries an all-cause mortality rate of 3.42 compared with F0 ^[152]^B2a. Novel biomarkers, IL-6 (ratio of means 2.56), uNGAL (2.42), and copeptin (2.33), outperform MELD for 90-day mortality prediction in decompensated cirrhosis ^[304]^A1a. For perioperative risk, the VOCAL-Penn model (C-statistic 0.859) outperforms MELD, MELD-Na, CTP, and Mayo Risk Score ^[309]^B3b^[60]^A1c. In ACLF, the CLIF-C ACLF score and China-CLIF (COSSH-ACLF II) score provide superior mortality prediction across aetiologies ^[131]^A1c^[305]^B2b.

Staging Progression and Recompensation

Decompensation is classified as acute (AD: grade 3 ascites, SBP, AKI) or non-acute (NAD: grade 2 ascites), with AD conferring higher transplant-free mortality (subdistribution HR 1.43, 95% CI 1.12-1.82) ^[223]^B2b. Recompensation, defined by resolution of ascites, encephalopathy, and jaundice off diuretics/lactulose, occurs in 34% overall (95% CI 27%-41%), highest in HBV (49%) and lowest in ALD (19%) ^[191]^B2a. Predictors include higher albumin, lower MELD, higher platelets, and female sex; recompensation improves survival (HR 2.81) ^[191]^B2a.

Table: Prognostic Scores at a Glance

Score	Components	Discriminative Use	Key Thresholds
CTP	Bilirubin, albumin, INR, ascites, encephalopathy	Surgical risk, HCC, variceal bleeding	A: 5-6, B: 7-9, C: 10-15
MELD	Bilirubin, INR, creatinine	90-day mortality, transplant allocation	>20 severe AH, >25 high mortality
MELD-Na	MELD + sodium	Same as MELD, better discrimination	≤28 predicts treatment benefit in AIH ^[293]^B3b
VOCAL-Penn	Age, albumin, platelets, bilirubin, surgery type, ASA	Postoperative mortality (30/90/180d)	C-statistic 0.859 ^[309]^B3b
CLIF-C ACLF	MELD, age, organ failures	ACLF 28/90-day mortality	Grade 1-3 severity ^[131]^A1c

Pearl: In patients with decompensated cirrhosis, a MELD-Na ≤28 with no grade 3-4 identifies a window where targeted therapy (e.g., immunosuppression in AIH, TIPS in ascites) can reverse decompensation; a 4-week MELD-Na drop ≥11 has 100% negative predictive value for death or transplant ^[293]^B3b.

Acute Management & Decompensation Events

▸Variceal hemorrhage: vasoactive drug (terlipressin/octreotide) before endoscopy, antibiotic prophylaxis, pre-emptive TIPS for high-risk Child-Pugh 10-13.
▸SBP: diagnostic paracentesis, empiric cefotaxime/ceftriaxone, albumin 1.5 g/kg at diagnosis.
▸Hepatic encephalopathy: lactulose first-line, add rifaximin if no response; secondary prophylaxis with both reduces recurrence.
▸HRS-AKI: discontinue diuretics, volume expand with albumin, then terlipressin or norepinephrine plus albumin; liver transplantation is definitive.

Rx Drug of Choice: For acute variceal hemorrhage: terlipressin (or octreotide in US) plus antibiotic prophylaxis. For HRS-AKI: terlipressin plus albumin.

! Warning: Terlipressin for HRS-AKI carries a risk of respiratory failure (11% vs 2% placebo); monitor oxygen saturation and consider norepinephrine as alternative [327].

Having established the severity stage, the clinician must be prepared to manage acute decompensation events, each requiring a distinct time-critical pathway.

Variceal Hemorrhage

Step 1: Resuscitation and vasoactive therapy, initiate as soon as variceal hemorrhage is suspected, before endoscopy. Give terlipressin 2 mg IV bolus then 1-2 mg IV q4-6h (or octreotide 50 mcg IV bolus then 50 mcg/h infusion) ^[63]^D5^[92]^A1c. Step 2: Endoscopic band ligation within 12 h of presentation ^[92]^A1c. Step 3: Antibiotic prophylaxis, 1 g IV daily for 5-7 days ^[92]^A1c. Step 4: Pre-emptive TIPS, consider in high-risk patients ( 10-13 or Child-Pugh 8-9 with active bleeding at endoscopy) to reduce mortality ^[118]^D5. Step 5: Monitor for rebleeding, continue vasoactive drugs for 2-5 days after hemostasis ^[63]^D5.

(SBP)

Step 1: Diagnostic , mandatory in any cirrhotic patient with new or clinical deterioration. Step 2: Empiric , 2 g IV q8h or ceftriaxone 2 g IV daily ^[238]^A1c. Step 3: Intravenous albumin, 1.5 g/kg at diagnosis, then 1 g/kg on day 3 ^[63]^D5^[238]^A1c. Step 4: Secondary prophylaxis, after resolution, start norfloxacin 400 mg PO daily or 1 DS tab PO daily ^[238]^A1c. Primary prophylaxis is indicated in patients with ascitic fluid protein <1.5 g/dL and advanced liver disease (Child-Pugh ≥9 or ≥15) ^[238]^A1c.

(HE)

Step 1: Identify and treat precipitant, infection, GI bleed, electrolyte disturbance, constipation, medication nonadherence. Step 2: Lactulose, 25 mL PO q1-2h until 2-3 soft stools, then titrate to 2-3 bowel movements per day ^[237]^A1c^[178]^A1a. Step 3: Add rifaximin, 550 mg PO BID if no improvement after 24-48 h of lactulose alone ^[140]^A1b^[144]^A1b. Step 4: In ICU patients, broad-spectrum antibiotics if infection suspected; rifaximin may not add benefit in ACLF ^[138]^A1b. Step 5: Secondary prophylaxis, lactulose plus rifaximin reduces HE recurrence (HR 0.42, 95% CI 0.28-0.64; NNT = 4) ^[144]^A1b.

-AKI (HRS-AKI)

Step 1: Exclude other causes, discontinue diuretics, hold nephrotoxins, volume expand with albumin 1 g/kg/day IV for 2 days ^[153]^D5. Step 2: If no response (creatinine not decreased by ≥0.3 mg/dL), start vasoconstrictor: terlipressin 0.5-1 mg IV q4-6h (or continuous infusion 2 mg/day) plus albumin 20-40 g/day ^[327]^A1b^[325]^A1b. Step 3: Alternative vasoconstrictor, norepinephrine 0.5-3 mg/h IV (equally effective, lower cost) ^[346]^D5. Step 4: Monitor, goal creatinine ≤1.5 mg/dL; watch for respiratory failure with terlipressin (11% vs 2% placebo) ^[327]^A1b. Step 5: , definitive therapy; terlipressin response improves post-transplant survival ^[342]^D5.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Vasoactive drug of choice for variceal hemorrhage	AGA 2023, octreotide is preferred in the US ^[63]^D5	EASL/Baveno VII, terlipressin is first-line ^[28]^D5^[92]^A1c	Moderate (regional availability)	Use octreotide in US, terlipressin elsewhere; both effective
Vasoconstrictor for HRS-AKI	FDA-approved terlipressin, superior HRS reversal (32% vs 17%) ^[327]^A1b	Norepinephrine, similar efficacy, lower cost, fewer respiratory AEs ^[346]^D5	Moderate (cost vs. regulatory approval)	Terlipressin is first-line if available; norepinephrine is acceptable alternative

Pearl: In , initiate vasoactive therapy before endoscopy and consider pre-emptive TIPS in high-risk patients (Child-Pugh 10-13) to reduce mortality; for HRS-AKI, terlipressin plus albumin improves renal recovery but carries a risk of respiratory failure that requires close monitoring ^[63]^D5^[118]^D5^[327]^A1b.

Vasoactive Drug Dosing for Variceal Hemorrhage and HRS-AKI

Indication	Drug	Dose	Duration	Key Monitoring
Variceal hemorrhage	Terlipressin	2 mg IV bolus, then 1-2 mg IV q4-6h	2-5 days	Heart rate, blood pressure, rebleeding
Variceal hemorrhage	Octreotide	50 mcg IV bolus, then 50 mcg/h infusion	2-5 days	Blood glucose, rebleeding
HRS-AKI	Terlipressin	0.5-1 mg IV q4-6h or 2 mg/day continuous infusion	Up to 14 days	Creatinine, respiratory status
HRS-AKI	Norepinephrine	0.5-3 mg/h IV	Up to 14 days	Blood pressure, creatinine

Long-term & Definitive Management

▸Etiology-directed therapy (antivirals, abstinence, resmetirom, immunosuppression) is the cornerstone; achieving disease control reduces HCC risk and can lead to fibrosis regression and recompensation.
▸Resmetirom and semaglutide are the first FDA-approved pharmacotherapies for MASH with stage 2-3 fibrosis; both show histological improvement in phase 3 trials with NNT ~5-6 for MASH resolution.
▸Recompensation occurs in ~35% of decompensated patients with effective etiology control, most commonly in HBV-related cirrhosis (49%); it is associated with a 67% reduction in mortality (OR 0.33).

HY High Yield: The threshold for HCC surveillance is cirrhosis of any etiology; patients who achieve recompensation remain at risk and should continue surveillance indefinitely.

Rx Drug of Choice: For HBV-related cirrhosis, entecavir or TAF are first-line due to high barrier to resistance and favorable safety; for MASH F2-3 fibrosis, resmetirom (80-100 mg PO daily) is the first FDA-approved agent.

Beyond the acute episode, the trajectory of cirrhosis hinges on effective suppression of the underlying disease driver and prevention of further decompensation. Etiology-directed therapy is the foundation upon which all other rests, and emerging evidence shows that fibrosis regression and even recompensation are achievable goals.

Etiology-Directed Therapy

Hepatitis B virus (HBV). All patients with cirrhosis and detectable HBV DNA should receive long-term nucleos(t)ide analogue therapy with , disoproxil fumarate (TDF), or tenofovir alafenamide (TAF) (EASL 2025, strong recommendation) ^[1]^A1c. At year 5, 85% of TAF-treated patients achieve HBV DNA <29 IU/mL with no resistance and favorable renal/bone safety ^[349]^A1b. Viral suppression reduces but does not eliminate HCC risk; surveillance must continue ^[1]^A1c.

Hepatitis C virus (HCV). Direct-acting antiviral (DAA) therapy achieves sustained virologic response (SVR) in >90% of patients, including those with decompensated cirrhosis. In the ASTRAL-4 trial, - plus ribavirin for 12 weeks yielded 94% SVR (95% CI 87-98) in B patients ^[302]^A1b. SVR is associated with reduced liver-related mortality and, in some, fibrosis regression.

Alcohol-associated liver disease (ALD). Abstinence is the most effective intervention. The ACG 2023 guideline strongly recommends a multidisciplinary integrated care model including hepatology, addiction medicine, and social workers ^[59]^A1c. A diagnosis of ALD itself often triggers behavior change, 56% report abstinence shortly after diagnosis, but relapse at 90 days occurs in 37% ^[289]^B2b. Pharmacotherapy for (e.g., baclofen, naltrexone) should be offered.

Metabolic dysfunction-associated steatohepatitis (MASH). Lifestyle modification targeting ≥7-10% weight loss remains first-line ^[97]^D5^[326]^A1c. Two pharmacotherapies now have regulatory support. Resmetirom (80 or 100 mg PO daily) was approved by the FDA in 2024 for MASH with F2-3 fibrosis based on MAESTRO-NASH: NASH resolution in 25.9-29.9% vs 9.7% placebo (P<0.001), and fibrosis improvement in 24.2-25.9% vs 14.2% (P<0.001) ^[143]^A1b. 2.4 mg SC weekly received accelerated FDA approval in August 2025 for MASH with F2-3 fibrosis after the ESSENCE trial: MASH resolution 62.9% vs 34.3% (P<0.001) and fibrosis reduction 36.8% vs 22.4% (P<0.001) ^[56]^A1c. Neither agent is approved for MASH cirrhosis; patients with compensated cirrhosis receiving semaglutide for another indication require careful monitoring. Efruxifermin, an FGF21 analogue, is under investigation; in the SYMMETRY trial at 96 weeks, 29% of patients on 50 mg achieved fibrosis improvement without worsening MASH vs 11% placebo (difference 16 percentage points, 95% CI 2-30) ^[244]^A1b. Vitamin E 800 IU daily may benefit nondiabetic patients with biopsy-proven MASH ^[352]^A1b. Pioglitazone improves histology but not fibrosis ^[352]^A1b.

(AIH). Immunosuppression improves survival even in decompensated cirrhosis, provided overt grade 3/4 is absent and ≤28 ^[293]^B3b. The BSG 2025 guideline recommends prednisolone (30-40 mg daily taper) plus azathioprine (1-2 mg/kg/day) ^[239]^A1c. Recompensation occurs in 49% of treated patients ^[293]^B3b.

Primary biliary cholangitis (PBC). Ursodeoxycholic acid (13-15 mg/kg/day) is first-line ^[193]^A1c. In those with inadequate response (alkaline phosphatase >1.67× ULN and/or elevated bilirubin), add obeticholic acid (5-10 mg/day). The POISE trial showed biochemical response in 46-47% vs 10% placebo (P<0.001) ^[351]^A1b.

Hemochromatosis . Phlebotomy targets ferritin <50 μg/L (induction) then <100 μg/L (maintenance) ^[235]^A1c^[99]^D5. Patients with advanced fibrosis require HCC surveillance.

Hepatitis D virus (HDV). Bulevirtide 2 mg or 10 mg SC daily achieved a combined virologic and biochemical response in 45-48% vs 2% control (P<0.001) ^[350]^A1b.

Disease Reversal and Recompensation

Effective etiology control can lead to fibrosis regression. Resmetirom and semaglutide are the first agents to show histological improvement in MASH fibrosis in phase 3 trials ^[56]^A1c^[143]^A1b. In the setting of decompensated cirrhosis, recompensation (defined by Baveno VII as resolution of , encephalopathy, and jaundice with stable liver function) occurs in approximately 35% of patients overall, 49% in HBV-related and 19% in alcohol-related disease ^[72]^A1a^[191]^B2a. Recompensation is associated with significantly lower odds of HCC (OR 0.55, 95% CI 0.35-0.87) and death (OR 0.33) ^[72]^A1a.

Surveillance and Preventive Care

HCC surveillance: Ultrasound with or without AFP every 6 months. The GALAD score (gender, age, AFP-L3, AFP, DCP) improves detection (AUC 0.78 vs 0.66 for AFP alone; P<0.001) ^[248]^B2b.
Variceal screening: Endoscopy is recommended at diagnosis of cirrhosis; non-invasive criteria (liver stiffness <20 kPa and platelets >150,000/mm³) can safely avoid endoscopy (Baveno VII) ^[28]^D5.
Primary prophylaxis of decompensation: Non-selective β-blockers reduce the risk of first decompensation in patients with clinically significant (PREDESCI; HR 0.51, 95% CI 0.26-0.97) ^[70]^A1b.

Nutritional and Lifestyle Management

Malnutrition affects >60% of patients ^[130]^A1c. The ACG 2025 guideline recommends:

Small frequent meals with a nighttime snack (7-10 PM) ^[133]^A1c.
Protein intake 1.2-1.5 g/kg/day; do not restrict protein in hepatic encephalopathy ^[133]^A1c.
Branched-chain amino acids did not improve sarcopenia vs whey protein in a recent RCT ^[357]^A1b.
Vitamin E 800 IU daily for selected nondiabetic MASH (PIVENS) ^[352]^A1b.
Two or more cups of coffee daily ^[133]^A1c.

For patients with decompensated cirrhosis who do not recompensate, liver transplantation remains the only definitive therapy, offering 1-year survival >85% ^[322]^D5. Detailed candidacy, -based allocation, and post-transplant care are covered in Section 10.

Pearl: Sustained suppression of the underlying liver disease, whether through antiviral therapy, abstinence, metabolic treatment, or immunosuppression, can halt fibrosis progression, enable recompensation in up to one-third of decompensated patients, and reduce the risk of HCC and death by approximately 50-70% ^[1]^A1c^[72]^A1a^[143]^A1b^[293]^B3b.

Etiology-Directed Pharmacotherapy Dosing

Disease	Drug	Starting dose	Target / max dose	Key monitoring	Evidence level
HBV	Entecavir	0.5 mg PO daily	0.5 mg daily (1 mg if lamivudine-resistant)	HBV DNA, ALT, Cr, HBsAg	1b ^[1]^A1c
HBV	Tenofovir alafenamide	25 mg PO daily	25 mg daily	Renal function, bone density	1b ^[349]^A1b
HCV	Sofosbuvir-velpatasvir ± ribavirin	400/100 mg PO daily	400/100 mg × 12 weeks	SVR12, CrCl, Hb (if ribavirin)	1b ^[302]^A1b
MASH	Resmetirom	80 mg PO daily	80 mg or 100 mg based on weight	LFTs, LDL-C, GI symptoms	1b ^[143]^A1b
MASH	Semaglutide (Wegovy)	0.25 mg SC weekly (escalate)	2.4 mg SC weekly	GI tolerance, pancreatitis, retinopathy	1b ^[56]^A1c
PBC	Ursodeoxycholic acid	13-15 mg/kg/day PO	13-15 mg/kg/day	Alk phos, bilirubin	1c ^[193]^A1c
PBC	Obeticholic acid	5 mg PO daily (titrate to 10 mg)	10 mg daily	Pruritus, lipid profile	1b ^[351]^A1b
AIH	Prednisolone + azathioprine	30-40 mg PO daily taper + 1-2 mg/kg/day	Maintenance 5-10 mg + 2 mg/kg	LFTs, glucose, CBC, TPMT	1c ^[239]^A1c
HDV	Bulevirtide	2 mg SC daily	Up to 10 mg daily	HDV RNA, ALT, bile acids	1b ^[350]^A1b
Hemochromatosis	Phlebotomy	500 mL weekly	Ferritin <50 (induction) → <100 (maintenance)	Ferritin, Hb, TSAT	1c ^[235]^A1c

Portal Hypertension & Decompensation Management

▸Non-selective beta-blockers (carvedilol preferred) prevent hepatic decompensation in CSPH irrespective of variceal status (PREDESCI).
▸Combination carvedilol + variceal band ligation is superior to either alone for primary prophylaxis of variceal bleeding in high-risk patients (CAVARLY).
▸Terlipressin plus albumin reverses HRS-AKI in 32% but is contraindicated in ACLF grade 3 due to respiratory failure risk (CONFIRM).

! Warning: Contraindicate terlipressin in HRS-AKI with ACLF grade 3 or baseline hypoxemia (SpO₂ <90%) - respiratory failure risk (CONFIRM [327, 373]).

HY High Yield: For high-risk patients (Child B+active bleeding or Child C <14) with acute variceal bleeding, pre-emptive TIPS within 72 hours reduces 1-year mortality by ~40% (HR 0.43, 95% CI 0.32-0.60) [298].

Etiological therapy and lifestyle modification set the stage, but itself must be targeted to prevent progression from compensated to decompensated disease. The following principles apply to patients with established clinically significant portal (CSPH; HVPG ≥10 mm Hg).

Step 1: Baseline Risk Stratification and Hemodynamic Modification

All patients with compensated cirrhosis and CSPH should be considered for non-selective beta-blockers (NSBB) to prevent hepatic decompensation, regardless of variceal status. The PREDESCI trial (n=201) demonstrated that NSBB (propranolol or ) reduced the composite endpoint of decompensation or death by 49% (HR 0.51, 95%; NNT = 9 over median 27 months) ^[70]^A1b. The benefit was driven by a **** reduction in incident (HR 0.44, 95% CI 0.20-0.97) ^[70]^A1b. For patients with new-onset uncomplicated ascites and no high-risk varices, carvedilol titrated to 12.5 mg once daily safely reduced ascites-related complications (38.5% vs 67.3%; p=0.03) and 1-year mortality (9.1% vs 24.2%; p=0.05) in the CARVE-AS trial ^[137]^A1b.

NSBB agent	Starting dose	Target dose	HVPG response assessment	Key considerations
Carvedilol	6.25 mg once daily	12.5 mg once daily	Titrate q3-5 days; target HR 55-65 bpm	Preferred due to α₁-blockade; contraindicated in asthma, bradycardia <50 bpm ^[71]^A1b
Propranolol	20 mg twice daily	40-160 mg twice daily	Titrate by HR and BP	Longer experience; higher dose requirements ^[70]^A1b
Nadolol	20 mg once daily	40-80 mg once daily	Adjust for renal function	Renally excluded; used less commonly ^[92]^A1c

Step 2: Primary Prophylaxis of Variceal Bleeding

For patients with high-risk (medium/large, red signs, or Child C), the combination of carvedilol plus variceal band ligation (VBL) is superior to either therapy alone. The CAVARLY trial (n=330, Child B/C) showed combination therapy reduced first variceal bleed by 62.9% vs VBL alone (HR 0.37, 95% CI 0.19-0.72) and 69.3% vs carvedilol alone (HR 0.31), with a 6.3% 1-year mortality in the combination arm vs 14.5-20% in monotherapy arms ^[65]^A1b. The underpowered CALIBRE trial (n=265) found no significant difference between carvedilol and VBL monotherapy ^[71]^A1b. Practice point: Upfront combination is preferred for high-risk patients, especially those with Child B/C cirrhosis.

Step 3: Management of Ascites and Volume Overload

First-line: Sodium restriction (<2 g/day) and combination diuretic therapy ( 100 mg/day + 40 mg/day, titrated upward as tolerated) ^[64]^D5. The AGA 2025 Clinical Practice Update recommends the lowest effective diuretic dose with regular electrolyte and renal monitoring ^[64]^D5.

: Large-volume (LVP) with albumin replacement (6-8 g of 20-25% albumin per liter removed for volumes >5 L) prevents paracentesis-induced circulatory dysfunction ^[64]^D5. Covered TIPS is superior to repeated LVP for transplant-free survival: 93% vs 52% at 1 year (p=0.003) in a randomized trial ^[371]^A1b. TIPS is not associated with increased HCC risk (OR 1.16, 95% CI 0.76-1.77) ^[123]^B2a. SGLT2 inhibitors ( , ) increase ascites resolution (OR 2.39) but carry signals for AKI and infection; they should be considered only as investigational therapy under close monitoring ^[125]^A1a.

Long-term albumin: The ANSWER trial (n=431) showed that 40 g/week albumin after a 2-week loading phase reduced mortality (95%; NNT = 8 over 18 months) in patients with uncomplicated ascites on optimal diuretics ^[150]^A1b. However, confirmatory trials are ongoing and albumin remains a second-tier option pending further data ^[260]^D5.

Step 4: Chronic Prophylaxis

Secondary prophylaxis: Lactulose titrated to 2-3 soft stools/day reduces overt HE recurrence (RR 0.48, 95% CI 0.37-0.63; high probability of mortality benefit in Bayesian analysis) ^[178]^A1a. For patients who breakthrough despite lactulose, add rifaximin 550 mg twice daily to reduce recurrent HE (22.1% vs 45.9% breakthrough events; HR 0.42, 95% CI 0.28-0.64) and HE-related hospitalizations (13.6% vs 22.6%; HR 0.50, 95% CI 0.29-0.87) ^[144]^A1b. The addition of L-ornithine L-aspartate (LOLA) 30 g/day continuous IV to lactulose + rifaximin improved HE recovery rates (92.5% vs 66%; p<0.001) and 28-day mortality (16.4% vs 41.8%; p=0.001) in severe HE ^[368]^A1b. Fecal microbiota transplant (FMT) from a rationally selected donor reduced hospitalizations and improved cognition in recurrent HE but is not yet standard ^[369]^A1b.

Step 5: Prevention and Management of -Acute Kidney Injury

Prevention: Avoid NSAIDs, excessive diuresis, and large-volume paracentesis without albumin. Prompt antibiotic treatment for (SBP) with albumin (1.5 g/kg on day 1, then 1 g/kg on day 3) reduces HRS-AKI ^[63]^D5. Treat any precipitating infection vigorously.

Treatment of established HRS-AKI: Combined terlipressin (continuous IV infusion 2 mg/day titrated to 12 mg/day) plus albumin (1 g/kg day 1, then 20-40 g/day) achieves verified HRS reversal in 32% vs 17% with placebo (p=0.006; CONFIRM trial) ^[327]^A1b. Continuous infusion is better tolerated than boluses (adverse events 35% vs 62%) and effective at lower doses ^[325]^A1b. Noradrenaline (0.5-3 mg/h) is an alternative but inferior to terlipressin in ACLF (40% vs 16.7% HRS reversal; p=0.004; 28-day survival 48.3% vs 20%; p=0.001) ^[370]^A1b. Caution: Terlipressin is associated with respiratory failure in patients with ACLF grade 3 (30% vs 0% placebo; p=0.01) and with hypoxemia (SpO₂ <90%); it should be avoided or used with extreme caution in this subgroup ^[373]^A1b.

Step 6: Recompensation as a Therapeutic Goal

Recompensation, defined as sustained resolution of ascites/HE off specific therapy, absence of variceal bleeding, and improved liver function, occurs in approximately 35% of decompensated patients who achieve sustained etiological control (meta-analysis, 27 studies, n=9063) ^[72]^A1a. Rates are highest in HBV (50%) and lowest in PBC (15%) ^[72]^A1a. Recompensation is associated with reduced HCC (OR 0.55, 95% CI 0.35-0.87), death (OR 0.33), and liver-related death (OR 0.21) ^[72]^A1a. Achieving etiological cure, whether through antiviral therapy, alcohol abstinence, or immunosuppression in AIH, is the prerequisite and should be pursued aggressively before delisting from transplant waitlists ^[321]^D5.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
NSBB safety in refractory ascites	EASL/Baveno VII - NSBB are indicated for primary prophylaxis, but caution with hypotension/renal impairment ^[28]^D5	Carve-AS trial - carvedilol safe and beneficial even in new-onset ascites, reducing AKI (34.6% vs 63.4%; p=0.003) ^[137]^A1b	Moderate (observational vs RCT evidence)	Use NSBB in ascites unless SBP <90 or AKI; monitor closely; consider carvedilol over propranolol

Warning: Do not give terlipressin to patients with HRS-AKI and ACLF grade 3 or baseline hypoxemia (SpO₂ <90%) due to risk of respiratory failure and excess 90-day mortality (11% vs 2% placebo) ^[327]^A1b^[373]^A1b.

Pearl: The combination of carvedilol plus VBL reduces first variceal bleed risk by over 60% compared with monotherapy in Child B/C cirrhosis (NNT to prevent one bleed = 5 over 1 year; CAVARLY trial ^[65]^A1b), and pre-emptive TIPS within 72 h for high-risk acute variceal bleeding (Child B+active bleeding, Child C<14) improves 1-year survival 86% vs 61% ^[298]^A1a.

NSBB Dosing and Evidence Summary

NSBB agent	Starting dose	Target dose	Key evidence
Carvedilol	6.25 mg once daily	12.5 mg once daily	PREDESCI ^[70]^A1b, CARVE-AS ^[137]^A1b, CAVARLY ^[65]^A1b
Propranolol	20 mg twice daily	40-160 mg twice daily	PREDESCI ^[70]^A1b
Nadolol	20 mg once daily	40-80 mg once daily	U.K. guidelines ^[92]^A1c

History and Evolution of Treatment

▸Landmark trials transformed cirrhosis management: restrictive transfusion [301], early TIPS [145], PREDECSI beta-blockers [70], and DAA-driven etiologic cure [354].
▸MASH pharmacotherapy advanced with resmetirom (first FDA-approved for F2-F3) [143] and semaglutide (accelerated approval for F2-F3) [56]; efruxifermin shows promise for F4 [244].
▸Decompensation can be reversed, the recompensation concept, supported by albumin [150], rifaximin [144], and terlipressin [327], allows delisting in selected patients [321].

HY High Yield: Recompensation, defined by resolution of ascites, absence of encephalopathy, and improvement in liver function, is achievable after sustained etiologic cure (e.g., DAA for HCV, alcohol abstinence) and may allow delisting from transplant waitlists [321].

Despite advances in managing portal hypertensive complications, the trajectory of cirrhosis treatment has shifted from reactive complication control toward etiologic cure and fibrosis regression, a transformation driven by landmark trials over the past three decades.

The Era of Complication Control (1990s-2000s)

Early treatment focused on life-threatening events. Vasoactive drugs (terlipressin, somatostatin, octreotide) plus endoscopic band ligation became standard for acute variceal bleeding, reducing rebleeding and mortality ^[63]^D5. The restrictive transfusion strategy, threshold hemoglobin <7 g/dL, improved survival (HR 0.55, 95% CI 0.33-0.92) compared with a liberal (9 g/dL) approach in patients with upper bleeding; NNT = 22 to prevent one death at 6 weeks ^[301]^A1b. Early transjugular intrahepatic portosystemic shunt (TIPS) within 72 hours in high-risk patients (Child C or B with active bleeding) reduced treatment failure from 50% to 3% and 1-year mortality from 39% to 14% (NNT = 4 to prevent one death) ^[145]^A1b. TIPS replaced surgical shunts as the preferred rescue therapy, although encephalopathy risk remained a trade-off; 6-mm stents lowered encephalopathy compared with 8-mm stents (20.3% vs. 42.0% at 2 years) without compromising survival ^[407]^A1b.

The Revolution of Etiologic Therapy (2000s-2020s)

For hepatitis B, oral nucleos(t)ide analogues ( , ) suppressed HBV DNA in >95% of treated patients and reversed fibrosis in some, displacing interferon and reducing HCC risk ^[132]^A1c. Tenofovir alafenamide (TAF) 25 mg daily provided equivalent viral suppression to tenofovir disoproxil fumarate with superior renal and bone safety over 5 years ^[349]^A1b.

For hepatitis C, direct-acting antivirals (DAAs) achieved sustained virologic response rates of 95-99%, rendering cirrhosis regression and even recompensation possible ^[354]^A1b. However, HCC risk persists after DAA therapy, with recurrence rates of 20 per 100 person-years; close surveillance remains mandatory ^[397]^A1a.

For non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), vitamin E 800 IU/day improved histology in non-diabetic patients (43% vs. 19% placebo, NNT = 5) but did not improve fibrosis ^[352]^A1b. Resmetirom, a thyroid hormone receptor-beta agonist, became the first FDA-approved drug for MASH with stage F2-F3 fibrosis: at 80 mg daily, 25.9% achieved NASH resolution without fibrosis worsening vs. 9.7% placebo (NNT = 6.2), and fibrosis improved in 24.2% vs. 14.2% (NNT = 10) ^[143]^A1b. (2.4 mg/week subcutaneous) received accelerated approval for MASH with F2-F3 fibrosis based on the ESSENCE trial: resolution of MASH in 62.9% vs. 34.3% (NNT = 3.5) ^[56]^A1c. In compensated MASH cirrhosis (F4), efruxifermin (50 mg/week) showed fibrosis improvement at 96 weeks (29% vs. 11% placebo; NNT = 5.6) in the SYMMETRY trial ^[244]^A1b.

For hepatitis delta, bulevirtide 2 mg/day subcutaneous reduced HDV RNA by ≥2 log₁₀ and normalized ALT in 45% at 48 weeks vs. 2% control (NNT = 2.3) ^[350]^A1b.

Decompensation Prevention and Reversal (2010s-present)

The PREDESCI trial demonstrated that non-selective beta-blockers (propranolol or ) in compensated cirrhosis with clinically significant reduced decompensation, primarily , by 49% (, 95%; NNT = 9 over median 37 months) ^[70]^A1b. The ANSWER trial showed that long-term albumin (40 g twice weekly × 2, then weekly) improved 18-month survival from 66% to 77% in patients with diuretic-treated ascites (NNT = 9) ^[150]^A1b. In severe , the combination of lactulose and rifaximin 550 mg twice daily was more effective than lactulose alone for reversal (76% vs. 51%; NNT = 4) and reduced mortality (24% vs. 49%) ^[140]^A1b. For secondary prophylaxis of encephalopathy, rifaximin 550 mg twice daily reduced breakthrough episodes (HR 0.42; NNT = 5) ^[144]^A1b. Terlipressin plus albumin reversed type 1 in 32% vs. 17% placebo (NNT = 7) ^[327]^A1b. In , albumin (1.5 g/kg on day 1, then 1 g/kg on day 3) reduced renal impairment from 33% to 10% and in-hospital mortality from 29% to 10% (NNT = 5) ^[399]^A1b.

Antifibrotic and Emerging Approaches

Early antifibrotic trials were disappointing. Belapectin, a galectin-3 inhibitor, did not reduce HVPG in NASH cirrhosis overall but reduced new varices in a subgroup without baseline varices ^[67]^A1b. Hydronidone 270 mg/day plus entecavir improved fibrosis by ≥1 Ishak stage in 54.8% vs. 25.6% placebo in CHB-related fibrosis (NNT = 3.4) ^[406]^A1b. Yaq-001, a gut-restricted adsorbent, reduced systemic inflammation and portal in animal models and was safe in a proof-of-concept trial ^[66]^C4. The concept of recompensation, resolution of ascites, encephalopathy, and jaundice after etiologic cure, has allowed delisting from transplant waitlists in selected patients ^[321]^D5.

remains the definitive therapy for decompensated cirrhosis, and the score guides organ allocation ^[367]^A1c. The next section details candidacy and peri-transplant .

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Primary prophylaxis of variceal bleeding in mild portal hypertension	Carvedilol first (AASLD 2025) ^[65]^A1b	Variceal band ligation non-inferior (BSG 2025) ^[71]^A1b	Weak	Shared decision-making; beta-blockers reduce decompensation beyond bleeding ^[70]^A1b
Albumin for hospitalized decompensated cirrhosis	Targeted albumin to ≥30 g/L (ATTIRE, no benefit over standard care) ^[353]^A1b	Long-term albumin in outpatients with ascites improves survival (ANSWER) ^[150]^A1b	Moderate	Albumin use is context-dependent; not all patients benefit

Pearl: The treatment of cirrhosis has evolved from reactive complication management to proactive etiologic cure and fibrosis regression, the single most impactful intervention remains addressing the underlying cause (suppress HBV, cure HCV, achieve alcohol abstinence, treat MASH) because disease recompensation and improved survival are now achievable outcomes ^[321]^D5.

Paradigm-Shifting Trials in Cirrhosis Management

Intervention	Landmark Trial	Key Result	NNT/NNH	Ref
Restrictive transfusion (Hb <7 g/dL) in UGIB	Villanueva 2013	6-week survival 95% vs. 91% (HR 0.55)	NNT=22	^[301]^A1b
Early TIPS in high-risk variceal bleeding	García-Pagán 2010	Treatment failure 3% vs. 50%; 1-year survival 86% vs. 61%	NNT=4 for survival	^[145]^A1b
Resmetirom 80 mg in NASH F2-F3	MAESTRO-NASH (Harrison 2024)	NASH resolution 25.9% vs. 9.7%; fibrosis improvement 24.2% vs. 14.2%	NNT=6.2; NNT=10	^[143]^A1b
Semaglutide 2.4 mg/wk in MASH F2-F3	ESSENCE (Bansal 2025)	MASH resolution 62.9% vs. 34.3%	NNT=3.5	^[56]^A1c
Rifaximin 550 mg BID for HE secondary prophylaxis	Bass 2010	Breakthrough HE 22% vs. 46% (HR 0.42)	NNT=5	^[144]^A1b
Terlipressin + albumin for HRS type 1	CONFIRM (Wong 2021)	HRS reversal 32% vs. 17%	NNT=7	^[327]^A1b
Long-term albumin (40 g/wk) in ascites	ANSWER (Caraceni 2018)	18-month survival 77% vs. 66%	NNT=9	^[150]^A1b
Bulevirtide 2 mg/d in chronic hepatitis D	MYR301 (Wedemeyer 2023)	Combined response 45% vs. 2% (ALT normal + HDV RNA drop)	NNT=2.3	^[350]^A1b

Liver Transplantation & MELD-Based Candidacy

▸Liver transplantation is the definitive therapy for decompensated cirrhosis; referral should occur at the first decompensation event.
▸The MELD-Na score drives organ allocation; exception points are available for HCC (Milan criteria), portopulmonary hypertension, and HRS-AKI.
▸Frailty (Liver Frailty Index) and sarcopenia independently predict waitlist mortality and should be incorporated into candidate assessment.

! Warning: Overcorrection of hyponatremia before or during liver transplantation (serum sodium rise ≥8 mEq/L in 24 hours) risks osmotic demyelination syndrome, which is often irreversible and fatal [319]. Use sodium-reduced fluids and monitor hourly intraoperatively.

HY High Yield: The Liver Frailty Index (grip strength, chair stands, balance) is a bedside tool that improves waitlist mortality prediction beyond MELD‑Na alone; a “frail” score (>80th percentile) identifies patients with 3‑fold higher risk of death or delisting [451].

While etiological treatment can induce recompensation in selected patients (up to 35% in meta-analyses ^[72]^A1a^[191]^B2a), (LT) remains the only definitive therapy for patients with decompensated cirrhosis who fail to improve. Since the introduction of the Model for End‑Stage Liver Disease ( ) score for organ allocation in 2002, priority is determined by objective estimates of short‑term mortality rather than waiting time ^[410]^D5^[183]^D5.

Indications for Liver Transplantation

LT is indicated for cirrhosis with complications that are refractory to medical : , , variceal hemorrhage, (HRS‑AKI), hepatocellular carcinoma (HCC), and acute‑on‑chronic liver failure (ACLF) ^[410]^D5^[96]^D5^[131]^A1c. Patients with decompensated cirrhosis should be referred for LT evaluation at the first decompensation event, as 1‑year mortality ranges from 20% to 57% depending on the stage ^[220]^D5^[410]^D5.

MELD Score and Organ Allocation

The MELD score (based on serum bilirubin, INR, and creatinine) predicts 90‑day mortality and drives allocation in most countries ^[410]^D5^[183]^D5. The MELD‑Na score, which incorporates serum sodium, improves predictive accuracy, particularly for patients with hyponatremia ^[85]^D5^[319]^D5. Correction of hyponatremia should not exceed ≥8 mEq/L in 24 hours to avoid ^[319]^D5. MELD exception points are granted for conditions where mortality is not adequately captured by the score, such as HCC (within : solitary tumor ≤5 cm or up to 3 nodules ≤3 cm), , and HRS‑AKI ^[271]^D5^[111]^D5^[320]^D5. The AFP model (integrating tumor size, number, and α‑fetoprotein) refines selection for HCC and independently predicts post‑LT recurrence ^[484]^B2b^[467]^D5.

Candidate Evaluation

Evaluation is a multidisciplinary process designed to identify contraindications and optimize outcomes ^[367]^A1c. Key domains include:

Cardiopulmonary fitness: cardiopulmonary exercise testing (CPET) independently predicts pre‑ and post‑transplant mortality; peak VO₂ is often severely reduced (mean 17.4 mL/kg/min) ^[447]^B2a. Cirrhotic cardiomyopathy (prevalence 26%-81%) increases perioperative cardiovascular risk ^[48]^D5^[466]^D5.
Frailty and sarcopenia: the Liver Frailty Index (grip strength, chair stands, balance) improves 3‑month waitlist mortality prediction when added to MELD‑Na (c‑statistic 0.82 vs 0.80; net reclassification index 19%) ^[451]^B2b. Sarcopenia (L3‑SMI <39 cm²/m² in women, <50 cm²/m² in men) independently predicts liver‑related events and mortality, independent of ^[127]^B3b^[479]^D5.
Psychosocial and alcohol use: for alcohol‑associated liver disease (ALD) - now the leading LT indication in many centers - a 6‑month abstinence period is no longer mandated for acute alcohol‑associated hepatitis; early LT in carefully selected candidates yields survival of 77% vs 23% with medical therapy alone ^[478]^D5^[454]^D5^[469]^D5. treatment is essential post‑LT ^[461]^D5.
Infectious screening: , COVID‑19 (32.7% mortality in LT candidates, especially with MELD ≥15) ^[444]^B2b^[483]^D5.

Waitlist Management and Bridging

The waiting period carries risk of further decompensation and death ^[470]^D5. Strategies to bridge patients to LT include:

Terlipressin for HRS‑AKI: home continuous terlipressin infusion (median 84 days) increased handgrip strength by 2.84 kg and reduced frequency by 58% in a cohort of 102 patients ^[460]^C4.
Transjugular intrahepatic portosystemic shunt (TIPS) for or variceal bleeding: in selected patients, TIPS reduces further decompensation (HR 0.44) and improves 2‑year survival (71% vs 63%) ^[200]^B2a. TIPS may also bridge patients with ACLF and fluid overload, with a 78% mortality reduction at 28 days ^[124]^B3b.
Nutritional support: nighttime snacks, branched‑chain amino acids, and avoidance of protein restriction mitigate sarcopenia ^[133]^A1c^[181]^D5.
MELD trajectory: a transient MELD increase of ≥5 points within 1 month (peak‑MELD) is associated with lower transplantation rates (HR 0.37) and warrants dynamic reassessment ^[488]^B2b.

Post‑Transplant Outcomes

One‑ and 5‑year patient survival after LT for cirrhosis is approximately 90% and 70%, respectively ^[445]^B2a^[485]^B2b. Survival is comparable across etiologies: for NASH, 1‑year mortality 12.5%, 5‑year 24.4%, 10‑year 37.9%; not significantly different from non‑NASH (HR 0.91) ^[448]^A1a. Post‑LT outcomes in ACLF patients are excellent when carefully selected (1‑year survival 91%) ^[485]^B2b.

Disease recurrence occurs in 10%-50% of patients with autoimmune liver disease (AIH, PBC, PSC) and is influenced by immunosuppression choice ^[445]^B2a^[339]^D5. NAFLD recurs as steatosis in the graft and may progress ^[462]^D5^[463]^D5. Return to harmful alcohol use post‑LT worsens survival due to extrahepatic comorbidities ^[454]^D5^[469]^D5.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Early LT for severe alcohol‑associated hepatitis	AASLD/ACG (2023, 2024): May be considered in selected patients who fail medical therapy and have low relapse risk ^[59]^A1c^[478]^D5^[454]^D5	EASL: Emphasizes need for structured psychosocial evaluation, but no fixed abstinence period ^[131]^A1c^[471]^D5	Consensus emerging; lack of RCT data	Widespread adoption is limited by organ scarcity and need for robust addiction support
MELD score “lock” for terlipressin responders	Proponents: Protects waitlist priority for patients whose MELD drops with HRS‑AKI treatment ^[320]^D5	Opponents: Equitable access not guaranteed; terlipressin response may improve overall survival ^[320]^D5	No consensus; European countries vary	UNOS has not yet adopted MELD lock; debate ongoing

Pearl

Pearl: LT outcomes are excellent when candidacy is guided by objective risk stratification (MELD‑Na, frailty, cardiopulmonary reserve) and multidisciplinary support; early referral at first decompensation is the single most modifiable determinant of access.

Controversies in Liver Transplantation for Cirrhosis

Question	Position A	Position B	Strength	Implication
Early LT for severe alcohol‑associated hepatitis	AASLD/ACG: Selected patients, no fixed abstinence, survival benefit 77% vs 23% ^[59]^A1c^[478]^D5	EASL: Structured psychosocial evaluation essential; organ scarcity remains a barrier ^[131]^A1c^[471]^D5	Consensus emerging; no RCT	Adoption limited by addiction support availability
MELD “lock” for terlipressin responders	Proponents: Preserves waitlist priority for HRS-AKI patients who improve ^[320]^D5	Opponents: Inequitable access; response may reflect true improvement ^[320]^D5	No US consensus; European variation	UNOS has not adopted; further research needed

Non-Portal-Hypertensive Complications and Multi-Organ Sequelae

▸HCC surveillance with ultrasound plus AFP every 6 months detects early-stage disease with 63% sensitivity; the GALAD score further improves detection.
▸Sarcopenia and malnutrition affect >60% of transplant candidates and are independently associated with mortality; protein restriction is contraindicated.
▸Cirrhosis-associated immune dysfunction (CAID) drives infection risk and ACLF; lactulose and rifaximin reduce overt hepatic encephalopathy.

HY High Yield: HCC surveillance with ultrasound plus AFP every 6 months is recommended for all patients with cirrhosis; adding AFP improves early detection from 47% to 63% [251].

offers definitive therapy, but cirrhosis remains a systemic disease driving multi-organ dysfunction beyond . A proinflammatory and pro-oxidant milieu triggers complications across the lungs, heart, bones, muscles, coagulation, and immunity ^[89]^D5^[166]^D5.

Hepatocellular Carcinoma

The most feared complication, HCC incidence in NAFLD is 0.44 per 1000 person‑years ^[141]^B2a. Surveillance ultrasound alone detects early-stage HCC with only 47% sensitivity; adding AFP raises this to 63% ^[251]^B2a. The GALAD score (gender, age, AFP‑L3, AFP, DCP) improves detection (AUC 0.78 vs 0.66 for AFP; P<0.001) ^[248]^B2b. Statin and use are each associated with reduced HCC risk (HR 0.52 and 0.48, respectively) ^[489]^B2a.

Cardiopulmonary Complications

Hepatopulmonary syndrome causes hypoxemia from intrapulmonary vascular dilatations. (POPH) precludes liver transplantation unless the mean pulmonary artery pressure is lowered with vasodilators (e.g., epoprostenol) ^[111]^D5. Cirrhotic cardiomyopathy, subclinical systolic/diastolic dysfunction with prolonged QT interval, becomes clinically overt under the hemodynamic stress of transplantation ^[184]^D5. ARDS occurs in 26.6% of ventilated cirrhotic patients, with 75.2% 28‑day mortality; higher and lower PaO₂/FiO₂ predict death ^[324]^B3b.

Coagulopathy

A rebalanced hemostatic state can tip toward both bleeding and thrombosis. In advanced cirrhosis with upper GI bleeding, tranexamic acid reduced 5‑day treatment failure from 13.3% to 6.3% (P=0.006) by preventing EVL‑site oozing, though mortality was unchanged ^[135]^A1b.

Sarcopenia, Frailty, and Malnutrition

Malnutrition affects >60% of transplant candidates ^[181]^D5. The ACG recommends small frequent meals, a nighttime snack, ≥2 cups of coffee daily, and vegetable protein sources ^[133]^A1c. Protein should never be restricted, even in ^[133]^A1c.

Immune Dysfunction and Infection

Cirrhosis‑associated immune dysfunction (CAID) couples systemic inflammation with functional immune deficits, predisposing to bacterial/fungal infections that often trigger ACLF ^[112]^D5. Lactulose reduces overt hepatic encephalopathy (RR 0.48; 95% CI 0.37‑0.63) ^[178]^A1a; rifaximin added to lactulose further lowers breakthrough encephalopathy (HR 0.42; 95% CI 0.28‑0.64) ^[144]^A1b.

Metabolic and Bone Disease

Diabetes complicates cirrhosis in ~30% of patients and worsens outcomes; HbA1c is unreliable in decompensated disease, and insulin therapy is preferred ^[164]^D5. Hepatic osteodystrophy, osteopenia or osteoporosis, is common; DXA screening is advised.

Supportive Care in Hospitalized Patients

Complication	Frequency	Prevention
HCC	0.44/1000 py (NAFLD)	Surveillance US + AFP q6mo ^[251]^B2a	Resection, ablation, , systemic therapy per
Sarcopenia	>60% of LT candidates ^[181]^D5	Nighttime snack, adequate protein ^[133]^A1c	Nutritional support, exercise
Infection (bacterial)	35% of ACLF triggers ^[151]^A1a	Targeted antibiotic prophylaxis	Early culture‑guided
ARDS	26.6% of ventilated ^[324]^B3b	Lung‑protective ventilation	Treat underlying cause, consider ECMO
Coagulopathy (UGIB)	13.3% failure (placebo) ^[135]^A1b	Vasoactive drugs + EVL	Tranexamic acid 1 g IV ^[135]^A1b

Pearl: The leading causes of death in cirrhosis are not solely liver‑related, cardiovascular disease and infection each contribute substantially; multidisciplinary care targeting extrahepatic organ systems is essential.

Prognosis & Natural History

▸Median survival drops from >15 years in compensated cirrhosis to ~2 years after first decompensation and ~9 months with further decompensation.
▸Recompensation occurs in about one-third of decompensated patients (35%, 95% CI 26-45%) and is associated with a 67% reduction in odds of death (OR 0.33).
▸Fibrosis stage is the strongest histological predictor of liver-related mortality (stage 4 vs 0: RR 11.13 for liver-related death in NAFLD).
▸ACLF complicates 35% of acute decompensation admissions and carries a 90-day mortality of 58%.

HY High Yield: A first decompensation event (ascites, variceal hemorrhage, or encephalopathy) shifts median survival from >15 years to ~2 years. Preventing decompensation is the central objective in compensated cirrhosis.

Having catalogued the myriad complications that define decompensated disease, we now turn to the natural history that binds them into a staged trajectory. Cirrhosis evolves through discrete prognostic phases: compensated, decompensated, and further decompensated, each with a starkly different outlook. Median survival is >15 years in compensated disease, ~2 years after the first decompensation event, and ~9 months with further decompensation ^[63]^D5^[118]^D5. The transition is driven by progressive , systemic inflammation, and the vasodilatory-hyperdynamic circulatory state that ultimately compromises renal perfusion ^[96]^D5.

Compensated to Decompensated Trajectory

The strongest predictor of decompensation is clinically significant portal (CSPH, hepatic venous pressure gradient ≥10 mm Hg). In the PREDESCI trial, non-selective β‑blockers reduced the risk of decompensation or death by 49% (HR 0.51, 95% CI 0.26-0.97; absolute risk 16% vs 27%; NNT ≈ 9) in compensated patients with CSPH ^[70]^A1b. A first decompensation event, , variceal hemorrhage, or overt encephalopathy, marks the watershed. Among patients presenting with ascites as the first event, those with acute decompensation (grade 3 ascites, , or acute kidney injury) have significantly higher transplant‑free mortality than those with non‑acute decompensation (sub‑distribution HR 1.43, 95% CI 1.12-1.82), particularly when hospitalisation is required ^[223]^B2b. Beyond the first decompensation, further decompensation portends a median survival of only 9 months ^[63]^D5.

Recompensation and Its Prognostic Significance

Recompensation, defined by resolution of ascites, encephalopathy, and variceal bleeding with sustained etiological control, occurs in approximately one‑third of decompensated patients. Pooled prevalence is 35% (95% CI 26-45%), highest in HBV‑related cirrhosis (49%) and lowest in alcoholic liver disease (19%) ^[72]^A1a^[191]^B2a. Recompensated patients have significantly lower odds of HCC (OR 0.55, 95% CI 0.35-0.87), death (OR 0.33), and liver‑related death (OR 0.21, 95% CI 0.10-0.45) ^[72]^A1a. Independent predictors include female sex, higher albumin, and lower /Child‑Turcotte‑Pugh scores ^[191]^B2a.

Risk Stratification and Prognostic Factors

Fibrosis stage, assessed by biopsy or non‑invasive tests, is the dominant determinant of liver‑related mortality across aetiologies. In NAFLD, stage 4 fibrosis (cirrhosis) confers an all‑cause mortality RR of 3.42 and a liver‑related mortality RR of 11.13 compared with stage 0 ^[152]^B2a. Prospective data show mortality per 100 person‑years rising from 0.32 (F0-F2) to 0.89 (F3) to 1.76 (F4) ^[154]^B2b. Genetic variants also refine prognosis: PNPLA3 rs738409‑GG homozygotes have a sub‑hazard ratio of 2.30 for major adverse liver outcomes and 2.83 for liver‑related mortality ^[307]^A1a. Lean individuals with MASLD face higher risks of liver‑related events (HR 2.14) and all‑cause mortality (HR 1.26) than non‑lean patients ^[170]^B2b.

Acute‑on‑chronic liver failure (ACLF) represents the most lethal phase. Among patients with acutely decompensated cirrhosis, ACLF prevalence is 35% globally, with 90‑day mortality reaching 58% (range 51-64%) ^[151]^A1a. This mortality has not improved appreciably over recent decades, underscoring the urgent need for better prevention and early transplant referral ^[156]^B2a.

Survival by Disease Stage

Stage	Median Survival	Key Features
Compensated	>15 years	No decompensation; CSPH may be present
Decompensated	~2 years	First event (ascites, bleeding, encephalopathy)
Further decompensated	~9 months	Recurrent complications, ACLF

Based on data from ^[63]^D5^[118]^D5.

Pearl: The transition from compensated to decompensated cirrhosis marks a prognostic watershed, median survival plummets from >15 years to ~2 years, making prevention of the first decompensation event, particularly with β‑blockers in CSPH, the central therapeutic objective.

Special Populations & Pregnancy

▸Pediatric cirrhosis requires weight-based DAA dosing (e.g., glecaprevir/pibrentasvir) and attention to nutritional compromise, MASLD comorbidities, and reversible cirrhotic cardiomyopathy [498, 502, 538].
▸Pregnancy in cirrhosis carries 3-5 fold increased risks of preterm birth and hypertensive complications, but liver-related decompensation is rare (<2%); multidisciplinary planning including pre-conception variceal screening is essential [523, 533].
▸Age is no barrier to effective HCV/HCC treatment in the elderly, but hepatic encephalopathy is often misdiagnosed as dementia; bisphosphonates reduce fracture risk [527, 529, 345, 509].

HY High Yield: In pregnancy with cirrhosis, variceal bleeding risk is highest in the second trimester; pre-conception screening and prophylaxis (beta-blocker or banding) reduce maternal mortality [316, 416].

The prognostic trajectories described above take on distinct contours in special populations, where altered drug metabolism, physiological changes, and comorbid conditions reshape the natural history of cirrhosis and demand tailored strategies.

Pediatrics

Pediatric cirrhosis presents unique diagnostic and therapeutic challenges. Imaging-based noninvasive liver disease assessment (including transient elastography) is likely as accurate in children as in adults for staging fibrosis ^[234]^B2a. In children with HCV, weight-based glecaprevir/pibrentasvir (GLE/PIB) - 250 mg GLE + 100 mg PIB for ≥30 to <45 kg, 200 mg GLE + 80 mg PIB for ≥20 to <30 kg, and 150 mg GLE + 60 mg PIB for 12 to <20 kg - achieves SVR12 rates of 96% ^[498]^C4. Pediatric MASLD carries a mortality rate of 398 per 100,000 person-years (3.4% overall, nearly half liver-related) and a cumulative cirrhosis incidence of 4.7%; high rates of extrahepatic comorbidities (dyslipidemia, , type 2 diabetes) require longitudinal surveillance ^[502]^B2b. In decompensated pediatric cirrhosis, relative adrenal insufficiency (RAI) is present in 54% and independently predicts complications (OR 3.19); the PELD-delta cortisol model outperforms PELD alone for prognostication ^[524]^B2b. Nutritional compromise is especially vulnerable in children, and cirrhotic cardiomyopathy - though reversible after - may prolong intensive care stay ^[532]^D5^[538]^B2b.

Pregnancy

Pregnancies complicated by cirrhosis have more than doubled over the past decade in the US, from 2.5 to 6.5 per 100,000 deliveries ^[523]^B2b. Cirrhosis independently increases the risk of hypertensive complications (OR 4.9 vs no chronic liver disease), (OR 2.8), and preterm birth (OR 3.1) ^[523]^B2b. In a population-based Canadian cohort, cirrhosis was associated with a 10-fold higher risk of intrahepatic (RR 10.64) and a 60% increased risk of preterm birth (RR 1.60), yet liver-related complications occurred in fewer than 2% of women (13% among those with prior decompensation) ^[533]^B2b. carries a 5-fold odds of preterm birth (OR 5.10) and increased risk of preeclampsia (OR 3.65) ^[521]^B2b. Multidisciplinary care, variceal screening before conception, and coordination of delivery in a tertiary center are recommended ^[240]^A1c^[316]^D5^[416]^D5. Assisted reproductive technology outcomes do not differ from controls in women with chronic liver disease ^[528]^B2b. Procedures and medications should not be withheld solely because of pregnancy; risk-benefit assessment is essential ^[240]^A1c.

Elderly

Age alone no longer constitutes a barrier to antiviral therapy. Direct-acting antiviral regimens achieve SVR12 rates exceeding 95% in elderly patients with HCV, with tolerability comparable to younger populations ^[527]^D5^[512]^A1a. In HCC, patients aged ≥70 years undergo radical treatments with survival comparable to younger patients, though they more frequently receive percutaneous ablation rather than resection or ^[529]^B2b. Autoimmune hepatitis in the elderly (≥60 years) more often presents asymptomatically and with established cirrhosis; glucocorticoids are effective and associated with less relapse after treatment withdrawal ^[511]^A1a. is frequently misdiagnosed as dementia in older patients; a trial of cirrhosis-directed therapy is warranted ^[345]^D5. Bisphosphonate use in elderly patients with cirrhosis reduced overall fracture risk (27.5% vs 33.0%, intention-to-treat) in a Medicare cohort, yet treatment continuation was inconsistent ^[509]^B2b.

Immunocompromised and Renal Impairment

In patients with HCV and end-stage renal disease (ESRD) on dialysis, / 400/100 mg daily for 12 weeks yields SVR12 rates of 95% with no unexpected adverse events ^[500]^C4. Glecaprevir/pibrentasvir for 12 weeks in stage 4-5 chronic kidney disease achieves 98% SVR12 (95% CI 95-100) ^[505]^C4. Ombitasvir/paritaprevir/ritonavir with dasabuvir (with or without ribavirin) produced 90% SVR12 in HCV genotype 1 and CKD stage 4-5, though ribavirin required dose reduction due to anemia ^[504]^C4. For hepatitis B, telbivudine was associated with improved estimated glomerular filtration rate (eGFR), particularly in patients at renal risk, yet and remain preferred; on-treatment monitoring of eGFR and phosphorus is recommended ^[501]^B2b^[536]^D5. Baseline serum creatinine is an independent predictor of sepsis in cirrhosis (adjusted OR 1.58 per 1 mg/dL increase) ^[547]^B2b. HCC systemic therapy outcomes in renal impairment, HIV, or autoimmune disease are less well studied; enrollment in dedicated trials is encouraged ^[518]^D5.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Beta-blocker continuation in pregnancy	AASLD/EASL: use if clinically indicated for variceal prevention	Observational caution in /low BP	Limited evidence; individualize	Propranolol/ can be continued in compensated cirrhosis; avoid in advanced decompensation ^[517]^D5

These population-specific considerations underscore the need for targeted prevention and surveillance strategies, which are addressed in the final section.

Pearl: In pregnancy with cirrhosis, variceal bleeding risk peaks in the second trimester; prophylactic non-selective beta-blockade or endoscopic band ligation should be addressed before conception if medium/large varices are present ^[316]^D5^[416]^D5.

Pediatric Glecaprevir/Pibrentasvir Weight-Based Dosing (DORA Study Part 2)

Weight	GLE dose	PIB dose
≥30 to <45 kg	250 mg	100 mg
≥20 to <30 kg	200 mg	80 mg
12 to <20 kg	150 mg	60 mg

Prevention, Screening & Surveillance

▸Universal HBV infant vaccination and birth dose are the most effective primary prevention for cirrhosis [270].
▸HCC surveillance with ultrasound ± AFP every 6 months is recommended for all cirrhosis, but utilization remains below 10% [490,251].
▸Statin therapy reduces HCC risk by 52% (HR 0.52) and all-cause mortality in cirrhosis (OR 0.59) in meta-analyses [489,155].

HY High Yield: HCC surveillance interval: every 6 months, not annually. A 12-month interval misses early-stage tumors that have time to progress beyond curative options [271].

! Warning: Surveillance is underutilized: only 8.8% of at-risk patients receive biannual ultrasound [490]. Consider integrating HCC screening into primary care quality metrics and automated reminders.

Building on the tailored for special populations, prevention of cirrhosis onset and progression begins with population-level interventions targeting its root causes. Primary prevention of cirrhosis requires reducing the burden of chronic viral hepatitis, (ALD), and metabolic dysfunction-associated steatotic liver disease (MASLD). Universal infant hepatitis B virus (HBV) immunization, including birth dose vaccination, is the most effective means to prevent chronic HBV infection ^[270]^D5. HBV vaccine has been available since 1981 and, with variable implementation, has sharply reduced prevalence where adopted ^[176]^D5. For ALD, public health policies such as minimum unit pricing of alcohol and restrictions on alcohol advertising reduce per capita consumption and cirrhosis mortality at the population level ^[552]^D5. For MASLD, lifestyle modification achieving ≥7% weight loss improves steatohepatitis and fibrosis; a and regular physical activity are first-line interventions ^[326]^A1c. Bariatric surgery and incretin-based therapies (e.g., , ) are options for those with obesity or type 2 diabetes ^[57]^A1c. Statin use is associated with a 52% reduction in HCC risk (HR 0.52, 95% CI 0.37-0.72) in observational studies with propensity matching ^[489]^B2a, and with reduced all-cause mortality in established cirrhosis (OR 0.59, 95% CI 0.48-0.71) ^[155]^B2a. also shows HCC risk reduction in MASLD (HR 0.59, 95% CI 0.43-0.81) ^[280]^B2a.

Secondary Prevention and Case-Finding

Secondary prevention focuses on detecting asymptomatic liver disease in at-risk populations. The EASL 2024 guideline recommends case-finding for MASLD with liver fibrosis using a stepwise approach: FIB-4 as initial test, followed by transient elastography or ELF if FIB-4 ≥1.3 ^[57]^A1c. This strategy is recommended in individuals with type 2 diabetes, obesity with ≥2 metabolic risk factors, or abnormal liver enzymes ^[57]^A1c. For HBV, APASL 2026 guidelines advocate universal HBsAg screening in all adults, with linkage to care and antiviral therapy for those meeting treatment criteria (HBV DNA >2000 IU/mL and elevated ALT, or any cirrhosis with detectable HBV DNA) ^[331]^A1c^[132]^A1c. For hepatitis C, the EASL 2025 guidelines emphasize simplified screening algorithms and pangenotypic direct-acting antiviral therapy, which is curative and reduces HCC risk by 34% after adjustment (HR 0.66, 95% CI 0.46-0.93) ^[1]^A1c^[306]^B2b.

Surveillance for Complications

HCC surveillance is recommended for all patients with cirrhosis irrespective of etiology, using abdominal ultrasound with or without alpha-fetoprotein (AFP) every 6 months ^[271]^D5^[251]^B2a. A meta-analysis found ultrasound alone detects early-stage HCC with only 47% sensitivity (95% CI 33%-61%); adding AFP improves sensitivity to 63% (95% CI 48%-75%), though with slightly lower specificity ^[251]^B2a. The GALAD score (gender, age, AFP-L3, AFP, DCP) outperforms AFP alone (AUC 0.78 vs 0.66) for detection within 12 months before clinical diagnosis ^[248]^B2b. Despite guidelines, only 8.8% of at-risk patients receive the recommended biannual surveillance ^[490]^B2a; improving adherence is a critical quality target. Variceal screening by esophagogastroduodenoscopy at diagnosis of cirrhosis is recommended for all patients, with repeat intervals guided by liver stiffness and platelet count ^[65]^A1b. For alcohol-associated cirrhosis, the 5- and 10-year cumulative HCC incidences are 3% and 9% respectively, supporting surveillance in this population ^[210]^B2a.

Patient Education and Recompensation

Key education points include: understanding that abstinence from alcohol in ALD cirrhosis improves survival (HR 0.61) and halves decompensation risk ^[157]^B2a; adherence to surveillance appointments; and awareness of signs of decompensation ( , confusion, jaundice). Recompensation, defined as resolution of ascites, encephalopathy, and jaundice off diuretics/lactulose, occurs in approximately one-third of decompensated patients who achieve etiological control, and is associated with lower odds of HCC (OR 0.55) and death (OR 0.33) ^[72]^A1a.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
AFP addition to ultrasound	AGA/AASLD: consider adding AFP to improve sensitivity ^[251]^B2a	AASLD 2023: ultrasound alone sufficient; AFP adds false positives	Moderate	Individualize based on patient risk and access to CT/MRI for follow-up
Surveillance in alcohol-associated cirrhosis	EASL: recommend 6-monthly ultrasound ^[57]^A1c	Some question cost-effectiveness given 5-year incidence 3% ^[210]^B2a	Low	Surveillance cohorts show higher detection; adherence to guidelines advised

Pearl: The single most impactful preventive measure in cirrhosis is smoking cessation, it reduces HCC risk by approximately 50% in patients with alcohol- or virally-mediated cirrhosis, yet is frequently overlooked in hepatology clinics ^[210]^B2a^[279]^B2a.

Primary Prevention Strategies for Cirrhosis

Strategy	Intervention	Target Population	Strength of Recommendation (Guideline)
HBV vaccination	Universal infant immunization + birth dose	All newborns	A (EASL 2025, APASL 2026) ^[1]^A1c^[331]^A1c
Alcohol policy	Minimum unit pricing, advertising bans	General population	B (ACG 2025) ^[552]^D5
MASLD lifestyle	≥7% weight loss, Mediterranean diet, exercise	Adults with obesity/T2D	A (EASL 2024) ^[57]^A1c
Statin use	Atorvastatin 20-40 mg daily (if no contraindication)	Cirrhosis patients with metabolic risk	C (AGA 2021) ^[326]^A1c
Direct-acting antivirals	Pangenotypic DAA for HCV	HCV viremic patients	A (EASL 2025) ^[1]^A1c

HCC Surveillance Recommendations by Guideline

Guideline (Year)	Modality	Frequency	Target Population
EASL 2025 ^[1]^A1c	Ultrasound ± AFP	6 months	All cirrhosis
AASLD 2023 ^[251]^B2a	Ultrasound with or without AFP	6 months	All cirrhosis
APASL 2026 ^[331]^A1c	Ultrasound + AFP	6 months	HBV cirrhosis
ACG 2025 ^[552]^D5	Ultrasound	6 months	Alcohol-associated cirrhosis

References

[1]
. “EASL Clinical Practice Guidelines on the management of hepatitis B virus infection.” Journal of hepatology (2025). PMID: 40348683 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, History and Evolution of Treatment, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History, Prevention, Screening & Surveillance
[2]
Garcia-Tsao G, Lim JK. “Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program.” The American journal of gastroenterology (2009). PMID: 19455106 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature, Clinical Presentation
[3]
Chang X, Lv C, Wang B et al.. “The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis.” Hepatology (Baltimore, Md.) (2023). PMID: 37611260 ↗
L2RCTCited in: Definition, Classification & Nomenclature, Clinical Presentation
[4]
Bruno BJ, Weavil JC, Ogle J et al.. “Oral LPCN 1148 improves sarcopenia and hepatic encephalopathy in male patients with cirrhosis: A randomized, placebo-controlled phase 2 trial.” Hepatology (Baltimore, Md.) (2025). PMID: 39513970 ↗
L1RCTCited in: Definition, Classification & Nomenclature
[5]
Wattacheril JJ, Abdelmalek MF, Lim JK et al.. “AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.” Gastroenterology (2023). PMID: 37542503 ↗
L5GUIDELINECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prevention, Screening & Surveillance
[6]
Loomba R, Clark VC, Mandorfer M et al.. “Multi-Society Expert Panel Consensus Guidance Regarding Clinical Assessment and Clinical Trial Endpoints in Adults With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease.” Gastroenterology (2025). PMID: 41390004 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature
[7]
Sun Y, Zhou J, Wang L et al.. “New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment.” Hepatology (Baltimore, Md.) (2017). PMID: 28027574 ↗
L5TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature
[8]
Sanyal AJ, Brunt EM, Kleiner DE et al.. “Endpoints and clinical trial design for nonalcoholic steatohepatitis.” Hepatology (Baltimore, Md.) (2011). PMID: 21520200 ↗
L1TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature
[9]
Lai JC, Wong GL, Tse YK et al.. “Histological severity, clinical outcomes and impact of antiviral treatment in indeterminate phase of chronic hepatitis B: A systematic review and meta-analysis.” Journal of hepatology (2024). PMID: 39577468 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature
[10]
Tapper EB, Goldberg D, Parikh ND et al.. “The Liver Cirrhosis Network Cohort Study: Cirrhosis Definition, Study Population, and Endpoints.” The American journal of gastroenterology (2024). PMID: 39018024 ↗
L5TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Clinical Presentation, Acute Management & Decompensation Events, Portal Hypertension & Decompensation Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prevention, Screening & Surveillance
[11]
Lv XH, Lu Q, Deng K et al.. “Prevalence and Characteristics of Covert/Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis: A Systematic Review and Meta-Analysis.” The American journal of gastroenterology (2023). PMID: 37856206 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Clinical Presentation, Liver Transplantation & MELD-Based Candidacy
[12]
Abu-Rumaileh M, Dhoop S, Pace J et al.. “Social Determinants of Health Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Prevalence and Severity: A Systematic Review and Meta-Analysis.” The American journal of gastroenterology (2025). PMID: 40094308 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature
[13]
Kamal S, Khan MA, Seth A et al.. “Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis.” The American journal of gastroenterology (2017). PMID: 28585556 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Clinical Presentation
[14]
Bajaj JS, Cordoba J, Mullen KD et al.. “Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement.” Alimentary pharmacology & therapeutics (2011). PMID: 21306407 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature
[15]
Jeon D, Kim YJ, Kim S et al.. “Liver Cirrhosis Increases the Risk of Herpes Zoster: A Nationwide Population-Based Cohort Study.” The American journal of gastroenterology (2023). PMID: 36746415 ↗
L2COHORTCited in: Definition, Classification & Nomenclature
[16]
Hagström H, Thiele M, Roelstraete B et al.. “Mortality in biopsy-proven alcohol-related liver disease: a population-based nationwide cohort study of 3453 patients.” Gut (2020). PMID: 32220902 ↗
L2COHORTCited in: Definition, Classification & Nomenclature
[17]
Shearer JE, Gonzalez JJ, Min T et al.. “Systematic review: development of a consensus code set to identify cirrhosis in electronic health records.” Alimentary pharmacology & therapeutics (2022). PMID: 35166399 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature
[18]
Lim MC, Quek EJW, Chan TYH et al.. “Systematic Review: Imaging-Based Morphological Criteria for Liver Cirrhosis-A Call to Standardise.” Alimentary pharmacology & therapeutics (2026). PMID: 41882492 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature
[19]
Tsochatzis EA, Senzolo M, Germani G et al.. “Systematic review: portal vein thrombosis in cirrhosis.” Alimentary pharmacology & therapeutics (2009). PMID: 19863496 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism
[20]
Xiao J, Yong JN, Ng CH et al.. “A Meta-Analysis and Systematic Review on the Global Prevalence, Risk Factors, and Outcomes of Coronary Artery Disease in Liver Transplantation Recipients.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2021). PMID: 34626045 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Prevention, Screening & Surveillance
[21]
Narang TK, Ahrens W, Russo MW. “Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2010). PMID: 21031537 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup
[22]
Osman KT, Nayfeh T, Abdelfattah AM et al.. “Secondary Prophylaxis of Gastric Variceal Bleeding: A Systematic Review and Network Meta-Analysis.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2021). PMID: 34860458 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature
[23]
Israelsen M, Thorhauge KH, Andersen P et al.. “Steatotic Liver Disease Classification Is Dynamic, Affecting Clinical Trial Eligibility and Subclass-Specific Treatments.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025). PMID: 40204204 ↗
L2TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature
[24]
Idalsoaga F, Díaz LA, Guizzetti L et al.. “Comparison Between Dynamic Models for Predicting Response to Corticosteroids in Alcohol-Associated Hepatitis: A Global Cohort Study.” Alimentary pharmacology & therapeutics (2025). PMID: 39967231 ↗
L2COHORTCited in: Definition, Classification & Nomenclature
[25]
Aggarwal A, Biswas S, Arora U et al.. “Definitions, Etiologies, and Outcomes of Acute on Chronic Liver Failure: A Systematic Review and Meta-analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 38750869 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature
[26]
Sellers ZM, Assis DN, Paranjape SM et al.. “Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations.” Hepatology (Baltimore, Md.) (2023). PMID: 37934656 ↗
L5OTHERCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, Prognosis & Natural History
[27]
Mironova M, Gopalakrishna H, Koh C et al.. “Portal sinusoidal vascular diseases: Assessment and therapy.” Hepatology (Baltimore, Md.) (2025). PMID: 40194304 ↗
L5OTHERCited in: Definition, Classification & Nomenclature, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Special Populations & Pregnancy
[28]
de Franchis R, Bosch J, Garcia-Tsao G et al.. “Baveno VII - Renewing consensus in portal hypertension.” Journal of hepatology (2021). PMID: 35120736 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management
[29]
Eslam M, Newsome PN, Sarin SK et al.. “A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.” Journal of hepatology (2020). PMID: 32278004 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification
[30]
Nadim MK, Kellum JA, Forni L et al.. “Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting.” Journal of hepatology (2024). PMID: 38527522 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[31]
D'Amico G, Bernardi M, Angeli P. “Towards a new definition of decompensated cirrhosis.” Journal of hepatology (2021). PMID: 34157322 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Portal Hypertension & Decompensation Management
[32]
Hernández-Gea V, Paradis V, Guindi M et al.. “A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF.” Journal of hepatology (2026). PMID: 42191459 ↗
L5GUIDELINECited in: Definition, Classification & Nomenclature, History and Evolution of Treatment, Special Populations & Pregnancy
[33]
Gallage S, Castro RE, Estall J et al.. “EASL position paper on preclinical models of steatotic liver disease.” Journal of hepatology (2026). PMID: 42191458 ↗
L5GUIDELINECited in: Definition, Classification & Nomenclature, History and Evolution of Treatment
[34]
Hernandez-Gea V, Paradis V, Guindi M et al.. “A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF.” Annals of hepatology (2026). PMID: 42191146 ↗
L5GUIDELINECited in: Definition, Classification & Nomenclature, History and Evolution of Treatment, Special Populations & Pregnancy
[35]
Akuta N, Kogiso T, Ikejima K et al.. “Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026.” Journal of gastroenterology (2026). PMID: 42120590 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature
[36]
Akuta N, Kogiso T, Ikejima K et al.. “Evidence-Based Clinical Practice Guidelines for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 2026.” Hepatology research : the official journal of the Japan Society of Hepatology (2026). PMID: 42118685 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature
[37]
Wang C, Felli E, Fallowfield JA et al.. “Vasomics of the liver.” Gut (2025). PMID: 40044498 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Long-term & Definitive Management, Portal Hypertension & Decompensation Management
[38]
Trebicka J, Hernaez R, Shawcross DL et al.. “Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers.” Gut (2024). PMID: 38527788 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[39]
Wu T, Li J, Shao L et al.. “Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure.” Gut (2017). PMID: 28928275 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[40]
Yang AH, Tincopa MA, Tavaglione F et al.. “Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA.” Gut (2024). PMID: 39117370 ↗
L4OTHERCited in: Definition, Classification & Nomenclature
[41]
Wong F, Nadim MK, Kellum JA et al.. “Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis.” Gut (2011). PMID: 21325171 ↗
L5OTHERCited in: Definition, Classification & Nomenclature
[42]
Xue H, Wang L, Sun D et al.. “Associations of Alcohol Consumption and Genetic Predisposition to Hepatic Steatosis With Liver-Related Events: Results From Large Population-Based Cohort Studies.” Gastroenterology (2025). PMID: 40379147 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[43]
Eaton JE, Talwalkar JA, Lazaridis KN et al.. “Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management.” Gastroenterology (2013). PMID: 23827861 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
[44]
Wong F, O'Leary JG, Reddy KR et al.. “New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection.” Gastroenterology (2013). PMID: 23999172 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[45]
Nault JC, Bioulac-Sage P, Zucman-Rossi J. “Hepatocellular benign tumors-from molecular classification to personalized clinical care.” Gastroenterology (2013). PMID: 23485860 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
[46]
Israelsen M, Francque S, Tsochatzis EA et al.. “Steatotic liver disease.” Lancet (London, England) (2024). PMID: 39488409 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[47]
Xie C, Elfeki MA, Dunn W et al.. “Clinical trial endpoints for metabolic dysfunction and alcohol associated steatotic liver disease.” Hepatology international (2026). PMID: 42156626 ↗
L5TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature
[48]
Chahal D, Liu H, Shamatutu C et al.. “Review article: comprehensive analysis of cirrhotic cardiomyopathy.” Alimentary pharmacology & therapeutics (2021). PMID: 33689169 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Liver Transplantation & MELD-Based Candidacy
[49]
Dong V, Nadim MK, Karvellas CJ. “Post-Liver Transplant Acute Kidney Injury.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2021). PMID: 33963666 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, Liver Transplantation & MELD-Based Candidacy, Prognosis & Natural History
[50]
de la Rosa G, Fondevila C, Navasa M. “Liver transplantation in Spain.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2016). PMID: 27197947 ↗
L5OTHERCited in: Definition, Classification & Nomenclature, Acute Management & Decompensation Events, Prevention, Screening & Surveillance
[51]
Acharya C, Bajaj JS. “Hepatic Encephalopathy and Liver Transplantation: The Past, Present, and Future Toward Equitable Access.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2021). PMID: 34018659 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Portal Hypertension & Decompensation Management
[52]
Boike JR, Thornburg BG, Asrani SK et al.. “North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2021). PMID: 34274511 ↗
L1REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management
[53]
Younossi ZM, Kalligeros M, Wong VW et al.. “Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026). PMID: 41950980 ↗
L1OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Severity, Staging & Risk Stratification
[54]
Czaja AJ. “Cholestatic phenotypes of autoimmune hepatitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2013). PMID: 24013108 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Presentation
[55]
Danpanichkul P, Ng CH, Tan DJH et al.. “The Global Burden of Alcohol-associated Cirrhosis and Cancer in Young and Middle-aged Adults.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 38428708 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[56]
Bansal MB, Patton H, Morgan TR et al.. “Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance.” Hepatology (Baltimore, Md.) (2025). PMID: 41201884 ↗
L1GUIDELINECited in: Pathophysiology & Mechanism, Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, History and Evolution of Treatment
[57]
. “EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).” Journal of hepatology (2024). PMID: 38851997 ↗
L1GUIDELINECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Liver Transplantation & MELD-Based Candidacy, Prevention, Screening & Surveillance
[58]
. “EASL Clinical Practice Guidelines on TIPS.” Journal of hepatology (2025). PMID: 40180845 ↗
L1GUIDELINECited in: Pathophysiology & Mechanism, Portal Hypertension & Decompensation Management, History and Evolution of Treatment
[59]
Jophlin LL, Singal AK, Bataller R et al.. “ACG Clinical Guideline: Alcohol-Associated Liver Disease.” The American journal of gastroenterology (2023). PMID: 38174913 ↗
L1GUIDELINECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[60]
Mahmud N, Fricker ZP, McElroy LM et al.. “ACG Clinical Guideline: Perioperative Risk Assessment and Management in Patients With Cirrhosis.” The American journal of gastroenterology (2025). PMID: 40899690 ↗
L1GUIDELINECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, History and Evolution of Treatment
[61]
O'Leary JG, Greenberg CS, Patton HM et al.. “AGA Clinical Practice Update: Coagulation in Cirrhosis.” Gastroenterology (2019). PMID: 30986390 ↗
L5GUIDELINECited in: Pathophysiology & Mechanism, Acute Management & Decompensation Events, Long-term & Definitive Management, History and Evolution of Treatment
[62]
Davis JPE, Lim JK, Francis FF et al.. “AGA Clinical Practice Update on Management of Portal Vein Thrombosis in Patients With Cirrhosis: Expert Review.” Gastroenterology (2024). PMID: 39708000 ↗
L5GUIDELINECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[63]
Garcia-Tsao G, Abraldes JG, Rich NE et al.. “AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.” Gastroenterology (2023). PMID: 37978969 ↗
L5GUIDELINECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[64]
Orman ES, Fortune BE, John BV et al.. “AGA Clinical Practice Update on the Management of Ascites, Volume Overload, and Hyponatremia in Cirrhosis: Expert Review.” Gastroenterology (2025). PMID: 41114681 ↗
L5GUIDELINECited in: Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Liver Transplantation & MELD-Based Candidacy
[65]
Tevethia HV, Pande A, Vijayaraghavan R et al.. “Combination of carvedilol with variceal band ligation in prevention of first variceal bleed in Child-Turcotte-Pugh B and C cirrhosis with high-risk oesophageal varices: the 'CAVARLY TRIAL'.” Gut (2024). PMID: 39067870 ↗
L1RCTCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History, Prevention, Screening & Surveillance
[66]
Liu J, MacNaughtan J, Kerbert AJC et al.. “Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbable, gut-restricted adsorbent in models and patients with cirrhosis.” Gut (2024). PMID: 38621924 ↗
L4RCTCited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, Portal Hypertension & Decompensation Management, History and Evolution of Treatment
[67]
Chalasani N, Abdelmalek MF, Garcia-Tsao G et al.. “Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension.” Gastroenterology (2019). PMID: 31812510 ↗
L1RCTCited in: Pathophysiology & Mechanism, Portal Hypertension & Decompensation Management, History and Evolution of Treatment
[68]
Albillos A, Bañares R, González M et al.. “Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis.” The American journal of gastroenterology (2007). PMID: 17391317 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism
[69]
Jamali T, Raasikh T, Bustamante G et al.. “Outcomes of Exercise Interventions in Patients With Advanced Liver Disease: A Systematic Review of Randomized Clinical Trials.” The American journal of gastroenterology (2022). PMID: 35973182 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism
[70]
Villanueva C, Albillos A, Genescà J et al.. “β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.” Lancet (London, England) (2019). PMID: 30910320 ↗
L1RCTCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Prognosis & Natural History
[71]
Tripathi D, Handley K, Holden L et al.. “Clinical Trial: A Multicentre Randomised Controlled Trial of Carvedilol Versus Variceal Band Ligation in Primary Prevention of Variceal Bleeding in Liver Cirrhosis (CALIBRE Trial).” Alimentary pharmacology & therapeutics (2025). PMID: 40241373 ↗
L1RCTCited in: Pathophysiology & Mechanism, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Prognosis & Natural History, Prevention, Screening & Surveillance
[72]
Goh XE, Goh MX, Chen VL et al.. “Prevalence and Clinical Outcomes of Recompensation in Decompensated Cirrhosis: A Systematic Review and Meta-Analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025). PMID: 40848912 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History, Prevention, Screening & Surveillance
[73]
Turco L, Villanueva C, La Mura V et al.. “Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2019). PMID: 31176013 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism
[74]
Fu Y, Maccioni L, Wang XW et al.. “Alcohol-associated liver cancer.” Hepatology (Baltimore, Md.) (2024). PMID: 38607725 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History, Prevention, Screening & Surveillance
[75]
Smith ML, Wade JB, Wolstenholme J et al.. “Gut microbiome-brain-cirrhosis axis.” Hepatology (Baltimore, Md.) (2023). PMID: 36866864 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management
[76]
Stravitz RT, Fontana RJ, Karvellas C et al.. “Future directions in acute liver failure.” Hepatology (Baltimore, Md.) (2023). PMID: 37183883 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Acute Management & Decompensation Events, History and Evolution of Treatment, Prognosis & Natural History
[77]
Caraceni P, Vargas V, Solà E et al.. “The Use of Rifaximin in Patients With Cirrhosis.” Hepatology (Baltimore, Md.) (2021). PMID: 33421158 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management
[78]
Ojha U, Kim S, Rhee CY et al.. “Endothelial RUNX3 controls LSEC dysfunction and angiocrine LRG1 signaling to prevent liver fibrosis.” Hepatology (Baltimore, Md.) (2024). PMID: 39042837 ↗
L5OTHERCited in: Pathophysiology & Mechanism
[79]
Li S, Zhou B, Xue M et al.. “Macrophage-specific FGF12 promotes liver fibrosis progression in mice.” Hepatology (Baltimore, Md.) (2023). PMID: 35753047 ↗
L5OTHERCited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification
[80]
De Gottardi A, Sempoux C, Berzigotti A. “Porto-sinusoidal vascular disorder.” Journal of hepatology (2022). PMID: 35690264 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup, Portal Hypertension & Decompensation Management
[81]
Andrews TS, Nakib D, Perciani CT et al.. “Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver.” Journal of hepatology (2024). PMID: 38199298 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[82]
Albillos A, de Gottardi A, Rescigno M. “The gut-liver axis in liver disease: Pathophysiological basis for therapy.” Journal of hepatology (2019). PMID: 31622696 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term & Definitive Management
[83]
Taru V, Szabo G, Mehal W et al.. “Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation.” Journal of hepatology (2024). PMID: 38908436 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Portal Hypertension & Decompensation Management
[84]
Robbins J, Halegoua-DeMarzio D, Basu Mallick A et al.. “Liver Transplantation in a Woman with Mahvash Disease.” The New England journal of medicine (2023). PMID: 37991855 ↗
L4CASE_REPORTCited in: Pathophysiology & Mechanism, Diagnosis & Workup, Acute Management & Decompensation Events, Portal Hypertension & Decompensation Management, Liver Transplantation & MELD-Based Candidacy
[85]
Alukal JJ, John S, Thuluvath PJ. “Hyponatremia in Cirrhosis: An Update.” The American journal of gastroenterology (2020). PMID: 33156095 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, Liver Transplantation & MELD-Based Candidacy
[86]
Simonetto DA, Singal AK, Garcia-Tsao G et al.. “ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation.” The American journal of gastroenterology (2020). PMID: 31895720 ↗
L1REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Portal Hypertension & Decompensation Management, Prevention, Screening & Surveillance
[87]
Adebayo D, Neong SF, Wong F. “Refractory Ascites in Liver Cirrhosis.” The American journal of gastroenterology (2019). PMID: 29973706 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Portal Hypertension & Decompensation Management
[88]
Ebert EC, Kierson M, Hagspiel KD. “Gastrointestinal and hepatic manifestations of sarcoidosis.” The American journal of gastroenterology (2008). PMID: 18853979 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup
[89]
Bernardi M, Angeli P, Claria J et al.. “Albumin in decompensated cirrhosis: new concepts and perspectives.” Gut (2020). PMID: 32102926 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[90]
Kong M, Zhou J, Kang A et al.. “Histone methyltransferase Suv39h1 regulates hepatic stellate cell activation and is targetable in liver fibrosis.” Gut (2024). PMID: 38176898 ↗
L5OTHERCited in: Pathophysiology & Mechanism
[91]
Li J, Liang X, Jiang J et al.. “PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF.” Gut (2021). PMID: 33431576 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Long-term & Definitive Management
[92]
Tripathi D, Stanley AJ, Hayes PC et al.. “U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients.” Gut (2015). PMID: 25887380 ↗
L1OTHERCited in: Pathophysiology & Mechanism, Acute Management & Decompensation Events, Portal Hypertension & Decompensation Management
[93]
Schwabe RF, Tabas I, Pajvani UB. “Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis.” Gastroenterology (2020). PMID: 32044315 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Prognosis & Natural History, Special Populations & Pregnancy, Prevention, Screening & Surveillance
[94]
Gao B, Bataller R. “Alcoholic liver disease: pathogenesis and new therapeutic targets.” Gastroenterology (2011). PMID: 21920463 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term & Definitive Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prevention, Screening & Surveillance
[95]
Hirschfield GM, Liu X, Xu C et al.. “Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants.” The New England journal of medicine (2009). PMID: 19458352 ↗
L3OTHERCited in: Pathophysiology & Mechanism
[96]
Ginès P, Krag A, Abraldes JG et al.. “Liver cirrhosis.” Lancet (London, England) (2021). PMID: 34543610 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[97]
Powell EE, Wong VW, Rinella M. “Non-alcoholic fatty liver disease.” Lancet (London, England) (2021). PMID: 33894145 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History, Prevention, Screening & Surveillance
[98]
Schuppan D, Afdhal NH. “Liver cirrhosis.” Lancet (London, England) (2008). PMID: 18328931 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Liver Transplantation & MELD-Based Candidacy, Prognosis & Natural History
[99]
Adams PC, Jeffrey G, Ryan J. “Haemochromatosis.” Lancet (London, England) (2023). PMID: 37121243 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History
[100]
Hartley JL, Davenport M, Kelly DA. “Biliary atresia.” Lancet (London, England) (2009). PMID: 19914515 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Acute Management & Decompensation Events, Liver Transplantation & MELD-Based Candidacy
[101]
von Seth E, Karlsen TH, Tanaka A et al.. “Primary sclerosing cholangitis.” Lancet (London, England) (2026). PMID: 41871593 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, Portal Hypertension & Decompensation Management, Liver Transplantation & MELD-Based Candidacy
[102]
Forner A, Llovet JM, Bruix J. “Hepatocellular carcinoma.” Lancet (London, England) (2012). PMID: 22353262 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Liver Transplantation & MELD-Based Candidacy
[103]
Murga O, Redzanova T, Perez JA et al.. “Efficacy and safety of clipping prior to cyanoacrylate embolization in gastric varices: a single-arm systematic review and meta-analysis.” Surgical endoscopy (2026). PMID: 42377512 ↗
L4SR_OBSCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, Prognosis & Natural History
[104]
Lizaola B, Bonder A, Trivedi HD et al.. “Review article: the diagnostic approach and current management of chylous ascites.” Alimentary pharmacology & therapeutics (2017). PMID: 28892178 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management
[105]
Hercun J, Asif B, Vittal A et al.. “Development of hepatic fibrosis in common variable immunodeficiency-related porto-sinusoidal vascular disorder.” Alimentary pharmacology & therapeutics (2024). PMID: 39090843 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Portal Hypertension & Decompensation Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae)
[106]
Idalsoaga F, Díaz LA, Ayares G et al.. “Review article: Oesophageal disorders in chronic liver disease.” Alimentary pharmacology & therapeutics (2024). PMID: 39082463 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup, Long-term & Definitive Management, Portal Hypertension & Decompensation Management
[107]
Tiede A, Stockhoff L, Rieland H et al.. “No value of non-selective beta-blockers after TIPS-insertion.” Alimentary pharmacology & therapeutics (2024). PMID: 39192553 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Long-term & Definitive Management, Portal Hypertension & Decompensation Management
[108]
Gairing SJ, Müller L, Kloeckner R et al.. “Review article: post-TIPSS hepatic encephalopathy-current knowledge and future perspectives.” Alimentary pharmacology & therapeutics (2022). PMID: 35181894 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Acute Management & Decompensation Events, Portal Hypertension & Decompensation Management
[109]
Kumar A, Sharma P, Arora A. “Review article: portal vein obstruction--epidemiology, pathogenesis, natural history, prognosis and treatment.” Alimentary pharmacology & therapeutics (2014). PMID: 25475582 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, History and Evolution of Treatment
[110]
Taylor SA, Whitington PF. “Neonatal acute liver failure.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2016). PMID: 26946058 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, Liver Transplantation & MELD-Based Candidacy, Special Populations & Pregnancy
[111]
Safdar Z, Bartolome S, Sussman N. “Portopulmonary hypertension: an update.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2012). PMID: 22674534 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[112]
Tranah TH, Kronsten VT, Shawcross DL. “Implications and Management of Cirrhosis-Associated Immune Dysfunction Before and After Liver Transplantation.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2021). PMID: 34738724 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[113]
Day CP. “Treatment of alcoholic liver disease.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2007). PMID: 17969070 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term & Definitive Management
[114]
Mallea J, Bolan C, Cortese C et al.. “Cystic Fibrosis-Associated Liver Disease in Lung Transplant Recipients.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2019). PMID: 31102574 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Portal Hypertension & Decompensation Management
[115]
Hassan S, Anouti A, Tan QKG et al.. “Liver transplantation for pediatric genetic and metabolic disorders.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2024). PMID: 39171972 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, Special Populations & Pregnancy
[116]
Moctezuma-Velazquez C, Kalainy S, Abraldes JG. “Beta-blockers in patients with advanced liver disease: Has the dust settled?” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2017). PMID: 28590564 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Portal Hypertension & Decompensation Management
[117]
Charlton M. “Obesity, hyperlipidemia, and metabolic syndrome.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2009). PMID: 19877024 ↗
L5OTHERCited in: Pathophysiology & Mechanism, Diagnosis & Workup
[118]
Abraldes JG, Caraceni P, Ghabril M et al.. “Update in the Treatment of the Complications of Cirrhosis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2023). PMID: 36972759 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[119]
Abushamat LA, Shah PA, Eckel RH et al.. “The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 38367743 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term & Definitive Management
[120]
Asrani SK, Simonetto DA, Kamath PS. “Acute-on-Chronic Liver Failure.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2015). PMID: 26188138 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae)
[121]
Mindikoglu AL, Pappas SC. “New Developments in Hepatorenal Syndrome.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2017). PMID: 28602971 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Liver Transplantation & MELD-Based Candidacy
[122]
Garcia-Pagán JC, Barrufet M, Cardenas A et al.. “Management of gastric varices.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2013). PMID: 23899955 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Portal Hypertension & Decompensation Management
[123]
Xu X, Jiang M, Fu Y et al.. “The effect of TIPS on the development of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis.” BMC gastroenterology (2026). PMID: 42366368 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Portal Hypertension & Decompensation Management, Prognosis & Natural History
[124]
Cervantes-Alvarez E, Gu W, Byrtus J et al.. “Short-term mortality is reduced and low grade ACLF reversed by TIPS in patients with fluid overload: a case-control study.” Clinical and translational gastroenterology (2026). PMID: 42407083 ↗
L3CASE_CONTROLCited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae)
[125]
Al Ghnaimat A, Ahmed NAT, Al-Azzawi OM et al.. “SGLT-2 Inhibitors for Ascites Management in Liver Cirrhosis: A Systematic Review and Meta-Analysis of Available Evidence.” International journal of hepatology (2026). PMID: 42358872 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Acute Management & Decompensation Events, Portal Hypertension & Decompensation Management
[126]
Tarek M, Ali AA, Biomy R et al.. “Model-informed dose optimization of carvedilol and nebivolol in cirrhotic patients: a pilot randomized clinical study.” Scientific reports (2026). PMID: 42297946 ↗
L1RCTCited in: Pathophysiology & Mechanism
[127]
Abow-Mohamed I, Alabdulkarim B, Zhao X et al.. “Low muscle mass predicts liver-related outcomes in cirrhosis, independent of portal hypertension: A retrospective cohort study.” Canadian liver journal (2026). PMID: 42404990 ↗
L3COHORTCited in: Pathophysiology & Mechanism, Portal Hypertension & Decompensation Management, Liver Transplantation & MELD-Based Candidacy
[128]
Thöne P, Saltini D, Calvão J et al.. “Changes in SSM Assessed via 100 Hz-VCTE Are Associated With Acute HVPG-Response to i.v. Propranolol: A European Multicentre Study.” Liver international : official journal of the International Association for the Study of the Liver (2026). PMID: 42424093 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Portal Hypertension & Decompensation Management
[129]
Raya Tonetti F, Han H, Fondevila MF et al.. “Non-absorbable antibiotics worsen alcohol-associated liver disease in gastric acid-suppressed mice.” Gut microbes (2026). PMID: 42421214 ↗
L5OTHERCited in: Pathophysiology & Mechanism, Portal Hypertension & Decompensation Management
[130]
. “EASL Clinical Practice Guidelines on nutrition in chronic liver disease.” Journal of hepatology (2018). PMID: 30144956 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[131]
. “EASL Clinical Practice Guidelines on acute-on-chronic liver failure.” Journal of hepatology (2023). PMID: 37364789 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, History and Evolution of Treatment, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[132]
. “EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.” Journal of hepatology (2017). PMID: 28427875 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Acute Management & Decompensation Events, Long-term & Definitive Management, History and Evolution of Treatment, Prevention, Screening & Surveillance
[133]
Singal AK, Wong RJ, Dasarathy S et al.. “ACG Clinical Guideline: Malnutrition and Nutritional Recommendations in Liver Disease.” The American journal of gastroenterology (2025). PMID: 40314389 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[134]
Singal AK, Bataller R, Ahn J et al.. “ACG Clinical Guideline: Alcoholic Liver Disease.” The American journal of gastroenterology (2018). PMID: 29336434 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, History and Evolution of Treatment, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History, Prevention, Screening & Surveillance
[135]
Kumar M, Venishetty S, Jindal A et al.. “Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis: A randomized controlled trial.” Hepatology (Baltimore, Md.) (2024). PMID: 38441903 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, History and Evolution of Treatment, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[136]
Long MT, Noureddin M, Lim JK. “AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.” Gastroenterology (2022). PMID: 35842345 ↗
L5GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, History and Evolution of Treatment, Prognosis & Natural History, Prevention, Screening & Surveillance
[137]
Khajuria R, Jindal A, Sharma MK et al.. “Efficacy and Safety of Carvedilol in Cirrhosis Patients With New-Onset Uncomplicated Ascites Without High-Risk Esophageal Varices (CARVE-AS Trial).” The American journal of gastroenterology (2025). PMID: 40689908 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[138]
Kulkarni AV, Avadhanam M, Karandikar P et al.. “Antibiotics With or Without Rifaximin for Acute Hepatic Encephalopathy in Critically Ill Patients With Cirrhosis: A Double-Blind, Randomized Controlled (ARiE) Trial.” The American journal of gastroenterology (2023). PMID: 37942950 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[139]
Chirapongsathorn S, Chang A, Malikhao S et al.. “One versus five days of octreotide infusion for acute esophageal variceal bleeding: a randomized controlled trial.” The American journal of gastroenterology (2025). PMID: 41090987 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[140]
Sharma BC, Sharma P, Lunia MK et al.. “A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.” The American journal of gastroenterology (2013). PMID: 23877348 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[141]
Younossi ZM, Koenig AB, Abdelatif D et al.. “Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.” Hepatology (Baltimore, Md.) (2016). PMID: 26707365 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History, Special Populations & Pregnancy, Prevention, Screening & Surveillance
[142]
Terrault N, Chen YC, Izumi N et al.. “Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.” Gastroenterology (2018). PMID: 29778606 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, History and Evolution of Treatment
[143]
Harrison SA, Bedossa P, Guy CD et al.. “A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.” The New England journal of medicine (2024). PMID: 38324483 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Long-term & Definitive Management, History and Evolution of Treatment
[144]
Bass NM, Mullen KD, Sanyal A et al.. “Rifaximin treatment in hepatic encephalopathy.” The New England journal of medicine (2010). PMID: 20335583 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae)
[145]
García-Pagán JC, Caca K, Bureau C et al.. “Early use of TIPS in patients with cirrhosis and variceal bleeding.” The New England journal of medicine (2010). PMID: 20573925 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[146]
Afdhal NH, Giannini EG, Tayyab G et al.. “Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.” The New England journal of medicine (2012). PMID: 22913681 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification
[147]
Feld JJ, Jacobson IM, Hézode C et al.. “Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.” The New England journal of medicine (2015). PMID: 26571066 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors
[148]
Roerecke M, Vafaei A, Hasan OSM et al.. “Alcohol Consumption and Risk of Liver Cirrhosis: A Systematic Review and Meta-Analysis.” The American journal of gastroenterology (2019). PMID: 31464740 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[149]
Younossi ZM, Ratziu V, Loomba R et al.. “Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.” Lancet (London, England) (2019). PMID: 31813633 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, History and Evolution of Treatment
[150]
Caraceni P, Riggio O, Angeli P et al.. “Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.” Lancet (London, England) (2018). PMID: 29861076 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[151]
Mezzano G, Juanola A, Cardenas A et al.. “Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis.” Gut (2021). PMID: 33436495 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[152]
Taylor RS, Taylor RJ, Bayliss S et al.. “Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.” Gastroenterology (2020). PMID: 32027911 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[153]
Flamm SL, Wong F, Ahn J et al.. “AGA Clinical Practice Update on the Evaluation and Management of Acute Kidney Injury in Patients With Cirrhosis: Expert Review.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2022). PMID: 36075500 ↗
L5GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Liver Transplantation & MELD-Based Candidacy
[154]
Sanyal AJ, Van Natta ML, Clark J et al.. “Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.” The New England journal of medicine (2021). PMID: 34670043 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Portal Hypertension & Decompensation Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[155]
Moraes BF, Leite GAPD, Silveira IB et al.. “Statin Therapy Independently Reduces Mortality and Liver Complications in Patients With Cirrhosis: An Updated Systematic Review and Meta-Analysis.” Alimentary pharmacology & therapeutics (2026). PMID: 41518144 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Prevention, Screening & Surveillance
[156]
Siddique MR, Haque M, Idalsoaga F et al.. “Meta-Analysis: Mortality Trends and Risk Factors in Severe Alcohol-Associated Hepatitis.” Alimentary pharmacology & therapeutics (2025). PMID: 40974371 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Liver Transplantation & MELD-Based Candidacy, Prognosis & Natural History
[157]
Lim WH, Tay P, Ng CH et al.. “Meta-analysis: Prevalence and impact of alcohol abstinence in alcohol-associated cirrhosis.” Alimentary pharmacology & therapeutics (2024). PMID: 38303565 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Staging & Risk Stratification, Prevention, Screening & Surveillance
[158]
Hitawala AA, Gopalakrishna H, Mironova M et al.. “Meta-analysis: Incidence of cirrhosis and hepatocellular carcinoma in patients with Fontan palliation.” Alimentary pharmacology & therapeutics (2024). PMID: 38497159 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prevention, Screening & Surveillance
[159]
Owrangi S, Paik JM, Golabi P et al.. “Meta-Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.” Alimentary pharmacology & therapeutics (2024). PMID: 39697043 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Prognosis & Natural History
[160]
Silva AC, Nogueira P, Machado MV. “Hepatic steatosis after liver transplantation: a systematic review and meta-analysis.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2023). PMID: 36735478 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification
[161]
Harrison SA, Loomba R, Dubourg J et al.. “Clinical Trial Landscape in NASH.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2023). PMID: 37059159 ↗
L5TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History, Prevention, Screening & Surveillance
[162]
Zamani M, Alizadeh-Tabari S, Ajmera V et al.. “Global Prevalence of Advanced Liver Fibrosis and Cirrhosis in the General Population: A Systematic Review and Meta-analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 39209202 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[163]
Liang TJ. “Hepatitis B: the virus and disease.” Hepatology (Baltimore, Md.) (2009). PMID: 19399811 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Long-term & Definitive Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History, Prevention, Screening & Surveillance
[164]
Castera L, Cusi K. “Diabetes and cirrhosis: Current concepts on diagnosis and management.” Hepatology (Baltimore, Md.) (2023). PMID: 36631005 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[165]
Estes C, Razavi H, Loomba R et al.. “Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.” Hepatology (Baltimore, Md.) (2017). PMID: 28802062 ↗
L2REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prevention, Screening & Surveillance
[166]
Fabrellas N, Carol M, Palacio E et al.. “Nursing Care of Patients With Cirrhosis: The LiverHope Nursing Project.” Hepatology (Baltimore, Md.) (2020). PMID: 31944340 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Acute Management & Decompensation Events, Long-term & Definitive Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae)
[167]
Devarbhavi H, Asrani SK, Arab JP et al.. “Global burden of liver disease: 2023 update.” Journal of hepatology (2023). PMID: 36990226 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History, Prevention, Screening & Surveillance
[168]
Byrne CD, Targher G. “NAFLD: a multisystem disease.” Journal of hepatology (2015). PMID: 25920090 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History, Prevention, Screening & Surveillance
[169]
Trivedi PJ, Hirschfield GM. “Recent advances in clinical practice: epidemiology of autoimmune liver diseases.” Gut (2021). PMID: 34266966 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[170]
Huo Z, Chen Y, Huang Y et al.. “Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts.” Gut (2026). PMID: 41093635 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Prognosis & Natural History, Prevention, Screening & Surveillance
[171]
Simon TG, Roelstraete B, Khalili H et al.. “Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.” Gut (2020). PMID: 33037056 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup
[172]
Chen X, Liu X, Xu T et al.. “Engineered virus-hunter vaccine overcomes HBV immune tolerance.” Gut (2026). PMID: 41198172 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Prevention, Screening & Surveillance
[173]
Toh MR, Wong EYT, Wong SH et al.. “Global Epidemiology and Genetics of Hepatocellular Carcinoma.” Gastroenterology (2023). PMID: 36738977 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prevention, Screening & Surveillance
[174]
Castera L, Friedrich-Rust M, Loomba R. “Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.” Gastroenterology (2019). PMID: 30660725 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
[175]
Alegre-Díaz J, Herrington W, López-Cervantes M et al.. “Diabetes and Cause-Specific Mortality in Mexico City.” The New England journal of medicine (2016). PMID: 27959614 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[176]
Trépo C, Chan HL, Lok A. “Hepatitis B virus infection.” Lancet (London, England) (2014). PMID: 24954675 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Prevention, Screening & Surveillance
[177]
Elborn JS. “Cystic fibrosis.” Lancet (London, England) (2016). PMID: 27140670 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
[178]
Kasmikha L, Chen X, Serper M et al.. “Systematic Review and Meta-Analysis of Lactulose for the Prevention and Treatment of Hepatic Encephalopathy.” Liver international : official journal of the International Association for the Study of the Liver (2026). PMID: 42402719 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History, Prevention, Screening & Surveillance
[179]
de Brito Nunes M, Knecht M, Schropp J et al.. “Post-Banding Ulcer Bleeding After Endoscopic Ligation: Incidence, Risk Factors and Outcomes in Patients With Cirrhosis.” Alimentary pharmacology & therapeutics (2025). PMID: 41368816 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors
[180]
Tan J, Surti B, Saab S. “Pregnancy and cirrhosis.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2008). PMID: 18668664 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Acute Management & Decompensation Events, Long-term & Definitive Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History, Special Populations & Pregnancy
[181]
Mazurak VC, Tandon P, Montano-Loza AJ. “Nutrition and the transplant candidate.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2017). PMID: 29072825 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[182]
Trebicka J, Sundaram V, Moreau R et al.. “Liver Transplantation for Acute-on-Chronic Liver Failure: Science or Fiction?” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2020). PMID: 32365422 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[183]
Durand F, Antoine C, Soubrane O. “Liver Transplantation in France.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2019). PMID: 30697904 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History, Prevention, Screening & Surveillance
[184]
Liu H, Jayakumar S, Traboulsi M et al.. “Cirrhotic cardiomyopathy: Implications for liver transplantation.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2017). PMID: 28407402 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae)
[185]
Lian LY, Chen QF, Xia T et al.. “Trajectory of liver-related events following incident cardiovascular disease in MASLD: A 15-year population-based cohort study.” Metabolism: clinical and experimental (2026). PMID: 42431256 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Acute Management & Decompensation Events, Long-term & Definitive Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prevention, Screening & Surveillance
[186]
Jiang MY, Wu JY, Lee YC et al.. “Direct-Acting Antiviral Therapy and Long-Term Outcomes in Dialysis Patients With Hepatitis C: A Real-world Cohort Study.” Open forum infectious diseases (2026). PMID: 42415732 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[187]
King J, Campbell C, Bains V et al.. “Aetiology and outcomes of emergency admissions for chronic liver disease in England, 2012-2019: a national cohort study using administrative data.” BMJ open gastroenterology (2026). PMID: 42373198 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Prognosis & Natural History
[188]
Younossi ZM, Wong G, Anstee QM et al.. “The Global Burden of Liver Disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2023). PMID: 37121527 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History, Prevention, Screening & Surveillance
[189]
Moon AM, Singal AG, Tapper EB. “Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2019). PMID: 31401364 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History, Prevention, Screening & Surveillance
[190]
Adams PC, Ryan JD. “Diagnosis and Treatment of Hemochromatosis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025). PMID: 39889898 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Long-term & Definitive Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[191]
Wang JY, Zhang MX, Su SH et al.. “Etiology-related differences in hepatic recompensation in decompensated cirrhosis under Baveno VII criteria: a systematic review and meta-analysis.” BMC gastroenterology (2026). PMID: 42420862 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Liver Transplantation & MELD-Based Candidacy, Prognosis & Natural History
[192]
Süffert LC, Pergher EAB, de Abreu HS et al.. “Burden and distribution of multidrug-resistant bacteria among hospitalized patients with cirrhosis: A systematic review and meta-analysis.” Clinics and research in hepatology and gastroenterology (2026). PMID: 42379292 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
[193]
. “EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.” Journal of hepatology (2017). PMID: 28427765 ↗
L1GUIDELINECited in: Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management
[194]
. “EASL Clinical Practice Guidelines on hepatitis delta virus.” Journal of hepatology (2023). PMID: 37364791 ↗
L1GUIDELINECited in: Clinical Presentation, Acute Management & Decompensation Events, Long-term & Definitive Management, History and Evolution of Treatment, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prevention, Screening & Surveillance
[195]
. “EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update.” Journal of hepatology (2021). PMID: 34166721 ↗
L1GUIDELINECited in: Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
[196]
. “EASL Clinical Practice Guidelines on vascular diseases of the liver.” Journal of hepatology (2025). PMID: 41224629 ↗
L1GUIDELINECited in: Clinical Presentation
[197]
Puente Á, Turón F, Martínez J et al.. “Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study.” Journal of hepatology (2025). PMID: 40691992 ↗
L1RCTCited in: Clinical Presentation, Portal Hypertension & Decompensation Management, Liver Transplantation & MELD-Based Candidacy
[198]
Hirschfield GM, Dyson JK, Alexander GJM et al.. “The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.” Gut (2018). PMID: 29593060 ↗
L1GUIDELINECited in: Clinical Presentation, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History
[199]
Villanueva C, Torres F, Sarin SK et al.. “Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.” Journal of hepatology (2022). PMID: 35661713 ↗
L1SR_OBSCited in: Clinical Presentation, Liver Transplantation & MELD-Based Candidacy
[200]
Larrue H, D'Amico G, Olivas P et al.. “TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis.” Journal of hepatology (2023). PMID: 37141993 ↗
L2SR_OBSCited in: Clinical Presentation, Liver Transplantation & MELD-Based Candidacy
[201]
Di Bisceglie AM, Shiffman ML, Everson GT et al.. “Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.” The New England journal of medicine (2008). PMID: 19052125 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History, Prevention, Screening & Surveillance
[202]
Serper M, Kaplan DE, Taddei TH et al.. “Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: A national cohort study.” Hepatology (Baltimore, Md.) (2022). PMID: 35984731 ↗
L2COHORTCited in: Clinical Presentation
[203]
Serper M, Tang H, Zhang S et al.. “Clinical outcomes and care for spontaneous bacterial peritonitis: A national cohort study.” Hepatology (Baltimore, Md.) (2025). PMID: 39879583 ↗
L2COHORTCited in: Clinical Presentation
[204]
Elhence H, Dodge JL, Kahn JA et al.. “Characteristics and Outcomes Among US Commercially Insured Transgender Adults With Cirrhosis: A National Cohort Study.” The American journal of gastroenterology (2024). PMID: 38916204 ↗
L2COHORTCited in: Clinical Presentation
[205]
Ajmera V, Kim BK, Yang K et al.. “Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants.” Gastroenterology (2022). PMID: 35788349 ↗
L1SR_OBSCited in: Clinical Presentation
[206]
Premkumar M, Dhiman RK, Duseja A et al.. “Recompensation of Chronic Hepatitis C-Related Decompensated Cirrhosis Following Direct-Acting Antiviral Therapy: Prospective Cohort Study From a Hepatitis C Virus Elimination Program.” Gastroenterology (2024). PMID: 39181168 ↗
L4COHORTCited in: Clinical Presentation, Liver Transplantation & MELD-Based Candidacy
[207]
Harrison SA, Ratziu V, Anstee QM et al.. “Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis.” Alimentary pharmacology & therapeutics (2023). PMID: 37786277 ↗
L5TRIAL_NONRANDOMCited in: Clinical Presentation, Diagnosis & Workup, History and Evolution of Treatment
[208]
Shung DL, Laine L. “Review article: Upper gastrointestinal bleeding - review of current evidence and implications for management.” Alimentary pharmacology & therapeutics (2024). PMID: 38517201 ↗
L1SR_OBSCited in: Clinical Presentation, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management
[209]
Villanueva C, Sapena V, Lo GH et al.. “Improving primary prophylaxis of variceal bleeding by adapting therapy to the clinical stage of cirrhosis. A competing-risk meta-analysis of individual participant data.” Alimentary pharmacology & therapeutics (2023). PMID: 38108646 ↗
L1SR_OBSCited in: Clinical Presentation, Long-term & Definitive Management
[210]
Huang DQ, Tan DJH, Ng CH et al.. “Hepatocellular Carcinoma Incidence in Alcohol-Associated Cirrhosis: Systematic Review and Meta-analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2022). PMID: 35940513 ↗
L2SR_OBSCited in: Clinical Presentation, Prevention, Screening & Surveillance
[211]
Clària J, Stauber RE, Coenraad MJ et al.. “Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure.” Hepatology (Baltimore, Md.) (2016). PMID: 27483394 ↗
L3OTHERCited in: Clinical Presentation, Acute Management & Decompensation Events
[212]
Guo C, Liu Z, Fan H et al.. “Machine-learning-based plasma metabolomic profiles for predicting long-term complications of cirrhosis.” Hepatology (Baltimore, Md.) (2024). PMID: 38630500 ↗
L2OTHERCited in: Clinical Presentation
[213]
Jiang P, Jia H, Qian X et al.. “Single-cell RNA sequencing reveals the immunoregulatory roles of PegIFN-α in patients with chronic hepatitis B.” Hepatology (Baltimore, Md.) (2023). PMID: 37368993 ↗
L4OTHERCited in: Clinical Presentation
[214]
De Martin E, Fulgenzi CAM, Celsa C et al.. “Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events.” Gut (2025). PMID: 39658265 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History, Prevention, Screening & Surveillance
[215]
Smets L, Viola MF, Boesch M et al.. “Intestinal blood vessel-associated macrophages and gut-vascular barrier dysfunction in cirrhosis.” Gut (2025). PMID: 41253495 ↗
L5OTHERCited in: Clinical Presentation
[216]
Moreau R, Jalan R, Gines P et al.. “Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.” Gastroenterology (2013). PMID: 23474284 ↗
L1OTHERCited in: Clinical Presentation
[217]
Camilleri M, Malhi H, Acosta A. “Gastrointestinal Complications of Obesity.” Gastroenterology (2017). PMID: 28192107 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[218]
Satre DD, Taj L, Wong RJ et al.. “A randomized controlled trial of stepped treatment to reduce unhealthy alcohol use in patients with chronic liver disease.” Hepatology (Baltimore, Md.) (2026). PMID: 42340251 ↗
L1RCTCited in: Clinical Presentation
[219]
Koch DG, Caplan M, Reuben A. “Pulmonary hypertension after liver transplantation: case presentation and review of the literature.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2009). PMID: 19326402 ↗
L4CASE_REPORTCited in: Clinical Presentation
[220]
Tsochatzis EA, Bosch J, Burroughs AK. “Liver cirrhosis.” Lancet (London, England) (2014). PMID: 24480518 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Acute Management & Decompensation Events, Long-term & Definitive Management, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae)
[221]
Hughes SA, Wedemeyer H, Harrison PM. “Hepatitis delta virus.” Lancet (London, England) (2011). PMID: 21511329 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[222]
Liaw YF, Chu CM. “Hepatitis B virus infection.” Lancet (London, England) (2009). PMID: 19217993 ↗
L5OTHERCited in: Clinical Presentation
[223]
Simonis L, Balcar L, Schedlbauer A et al.. “Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non-Acute Decompensation.” Alimentary pharmacology & therapeutics (2025). PMID: 40719565 ↗
L2OTHERCited in: Clinical Presentation, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Portal Hypertension & Decompensation Management, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History
[224]
Calzadilla Bertot L, Sòria A, Jimenez-Masip A et al.. “Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease-Related Cirrhosis: The ABID-LSM Model.” Alimentary pharmacology & therapeutics (2025). PMID: 40491328 ↗
L2OTHERCited in: Clinical Presentation
[225]
Seth AK, Badminton MN, Mirza D et al.. “Liver transplantation for porphyria: who, when, and how?” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2007). PMID: 17763398 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[226]
King JJ, Halliday N, Mantovani A et al.. “Bacterascites confers poor patient prognosis beyond MELD prediction.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2023). PMID: 36691984 ↗
L2OTHERCited in: Clinical Presentation
[227]
Shankar N, Kuo L, Krugliak Cleveland N et al.. “Point-of-Care Ultrasound in Gastroenterology and Hepatology.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025). PMID: 39793722 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[228]
Gidener T, Ahmed OT, Larson JJ et al.. “Liver Stiffness by Magnetic Resonance Elastography Predicts Future Cirrhosis, Decompensation, and Death in NAFLD.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2020). PMID: 33010409 ↗
L2OTHERCited in: Clinical Presentation
[229]
Acharya C, Bajaj JS. “Altered Microbiome in Patients With Cirrhosis and Complications.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2018). PMID: 30099098 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[230]
Bălăceanu LA, Iacobescu CG, Grigorescu IV et al.. “Changing Etiological Patterns and Predictors of In-Hospital Mortality in Decompensated Cirrhosis: A 10-Year Cohort Study Before and After COVID-19.” Diseases (Basel, Switzerland) (2026). PMID: 42346295 ↗
L2COHORTCited in: Clinical Presentation, Severity, Staging & Risk Stratification
[231]
Au M, Mah XJ, Yeoh SW et al.. “A prospective study of 12-month survival of patients with cirrhosis admitted to intensive care.” Internal medicine journal (2026). PMID: 42333749 ↗
L2COHORTCited in: Clinical Presentation, Acute Management & Decompensation Events, Liver Transplantation & MELD-Based Candidacy
[232]
Chen L, Shi G, Huang Y et al.. “Anesthesia management for laparoscopic cholecystectomy and choledochoscopy-assisted intrahepatic bile duct stone extraction in a patient with situs inversus totalis, decompensated cirrhosis, and respiratory insufficiency: a case report.” BMC anesthesiology (2026). PMID: 42286451 ↗
L4CASE_REPORTCited in: Clinical Presentation
[233]
Zhang L, Strotzer QD, Kupke LS et al.. “Stereotactic Microwave Ablation of Early-Stage Hepatocellular Carcinoma in Patients with Transjugular Intrahepatic Portosystemic Shunts: A Matched Case-Control Study.” Cardiovascular and interventional radiology (2026). PMID: 42397406 ↗
L3CASE_CONTROLCited in: Clinical Presentation, Severity, Staging & Risk Stratification, Portal Hypertension & Decompensation Management, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae)
[234]
Duarte-Rojo A, Taouli B, Leung DH et al.. “Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline.” Hepatology (Baltimore, Md.) (2024). PMID: 38489521 ↗
L2GUIDELINECited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Special Populations & Pregnancy
[235]
. “EASL Clinical Practice Guidelines on haemochromatosis.” Journal of hepatology (2022). PMID: 35662478 ↗
L1GUIDELINECited in: Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, History and Evolution of Treatment, Prevention, Screening & Surveillance
[236]
. “EASL Clinical Practice Guidelines on the management of autoimmune hepatitis.” Journal of hepatology (2025). PMID: 40348684 ↗
L1GUIDELINECited in: Diagnosis & Workup, Acute Management & Decompensation Events, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prevention, Screening & Surveillance
[237]
Bajaj JS, Jakab SS, Jesudian AB et al.. “ACG Clinical Guideline: Hepatic Encephalopathy.” The American journal of gastroenterology (2026). PMID: 41773757 ↗
L1GUIDELINECited in: Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae)
[238]
Aithal GP, Palaniyappan N, China L et al.. “Guidelines on the management of ascites in cirrhosis.” Gut (2020). PMID: 33067334 ↗
L1GUIDELINECited in: Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, History and Evolution of Treatment
[239]
Gleeson D, Bornand R, Brownlee A et al.. “British Society of Gastroenterology guidelines for diagnosis and management of autoimmune hepatitis.” Gut (2025). PMID: 40169244 ↗
L1GUIDELINECited in: Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, History and Evolution of Treatment
[240]
Kothari S, Afshar Y, Friedman LS et al.. “AGA Clinical Practice Update on Pregnancy-Related Gastrointestinal and Liver Disease: Expert Review.” Gastroenterology (2024). PMID: 39140906 ↗
L1GUIDELINECited in: Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Liver Transplantation & MELD-Based Candidacy, Special Populations & Pregnancy
[241]
Sherman KE, Goodman ZD, Sullivan ST et al.. “Liver biopsy in cirrhotic patients.” The American journal of gastroenterology (2007). PMID: 17324127 ↗
L4RCTCited in: Diagnosis & Workup
[242]
Xiao G, Zhu S, Xiao X et al.. “Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis.” Hepatology (Baltimore, Md.) (2017). PMID: 28586172 ↗
L1SR_OBSCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification
[243]
Indre MG, Leucuta DC, Lupsor-Platon M et al.. “Diagnostic accuracy of 2D-SWE ultrasound for liver fibrosis assessment in MASLD: A multilevel random effects model meta-analysis.” Hepatology (Baltimore, Md.) (2024). PMID: 39689354 ↗
L1SR_OBSCited in: Diagnosis & Workup
[244]
Noureddin M, Rinella ME, Chalasani NP et al.. “Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.” The New England journal of medicine (2025). PMID: 40341827 ↗
L1RCTCited in: Diagnosis & Workup, Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History
[245]
Burton BK, Balwani M, Feillet F et al.. “A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency.” The New England journal of medicine (2015). PMID: 26352813 ↗
L1RCTCited in: Diagnosis & Workup
[246]
Salkic NN, Jovanovic P, Hauser G et al.. “FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.” The American journal of gastroenterology (2014). PMID: 24535095 ↗
L1SR_OBSCited in: Diagnosis & Workup
[247]
Yoosuf S, Singh P, Khaitan A et al.. “Prevalence of Celiac Disease in Patients With Liver Diseases: A Systematic Review and Meta-Analyses.” The American journal of gastroenterology (2022). PMID: 36599134 ↗
L1SR_OBSCited in: Diagnosis & Workup
[248]
Marsh TL, Parikh ND, Roberts LR et al.. “A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis.” Gastroenterology (2024). PMID: 39293548 ↗
L2TRIAL_NONRANDOMCited in: Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prevention, Screening & Surveillance
[249]
Poordad F, Lawitz E, Kowdley KV et al.. “Exploratory study of oral combination antiviral therapy for hepatitis C.” The New England journal of medicine (2013). PMID: 23281975 ↗
L2TRIAL_NONRANDOMCited in: Diagnosis & Workup
[250]
Mózes FE, Lee JA, Selvaraj EA et al.. “Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.” Gut (2021). PMID: 34001645 ↗
L1SR_OBSCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification
[251]
Tzartzeva K, Obi J, Rich NE et al.. “Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis.” Gastroenterology (2018). PMID: 29425931 ↗
L2SR_OBSCited in: Diagnosis & Workup, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prevention, Screening & Surveillance
[252]
Serra-Burriel M, Juanola A, Serra-Burriel F et al.. “Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study.” Lancet (London, England) (2023). PMID: 37572680 ↗
L2COHORTCited in: Diagnosis & Workup
[253]
Butaye E, Somers N, Grossar L et al.. “Systematic review: Glycomics as diagnostic markers for hepatocellular carcinoma.” Alimentary pharmacology & therapeutics (2023). PMID: 37877758 ↗
L2SR_OBSCited in: Diagnosis & Workup
[254]
Mazhar A, Russo MW. “Systematic review: non-invasive prognostic tests for primary sclerosing cholangitis.” Alimentary pharmacology & therapeutics (2021). PMID: 33608929 ↗
L2SR_OBSCited in: Diagnosis & Workup
[255]
Ng CH, Tan DJH, Lim XC et al.. “A Diagnostic Test Meta-Analysis Evaluating Imaging-Based and Blood Biomarker-Based Assessment Tools for Fibrosis After Liver Transplantation.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2021). PMID: 34714966 ↗
L2SR_OBSCited in: Diagnosis & Workup
[256]
Schmeltzer PA, Russo MW. “Clinical narrative: autoimmune hepatitis.” The American journal of gastroenterology (2018). PMID: 29755125 ↗
L5CASE_REPORTCited in: Diagnosis & Workup
[257]
Siddiqi H, Huang DQ, Mittal N et al.. “Repeatability of vibration-controlled transient elastography versus magnetic resonance elastography in patients with cirrhosis: A prospective study.” Alimentary pharmacology & therapeutics (2024). PMID: 38863232 ↗
L4COHORTCited in: Diagnosis & Workup
[258]
Singh S, Allen AM, Wang Z et al.. “Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2014). PMID: 24768810 ↗
L2SR_OBSCited in: Diagnosis & Workup, History and Evolution of Treatment, Prognosis & Natural History
[259]
Levy C, Bowlus CL. “Primary biliary cholangitis: Personalizing second-line therapies.” Hepatology (Baltimore, Md.) (2024). PMID: 39707635 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup
[260]
Trebicka J, Garcia-Tsao G. “Controversies regarding albumin therapy in cirrhosis.” Hepatology (Baltimore, Md.) (2023). PMID: 37540192 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, Prognosis & Natural History
[261]
Heneghan MA, Lohse AW. “Update in clinical science: Autoimmune hepatitis.” Journal of hepatology (2025). PMID: 39864459 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Long-term & Definitive Management
[262]
Fujii H, Iwaki M, Hayashi H et al.. “Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2022). PMID: 35051649 ↗
L2COHORTCited in: Diagnosis & Workup, Liver Transplantation & MELD-Based Candidacy, Prognosis & Natural History, Prevention, Screening & Surveillance
[263]
Silvey S, Patel N, Tsai SY et al.. “Higher Rate of Spontaneous Bacterial Peritonitis Recurrence With Secondary Spontaneous Bacterial Peritonitis Prophylaxis Compared With No Prophylaxis in 2 National Cirrhosis Cohorts.” The American journal of gastroenterology (2024). PMID: 39235290 ↗
L2OTHERCited in: Diagnosis & Workup
[264]
Hytiroglou P, Theise ND. “Telomerase activation in human hepatocarcinogenesis.” The American journal of gastroenterology (2006). PMID: 16635228 ↗
L5OTHERCited in: Diagnosis & Workup, Prevention, Screening & Surveillance
[265]
Younossi ZM, Bernstein D, Shiffman ML et al.. “Diagnosis and Management of Primary Biliary Cholangitis.” The American journal of gastroenterology (2019). PMID: 30429590 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup
[266]
Targher G, Byrne CD, Tilg H. “MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.” Gut (2024). PMID: 38228377 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prevention, Screening & Surveillance
[267]
Ren Z, Li A, Jiang J et al.. “Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma.” Gut (2018). PMID: 30045880 ↗
L3OTHERCited in: Diagnosis & Workup
[268]
Simon TG, Roelstraete B, Hagström H et al.. “Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort.” Gut (2021). PMID: 34489307 ↗
L2OTHERCited in: Diagnosis & Workup
[269]
Pose E, Piano S, Juanola A et al.. “Hepatorenal Syndrome in Cirrhosis.” Gastroenterology (2024). PMID: 38246506 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, Liver Transplantation & MELD-Based Candidacy, Prognosis & Natural History
[270]
Jeng WJ, Papatheodoridis GV, Lok ASF. “Hepatitis B.” Lancet (London, England) (2023). PMID: 36774930 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prevention, Screening & Surveillance
[271]
Forner A, Reig M, Bruix J. “Hepatocellular carcinoma.” Lancet (London, England) (2018). PMID: 29307467 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Long-term & Definitive Management, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History, Prevention, Screening & Surveillance
[272]
Razumilava N, Gores GJ. “Cholangiocarcinoma.” Lancet (London, England) (2014). PMID: 24581682 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, Liver Transplantation & MELD-Based Candidacy
[273]
Stravitz RT, Lee WM. “Acute liver failure.” Lancet (London, England) (2019). PMID: 31498101 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Acute Management & Decompensation Events, Long-term & Definitive Management, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae)
[274]
Powell LW, Seckington RC, Deugnier Y. “Haemochromatosis.” Lancet (London, England) (2016). PMID: 26975792 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup
[275]
Spearman CW, Dusheiko GM, Hellard M et al.. “Hepatitis C.” Lancet (London, England) (2019). PMID: 31631857 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Prevention, Screening & Surveillance
[276]
Dietvorst CAW, Konings LAM, Saidi AN et al.. “Effect of an early time restricted eating Mediterranean diet compared to naltrexone/bupropion on liver fibrosis in people with cardiometabolic risk factors in a hospital outpatient clinic: study protocol for a randomised controlled trial (MEDFAST trial).” BMJ open (2026). PMID: 42350004 ↗
L5TRIAL_NONRANDOMCited in: Diagnosis & Workup, Prevention, Screening & Surveillance
[277]
Daruwalla C, Calderon E, Mathew C et al.. “Outcome scoring systems for locoregional therapy in hepatocellular carcinoma: a systematic review.” Gut (2026). PMID: 42425732 ↗
L2SR_OBSCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History, Prevention, Screening & Surveillance
[278]
Boehncke WH, Constantin MM, Carrascosa-Carrillo JM et al.. “A Systematic Literature Review on Methotrexate Hepatotoxicity in Psoriasis Management: Preconceived Notion or Real Threat?” Acta dermato-venereologica (2026). PMID: 42403312 ↗
L2SR_OBSCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management
[279]
Chinaka I, Schofield A, Amos CI et al.. “Multi-ancestry genome-wide association meta-analysis of hepatocellular carcinoma identifies eight risk loci including MAP3K9, DHRS1, MTTP, and 8q24.21.” HGG advances (2026). PMID: 42357869 ↗
L2SR_OBSCited in: Diagnosis & Workup, Prevention, Screening & Surveillance
[280]
Jamal F, Hamad A, Elshaer A et al.. “Aspirin Use and Liver-Related Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.” Biomedicines (2026). PMID: 42351677 ↗
L2SR_OBSCited in: Diagnosis & Workup, Acute Management & Decompensation Events, Prevention, Screening & Surveillance
[281]
Chan WK, Petta S, Noureddin M et al.. “Diagnosis and non-invasive assessment of MASLD in type 2 diabetes and obesity.” Alimentary pharmacology & therapeutics (2024). PMID: 38813831 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Prevention, Screening & Surveillance
[282]
Bond A, Huijbers A, Pironi L et al.. “Review article: diagnosis and management of intestinal failure-associated liver disease in adults.” Alimentary pharmacology & therapeutics (2019). PMID: 31342540 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup
[283]
Stirnimann G, Ebadi M, Czaja AJ et al.. “Recurrent and De Novo Autoimmune Hepatitis.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2019). PMID: 30375180 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Long-term & Definitive Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History, Special Populations & Pregnancy, Prevention, Screening & Surveillance
[284]
Martin Mateos R, Albillos A. “Sepsis in Patients With Cirrhosis Awaiting Liver Transplantation: New Trends and Management.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2019). PMID: 31408581 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup
[285]
Taouli B, Krinsky GA. “Diagnostic imaging of hepatocellular carcinoma in patients with cirrhosis before liver transplantation.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2006). PMID: 17051556 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Prevention, Screening & Surveillance
[286]
Al-Hasan M, Mehta N, Yang JD et al.. “Role of biomarkers in the diagnosis and management of HCC.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2024). PMID: 38738964 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Prevention, Screening & Surveillance
[287]
Durand F, Belghiti J, Paradis V. “Liver transplantation for hepatocellular carcinoma: role of biopsy.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2007). PMID: 17969095 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Prevention, Screening & Surveillance
[288]
Chen H, Han X, Qian C et al.. “Serum IgG, definite anti-dsDNA positivity, and advanced HBV-related liver disease: a laboratory-based retrospective study.” Clinica chimica acta; international journal of clinical chemistry (2026). PMID: 42419669 ↗
L3COHORTCited in: Diagnosis & Workup, Long-term & Definitive Management, History and Evolution of Treatment, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prevention, Screening & Surveillance
[289]
Kann AE, Madsen LG, Rønn JH et al.. “Changes in alcohol use following a diagnosis of alcohol-related liver disease: a clinical cohort study.” JHEP reports : innovation in hepatology (2026). PMID: 42392507 ↗
L2COHORTCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management
[290]
Yoon JH, Choi JI, Yoo J et al.. “Comparison of Annual Dynamic Abbreviated MRI and Biannual Ultrasound for HCC Surveillance in a High-Risk Group: Two-Center Cohort Study.” Liver cancer (2025). PMID: 42338694 ↗
L2COHORTCited in: Diagnosis & Workup
[291]
Rui F, Xu L, Yeo YH et al.. “Machine Learning-Based Models for Advanced Fibrosis and Cirrhosis Diagnosis in Chronic Hepatitis B Patients With Hepatic Steatosis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 38906440 ↗
L2OTHERCited in: Diagnosis & Workup
[292]
Shah AG, Lydecker A, Murray K et al.. “Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2009). PMID: 19523535 ↗
L2OTHERCited in: Diagnosis & Workup
[293]
Arvaniti P, Rodríguez-Tajes S, Padilla M et al.. “Hepatic Encephalopathy and MELD-Na Predict Treatment Benefit in Autoimmune Hepatitis-related Decompensated Cirrhosis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025). PMID: 40210079 ↗
L3OTHERCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, Liver Transplantation & MELD-Based Candidacy
[294]
Lam L, Soret PA, Lemoinne S et al.. “Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 39019421 ↗
L3OTHERCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Liver Transplantation & MELD-Based Candidacy
[295]
Siddiqui MS, Vuppalanchi R, Van Natta ML et al.. “Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2018). PMID: 29705261 ↗
L2OTHERCited in: Diagnosis & Workup
[296]
Mohanty A, Stead AE, Telep LE et al.. “Hepatocellular carcinoma risk reduction associated with antiviral treatment in patients with noncirrhotic chronic hepatitis B: a systematic literature review and comparative meta-analysis.” BMC gastroenterology (2026). PMID: 42363070 ↗
L2SR_OBSCited in: Diagnosis & Workup
[297]
Tapper EB, Salim N, Baki J et al.. “Pickle Juice Intervention for Cirrhotic Cramps Reduction: The PICCLES Randomized Controlled Trial.” The American journal of gastroenterology (2022). PMID: 35416793 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Prognosis & Natural History
[298]
Nicoară-Farcău O, Han G, Rudler M et al.. “Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis.” Hepatology (Baltimore, Md.) (2023). PMID: 37782566 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification, Portal Hypertension & Decompensation Management
[299]
Clements O, Eliahoo J, Kim JU et al.. “Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.” Journal of hepatology (2019). PMID: 31536748 ↗
L3SR_OBSCited in: Severity, Staging & Risk Stratification
[300]
Tantai X, Liu Y, Yeo YH et al.. “Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis.” Journal of hepatology (2021). PMID: 34785325 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification
[301]
Villanueva C, Colomo A, Bosch A et al.. “Transfusion strategies for acute upper gastrointestinal bleeding.” The New England journal of medicine (2013). PMID: 23281973 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History
[302]
Curry MP, O'Leary JG, Bzowej N et al.. “Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.” The New England journal of medicine (2015). PMID: 26569658 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management
[303]
Poordad F, Hezode C, Trinh R et al.. “ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.” The New England journal of medicine (2014). PMID: 24725237 ↗
L1RCTCited in: Severity, Staging & Risk Stratification
[304]
Juanola A, Ma AT, de Wit K et al.. “Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis.” Gut (2023). PMID: 37884354 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification, Liver Transplantation & MELD-Based Candidacy
[305]
Luo J, Hu M, Feng T et al.. “Performance of the China-CLIF framework in acute-on-chronic liver failure: a multicohort study across all aetiologies.” Gut (2025). PMID: 40713188 ↗
L2COHORTCited in: Severity, Staging & Risk Stratification, Liver Transplantation & MELD-Based Candidacy
[306]
Carrat F, Fontaine H, Dorival C et al.. “Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.” Lancet (London, England) (2019). PMID: 30765123 ↗
L2COHORTCited in: Severity, Staging & Risk Stratification, Liver Transplantation & MELD-Based Candidacy, Prevention, Screening & Surveillance
[307]
Kubina M, Prasitsumrit V, Tan J et al.. “Meta-Analysis: Effects of Steatotic Liver Disease-Associated Genetic Risk Alleles on Longitudinal Outcomes.” Alimentary pharmacology & therapeutics (2025). PMID: 40580198 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification, Prognosis & Natural History, Prevention, Screening & Surveillance
[308]
Salem R, Johnson GE, Kim E et al.. “Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study.” Hepatology (Baltimore, Md.) (2021). PMID: 33739462 ↗
L4OTHERCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management
[309]
Mahmud N, Fricker Z, Hubbard RA et al.. “Risk Prediction Models for Post-Operative Mortality in Patients With Cirrhosis.” Hepatology (Baltimore, Md.) (2020). PMID: 32939786 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification
[310]
Man S, Deng Y, Ma Y et al.. “Prevalence of Liver Steatosis and Fibrosis in the General Population and Various High-Risk Populations: A Nationwide Study With 5.7 Million Adults in China.” Gastroenterology (2023). PMID: 37380136 ↗
L4OTHERCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management
[311]
Abul-Husn NS, Cheng X, Li AH et al.. “A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease.” The New England journal of medicine (2018). PMID: 29562163 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification
[312]
Verweij N, Haas ME, Nielsen JB et al.. “Germline Mutations in CIDEB and Protection against Liver Disease.” The New England journal of medicine (2022). PMID: 35939579 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification
[313]
Carey EJ, Ali AH, Lindor KD. “Primary biliary cirrhosis.” Lancet (London, England) (2015). PMID: 26364546 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, History and Evolution of Treatment, Liver Transplantation & MELD-Based Candidacy
[314]
Hirschfield GM, Karlsen TH, Lindor KD et al.. “Primary sclerosing cholangitis.” Lancet (London, England) (2013). PMID: 23810223 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification
[315]
Selmi C, Bowlus CL, Gershwin ME et al.. “Primary biliary cirrhosis.” Lancet (London, England) (2011). PMID: 21529926 ↗
L5OTHERCited in: Severity, Staging & Risk Stratification
[316]
Faulkes RE, Chauhan A, Knox E et al.. “Review article: chronic liver disease and pregnancy.” Alimentary pharmacology & therapeutics (2020). PMID: 32598048 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Special Populations & Pregnancy
[317]
Sinha R, Gillespie SL, Brinkman P et al.. “Volatomics for Diagnosis and Risk Stratification of MASLD: A Proof-Of-Concept Study.” Alimentary pharmacology & therapeutics (2025). PMID: 40391721 ↗
L4OTHERCited in: Severity, Staging & Risk Stratification
[318]
Butt MF, Jalan R. “Review article: Emerging and current management of acute-on-chronic liver failure.” Alimentary pharmacology & therapeutics (2023). PMID: 37589507 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Long-term & Definitive Management, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae)
[319]
Leise M, Cárdenas A. “Hyponatremia in Cirrhosis: Implications for Liver Transplantation.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2018). PMID: 30129266 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Acute Management & Decompensation Events, Liver Transplantation & MELD-Based Candidacy
[320]
Przybyszewski EM, Wilechansky RM, McLean Diaz P et al.. “Controversies in terlipressin and transplantation in the United States: How do we MELD the two?” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2024). PMID: 38537069 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Portal Hypertension & Decompensation Management, Liver Transplantation & MELD-Based Candidacy
[321]
Tonon M, Gagliardi R, Zeni N et al.. “Recompensation of cirrhosis in candidates of transplant: Tips and tricks for delisting.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2024). PMID: 38926937 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Portal Hypertension & Decompensation Management, History and Evolution of Treatment
[322]
Terrault NA, Francoz C, Berenguer M et al.. “Liver Transplantation 2023: Status Report, Current and Future Challenges.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2023). PMID: 37084928 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prevention, Screening & Surveillance
[323]
Rivera-Esteban J, Muñoz-Martínez S, Higuera M et al.. “Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 38604295 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment
[324]
Celier A, Ordan MA, Lanore A et al.. “Characteristics and prognosis of patients with cirrhosis presenting with acute respiratory distress syndrome: A bicentric retrospective study.” Journal of intensive medicine (2026). PMID: 42396246 ↗
L3COHORTCited in: Severity, Staging & Risk Stratification, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae)
[325]
Cavallin M, Piano S, Romano A et al.. “Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study.” Hepatology (Baltimore, Md.) (2016). PMID: 26659927 ↗
L1RCTCited in: Acute Management & Decompensation Events, Portal Hypertension & Decompensation Management, History and Evolution of Treatment
[326]
Younossi ZM, Corey KE, Lim JK. “AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review.” Gastroenterology (2020). PMID: 33307021 ↗
L1GUIDELINECited in: Acute Management & Decompensation Events, Long-term & Definitive Management, History and Evolution of Treatment, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History, Prevention, Screening & Surveillance
[327]
Wong F, Pappas SC, Curry MP et al.. “Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.” The New England journal of medicine (2021). PMID: 33657294 ↗
L1RCTCited in: Acute Management & Decompensation Events, Long-term & Definitive Management, Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Prognosis & Natural History
[328]
Bajaj JS, Kwo P, Pappas SC et al.. “Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies.” Alimentary pharmacology & therapeutics (2025). PMID: 40704461 ↗
L4RCTCited in: Acute Management & Decompensation Events, Portal Hypertension & Decompensation Management
[329]
Odewole M, Sen A, Okoruwa E et al.. “Systematic review with meta-analysis: incidence of variceal hemorrhage in patients with cirrhosis undergoing transesophageal echocardiography.” Alimentary pharmacology & therapeutics (2022). PMID: 35343613 ↗
L1SR_OBSCited in: Acute Management & Decompensation Events
[330]
Hernández-Gea V, Baiges A, Turon F et al.. “Idiopathic Portal Hypertension.” Hepatology (Baltimore, Md.) (2018). PMID: 30066417 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Decompensation Events, Portal Hypertension & Decompensation Management, History and Evolution of Treatment
[331]
You H, Maiwall R, Chen J et al.. “APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update.” Hepatology international (2026). PMID: 42365189 ↗
L1GUIDELINECited in: Acute Management & Decompensation Events, Prevention, Screening & Surveillance
[332]
Bajaj JS, O'Leary JG, Lai JC et al.. “Acute-on-Chronic Liver Failure Clinical Guidelines.” The American journal of gastroenterology (2022). PMID: 35006099 ↗
L1REVIEW_NARRATIVECited in: Acute Management & Decompensation Events, Long-term & Definitive Management
[333]
Liang X, Luo J, Zhou Q et al.. “Single-cell multimodal analysis reveals the dynamic immunopathogenesis of HBV-ACLF progression.” Gut (2026). PMID: 40841166 ↗
L3OTHERCited in: Acute Management & Decompensation Events, History and Evolution of Treatment
[334]
Pinter M, Fulgenzi CAM, Pinato DJ et al.. “Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunction.” Gut (2025). PMID: 40301119 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Decompensation Events, History and Evolution of Treatment, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prevention, Screening & Surveillance
[335]
Rahim MN, Williamson C, Kametas NA et al.. “Pregnancy and the liver.” Lancet (London, England) (2025). PMID: 39922676 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Decompensation Events, Liver Transplantation & MELD-Based Candidacy, Special Populations & Pregnancy
[336]
Burroughs AK, Sabin CA, Rolles K et al.. “3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome.” Lancet (London, England) (2006). PMID: 16427491 ↗
L2OTHERCited in: Acute Management & Decompensation Events
[337]
Silvey S, Patel N, O'Leary JG et al.. “Spontaneous Bacterial Peritonitis Is Associated With High Mortality, Which Interacts With Antibiotic Prophylaxis in a National Cirrhosis Cohort.” Alimentary pharmacology & therapeutics (2025). PMID: 41423725 ↗
L2OTHERCited in: Acute Management & Decompensation Events
[338]
Hofer BS, Burghart L, Halilbasic E et al.. “Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis.” Alimentary pharmacology & therapeutics (2024). PMID: 38409879 ↗
L2OTHERCited in: Acute Management & Decompensation Events, Portal Hypertension & Decompensation Management
[339]
Liberal R, Zen Y, Mieli-Vergani G et al.. “Liver transplantation and autoimmune liver diseases.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2013). PMID: 23873751 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Decompensation Events, Long-term & Definitive Management, Liver Transplantation & MELD-Based Candidacy
[340]
Northup P, Reutemann B. “Management of Coagulation and Anticoagulation in Liver Transplantation Candidates.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2018). PMID: 30142249 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Decompensation Events, Long-term & Definitive Management, History and Evolution of Treatment
[341]
Putignano A, Gustot T. “New concepts in acute-on-chronic liver failure: Implications for liver transplantation.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2017). PMID: 27750389 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Decompensation Events, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae)
[342]
Lizaola-Mayo B, Vargas HE. “Hepatorenal Syndrome-Acute Kidney Injury in Liver Transplantation.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2023). PMID: 37625863 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Decompensation Events, Portal Hypertension & Decompensation Management, Liver Transplantation & MELD-Based Candidacy
[343]
Fallahzadeh MA, Rahimi RS. “Hepatic Encephalopathy: Current and Emerging Treatment Modalities.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2022). PMID: 35940731 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Decompensation Events, Portal Hypertension & Decompensation Management
[344]
Adebayo D, Wong F. “Pathophysiology of Hepatorenal Syndrome - Acute Kidney Injury.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2023). PMID: 37625861 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Decompensation Events
[345]
Bajaj JS, Gentili A, Wade JB et al.. “Specific Challenges in Geriatric Cirrhosis and Hepatic Encephalopathy.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2022). PMID: 35940730 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Decompensation Events, Portal Hypertension & Decompensation Management, Special Populations & Pregnancy
[346]
Duong N, Kakadiya P, Bajaj JS. “Current Pharmacologic Therapies for Hepatorenal Syndrome-Acute Kidney Injury.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2023). PMID: 37625864 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Decompensation Events
[347]
Motazedian N, Dehghani SM, Shamsaeefar A et al.. “Natural history and the outcome of complications of children with progressive familial intrahepatic cholestasis in a resource-limited setting: A cohort study.” Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology (2026). PMID: 42420132 ↗
L2COHORTCited in: Acute Management & Decompensation Events, Liver Transplantation & MELD-Based Candidacy
[348]
Ng MK, Mastrokostas LE, Mastrokostas PG et al.. “Predictors of In-Hospital Mortality After Operative Cervical Spinal Cord Injury: A National Trauma Data Bank Analysis From 2021 to 2023.” Global spine journal (2026). PMID: 42427184 ↗
L2OTHERCited in: Acute Management & Decompensation Events
[349]
Chan HLY, Buti M, Lim YS et al.. “Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety.” The American journal of gastroenterology (2023). PMID: 37561058 ↗
L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment
[350]
Wedemeyer H, Aleman S, Brunetto MR et al.. “A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.” The New England journal of medicine (2023). PMID: 37345876 ↗
L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment
[351]
Nevens F, Andreone P, Mazzella G et al.. “A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.” The New England journal of medicine (2016). PMID: 27532829 ↗
L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment, Liver Transplantation & MELD-Based Candidacy
[352]
Sanyal AJ, Chalasani N, Kowdley KV et al.. “Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.” The New England journal of medicine (2010). PMID: 20427778 ↗
L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History
[353]
China L, Freemantle N, Forrest E et al.. “A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis.” The New England journal of medicine (2021). PMID: 33657293 ↗
L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment
[354]
Ferenci P, Bernstein D, Lalezari J et al.. “ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.” The New England journal of medicine (2014). PMID: 24795200 ↗
L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment
[355]
Roberts AT, Makar J, Abdelmalak J et al.. “Management of Muscle Cramps in Patients With Cirrhosis: A Systematic Review of Randomised Controlled Trials.” Alimentary pharmacology & therapeutics (2024). PMID: 39548657 ↗
L1SR_MA_RCTCited in: Long-term & Definitive Management
[356]
Lammers WJ, van Buuren HR, Hirschfield GM et al.. “Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.” Gastroenterology (2014). PMID: 25160979 ↗
L2SR_OBSCited in: Long-term & Definitive Management, Liver Transplantation & MELD-Based Candidacy, Prognosis & Natural History
[357]
Hey P, Hoermann R, Sinclair M et al.. “Branched-chain amino acid supplementation does not improve measures of sarcopenia in cirrhosis: results of a randomised controlled trial.” Alimentary pharmacology & therapeutics (2024). PMID: 38404263 ↗
L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment
[358]
Ha S, Wong VW, Zhang X et al.. “Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma.” Gut (2024). PMID: 38950910 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prevention, Screening & Surveillance
[359]
Urban S, Neumann-Haefelin C, Lampertico P. “Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease.” Gut (2021). PMID: 34103404 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Prevention, Screening & Surveillance
[360]
Intagliata NM, Caldwell SH, Tripodi A. “Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis.” Gastroenterology (2019). PMID: 30771355 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Portal Hypertension & Decompensation Management
[361]
Martinello M, Solomon SS, Terrault NA et al.. “Hepatitis C.” Lancet (London, England) (2023). PMID: 37741678 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prevention, Screening & Surveillance
[362]
Boccatonda A, Campello E, Napolitano A et al.. “Viscoelastic Tests in Cirrhotic Patients Undergoing Invasive Procedures: A Systematic Review and Meta-Analysis of RCTs.” Liver international : official journal of the International Association for the Study of the Liver (2026). PMID: 42415305 ↗
L1SR_OBSCited in: Long-term & Definitive Management, Prognosis & Natural History
[363]
Yardeni D, Ghany MG. “Review article: hepatitis B-current and emerging therapies.” Alimentary pharmacology & therapeutics (2022). PMID: 35224760 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae)
[364]
Tapper EB, Ufere NN, Huang DQ et al.. “Review article: current and emerging therapies for the management of cirrhosis and its complications.” Alimentary pharmacology & therapeutics (2022). PMID: 35235219 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Portal Hypertension & Decompensation Management
[365]
Lok J, Dusheiko G, Carey I et al.. “Review article: novel biomarkers in hepatitis B infection.” Alimentary pharmacology & therapeutics (2022). PMID: 35770458 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History
[366]
Noureddin M, Charlton MR, Harrison SA et al.. “Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 39038768 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prevention, Screening & Surveillance
[367]
Dove L, Chadha RM, Lai JC et al.. “AASLD AST Practice Guideline on adult liver transplantation: Candidate evaluation.” Hepatology (Baltimore, Md.) (2025). PMID: 41405234 ↗
L1GUIDELINECited in: Portal Hypertension & Decompensation Management, History and Evolution of Treatment, Liver Transplantation & MELD-Based Candidacy, Prevention, Screening & Surveillance
[368]
Jain A, Sharma BC, Mahajan B et al.. “L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial.” Hepatology (Baltimore, Md.) (2021). PMID: 34822189 ↗
L1RCTCited in: Portal Hypertension & Decompensation Management, History and Evolution of Treatment
[369]
Bajaj JS, Kassam Z, Fagan A et al.. “Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial.” Hepatology (Baltimore, Md.) (2017). PMID: 28586116 ↗
L1RCTCited in: Portal Hypertension & Decompensation Management, Liver Transplantation & MELD-Based Candidacy
[370]
Arora V, Maiwall R, Rajan V et al.. “Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure.” Hepatology (Baltimore, Md.) (2019). PMID: 30076614 ↗
L1RCTCited in: Portal Hypertension & Decompensation Management
[371]
Bureau C, Thabut D, Oberti F et al.. “Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites.” Gastroenterology (2016). PMID: 27663604 ↗
L1RCTCited in: Portal Hypertension & Decompensation Management
[372]
Nicoară-Farcău O, Han G, Rudler M et al.. “Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data.” Gastroenterology (2020). PMID: 32980344 ↗
L1SR_OBSCited in: Portal Hypertension & Decompensation Management
[373]
Wong F, Pappas SC, Reddy KR et al.. “Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure.” Alimentary pharmacology & therapeutics (2022). PMID: 35995728 ↗
L1RCTCited in: Portal Hypertension & Decompensation Management
[374]
Engelmann C, Clària J, Szabo G et al.. “Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.” Journal of hepatology (2021). PMID: 34039492 ↗
L5REVIEW_NARRATIVECited in: Portal Hypertension & Decompensation Management
[375]
D'Amico G, Morabito A, D'Amico M et al.. “Clinical states of cirrhosis and competing risks.” Journal of hepatology (2017). PMID: 29111320 ↗
L5REVIEW_NARRATIVECited in: Portal Hypertension & Decompensation Management
[376]
Tilg H, Cani PD, Mayer EA. “Gut microbiome and liver diseases.” Gut (2016). PMID: 27802157 ↗
L5REVIEW_NARRATIVECited in: Portal Hypertension & Decompensation Management
[377]
Häussinger D, Schliess F. “Pathogenetic mechanisms of hepatic encephalopathy.” Gut (2008). PMID: 18628377 ↗
L5REVIEW_NARRATIVECited in: Portal Hypertension & Decompensation Management
[378]
Bosch J, Gracia-Sancho J, Abraldes JG. “Cirrhosis as new indication for statins.” Gut (2020). PMID: 32139553 ↗
L5REVIEW_NARRATIVECited in: Portal Hypertension & Decompensation Management
[379]
Tranah TH, Edwards LA, Schnabl B et al.. “Targeting the gut-liver-immune axis to treat cirrhosis.” Gut (2020). PMID: 33060124 ↗
L5REVIEW_NARRATIVECited in: Portal Hypertension & Decompensation Management
[380]
Vanderschueren E, Praktiknjo M, Wiest R et al.. “Recent advances in clinical practice endohepatology: the endoscopic liver rush.” Gut (2025). PMID: 40707208 ↗
L5REVIEW_NARRATIVECited in: Portal Hypertension & Decompensation Management
[381]
Kwo PY, Masuoka HC, Schaefer EA et al.. “Evaluation of Abnormal Liver Biochemical Test Results.” Gastroenterology (2026). PMID: 41831501 ↗
L5REVIEW_NARRATIVECited in: Portal Hypertension & Decompensation Management, History and Evolution of Treatment
[382]
Kato S, Hikita H, Tsukamoto O et al.. “Activation of the Integrin αV-YAP-CTGF Axis in Liver Sinusoidal Endothelial Cells Promotes Liver Fibrogenesis, Leading to Portal Hypertension and Liver Carcinogenesis in Congestive Hepatopathy.” Gastroenterology (2026). PMID: 41758081 ↗
L5OTHERCited in: Portal Hypertension & Decompensation Management
[383]
Noureddin M, Goodman Z, Tai D et al.. “Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis.” Alimentary pharmacology & therapeutics (2023). PMID: 36647687 ↗
L4OTHERCited in: Portal Hypertension & Decompensation Management
[384]
Sharma P, Moore K, Ganger D et al.. “Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2020). PMID: 32574418 ↗
L5REVIEW_NARRATIVECited in: Portal Hypertension & Decompensation Management
[385]
Chen H, Turon F, Hernández-Gea V et al.. “Nontumoral portal vein thrombosis in patients awaiting liver transplantation.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2016). PMID: 26684272 ↗
L5REVIEW_NARRATIVECited in: Portal Hypertension & Decompensation Management
[386]
Flamm SL, Brown K, Wadei HM et al.. “The Current Management of Hepatorenal Syndrome-Acute Kidney Injury in the United States and the Potential of Terlipressin.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2021). PMID: 33848394 ↗
L5REVIEW_NARRATIVECited in: Portal Hypertension & Decompensation Management
[387]
Jakab SS, Garcia-Tsao G. “Screening and Surveillance of Varices in Patients With Cirrhosis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2018). PMID: 29551741 ↗
L5REVIEW_NARRATIVECited in: Portal Hypertension & Decompensation Management, History and Evolution of Treatment
[388]
Hussain A, John S, Thomas K et al.. “Indwelling Pleural Catheter as a Safe and Convenient Alternative to Serial Thoracentesis for the Management of Hepatic Hydrothorax: A Retrospective Propensity-Matched Cohort Study.” Journal of bronchology & interventional pulmonology (2026). PMID: 42307745 ↗
L2COHORTCited in: Portal Hypertension & Decompensation Management, Liver Transplantation & MELD-Based Candidacy
[389]
Ali K, Desai K, Rahmani J et al.. “Association of decompensated cirrhosis with acute clinical and financial outcomes following cardiac operations.” Surgery (2026). PMID: 42424762 ↗
L2OTHERCited in: Portal Hypertension & Decompensation Management
[390]
Jonasson E, Grønkjær LL, Jacobsen BG et al.. “Neurofilament Light Chain in Cerebrospinal Fluid and Blood Identifies Patients With Minimal and Overt Hepatic Encephalopathy.” Liver international : official journal of the International Association for the Study of the Liver (2026). PMID: 42422896 ↗
L3OTHERCited in: Portal Hypertension & Decompensation Management
[391]
. “EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis.” Journal of hepatology (2022). PMID: 35300861 ↗
L1GUIDELINECited in: History and Evolution of Treatment
[392]
Blei AT, Córdoba J. “Hepatic Encephalopathy.” The American journal of gastroenterology (2001). PMID: 11467622 ↗
L1GUIDELINECited in: History and Evolution of Treatment
[393]
Loomba R, Noureddin M, Kowdley KV et al.. “Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.” Hepatology (Baltimore, Md.) (2021). PMID: 33169409 ↗
L1RCTCited in: History and Evolution of Treatment
[394]
Bosch J, García-Pagán JC. “Prevention of variceal rebleeding.” Lancet (London, England) (2003). PMID: 12648985 ↗
L5RCTCited in: History and Evolution of Treatment
[395]
Lampertico P, Anolli MP, Roulot D et al.. “Antiviral therapy for chronic hepatitis delta: new insights from clinical trials and real-life studies.” Gut (2025). PMID: 39663120 ↗
L5TRIAL_NONRANDOMCited in: History and Evolution of Treatment
[396]
Liu Y, Guo G, Zheng L et al.. “Effectiveness of Fenofibrate in Treatment-Naive Patients With Primary Biliary Cholangitis: A Randomized Clinical Trial.” The American journal of gastroenterology (2023). PMID: 36892506 ↗
L1RCTCited in: History and Evolution of Treatment
[397]
Sapena V, Enea M, Torres F et al.. “Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis.” Gut (2021). PMID: 33741640 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[398]
Niu J, Gao Y, Wang G et al.. “Rice-derived recombinant human serum albumin as an alternative to human plasma for patients with decompensated liver cirrhosis: a randomised, double-blind, positive-controlled and non-inferiority trial.” Gut (2025). PMID: 40555465 ↗
L1RCTCited in: History and Evolution of Treatment
[399]
Sort P, Navasa M, Arroyo V et al.. “Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.” The New England journal of medicine (1999). PMID: 10432325 ↗
L1RCTCited in: History and Evolution of Treatment
[400]
Townsend SA, Edgar RG, Ellis PR et al.. “Systematic review: the natural history of alpha-1 antitrypsin deficiency, and associated liver disease.” Alimentary pharmacology & therapeutics (2018). PMID: 29446109 ↗
L2SR_OBSCited in: History and Evolution of Treatment, Prognosis & Natural History
[401]
Kanneganti M, Marrero JA, Parikh ND et al.. “Clinical outcomes of patients with Liver Imaging Reporting and Data System 3 or Liver Imaging Reporting and Data System 4 observations in patients with cirrhosis: A systematic review.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2022). PMID: 35980600 ↗
L2SR_OBSCited in: History and Evolution of Treatment
[402]
Jalan-Sakrikar N, Guicciardi ME, O'Hara SP et al.. “Central role for cholangiocyte pathobiology in cholestatic liver diseases.” Hepatology (Baltimore, Md.) (2024). PMID: 39250501 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[403]
Peiseler M, Schwabe R, Hampe J et al.. “Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits.” Journal of hepatology (2022). PMID: 35750137 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Liver Transplantation & MELD-Based Candidacy
[404]
Bajaj JS, Weinberg EM, Reddy KR et al.. “Safety and efficacy of continuous infusion terlipressin (BIV201): A phase 2 trial in patients with decompensated cirrhosis and refractory ascites.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2025). PMID: 40272365 ↗
L4RCTCited in: History and Evolution of Treatment
[405]
Abdelmalek MF, Sanyal AJ, Nakajima A et al.. “Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2023). PMID: 37088458 ↗
L1RCTCited in: History and Evolution of Treatment
[406]
Cai X, Liu X, Xie W et al.. “Hydronidone for the Treatment of Liver Fibrosis Related to Chronic Hepatitis B: A Phase 2 Randomized Controlled Trial.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2022). PMID: 35842120 ↗
L1RCTCited in: History and Evolution of Treatment
[407]
Zhang W, Zhang M, Xiao J et al.. “Efficacy of 6-mm and 8-mm Transjugular Intrahepatic Portosystemic Shunt for Variceal Bleeding: A Randomized Controlled Trial.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025). PMID: 40633893 ↗
L1RCTCited in: History and Evolution of Treatment
[408]
Biswas S, Vaishnav M, Gamanagatti S et al.. “Endoscopic Glue Injection vs Glue Plus BRTO or TIPSS for Preventing Gastric Variceal Bleeding: A Randomized Controlled Trial.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 38969074 ↗
L1RCTCited in: History and Evolution of Treatment
[409]
Stickel F, Hampe J. “Genetic determinants of alcoholic liver disease.” Gut (2011). PMID: 22110053 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[410]
O'Leary JG, Lepe R, Davis GL. “Indications for liver transplantation.” Gastroenterology (2008). PMID: 18471553 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Liver Transplantation & MELD-Based Candidacy
[411]
Talwalkar JA, Lindor KD. “Primary biliary cirrhosis.” Lancet (London, England) (2003). PMID: 12853201 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[412]
De Angelis Rigotti F, Wiedmann L, Hubert MO et al.. “Semaphorin 3C exacerbates liver fibrosis.” Hepatology (Baltimore, Md.) (2023). PMID: 37055018 ↗
L3OTHERCited in: History and Evolution of Treatment
[413]
Amangurbanova M, Huang DQ, Loomba R. “Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD.” Alimentary pharmacology & therapeutics (2022). PMID: 36349732 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[414]
Angulo P. “GI epidemiology: nonalcoholic fatty liver disease.” Alimentary pharmacology & therapeutics (2007). PMID: 17402991 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[415]
Varela M, Sala M, Llovet JM et al.. “Review article: natural history and prognostic prediction of patients with hepatocellular carcinoma.” Alimentary pharmacology & therapeutics (2003). PMID: 12786620 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[416]
Allen AM, Hay JE. “Review article: the management of cirrhosis in women.” Alimentary pharmacology & therapeutics (2014). PMID: 25263269 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Liver Transplantation & MELD-Based Candidacy, Special Populations & Pregnancy
[417]
Kao JH, Hu TH, Jia J et al.. “East Asia expert opinion on treatment initiation for chronic hepatitis B.” Alimentary pharmacology & therapeutics (2020). PMID: 32951256 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[418]
Alberti A, Vario A, Ferrari A et al.. “Review article: chronic hepatitis C--natural history and cofactors.” Alimentary pharmacology & therapeutics (2005). PMID: 16225479 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[419]
Myers RP, Lee SS. “Cirrhotic cardiomyopathy and liver transplantation.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2000). PMID: 10915191 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[420]
Lencioni R, Cioni D, Crocetti L et al.. “Percutaneous ablation of hepatocellular carcinoma: state-of-the-art.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2004). PMID: 14762847 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[421]
Gane EJ. “The natural history of recurrent hepatitis C and what influences this.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2008). PMID: 18825724 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[422]
Gane E. “The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2003). PMID: 14586892 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[423]
Neuberger J. “Recurrent primary biliary cirrhosis.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2003). PMID: 12783392 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[424]
Berenguer M. “Host and donor risk factors before and after liver transplantation that impact HCV recurrence.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2003). PMID: 14586894 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[425]
Marchetti P. “New-onset diabetes after liver transplantation: from pathogenesis to management.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2005). PMID: 15915488 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[426]
Pagadala M, Dasarathy S, Eghtesad B et al.. “Posttransplant metabolic syndrome: an epidemic waiting to happen.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2009). PMID: 19938136 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[427]
Rowe IA, Wong VW, Loomba R. “Treatment Candidacy for Pharmacologic Therapies for NASH.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2021). PMID: 33711479 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[428]
Arab JP, Addolorato G, Mathurin P et al.. “Alcohol-Associated Liver Disease: Integrated Management With Alcohol Use Disorder.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2023). PMID: 36858144 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[429]
Yuen MF, Gane E, Holmes JA et al.. “The small interfering RNA imdusiran as single and multiple doses in healthy, randomised individuals and non-randomised individuals with chronic hepatitis B (AB-729-001): a phase 1a/b trial.” The lancet. Gastroenterology & hepatology (2026). PMID: 42173110 ↗
L2RCTCited in: History and Evolution of Treatment
[430]
Kulkarni AV, Venishetty S, Prasanna S et al.. “Midodrine versus placebo in patients with acute-on-chronic liver failure with ascites-A randomized trial (MIDAS trial).” Hepatology communications (2026). PMID: 42172504 ↗
L1RCTCited in: History and Evolution of Treatment
[431]
Lozano R, Naghavi M, Foreman K et al.. “Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.” Lancet (London, England) (2012). PMID: 23245604 ↗
L2OTHERCited in: History and Evolution of Treatment
[432]
. “Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015.” Lancet (London, England) (2016). PMID: 27733281 ↗
L2OTHERCited in: History and Evolution of Treatment
[433]
Metcalf JV, Mitchison HC, Palmer JM et al.. “Natural history of early primary biliary cirrhosis.” Lancet (London, England) (1996). PMID: 8937278 ↗
L2OTHERCited in: History and Evolution of Treatment
[434]
Swales JD. “On the inappropriate in hypertension research.” Lancet (London, England) (1977). PMID: 71508 ↗
L5OTHERCited in: History and Evolution of Treatment
[435]
Luo BH, Han GH. “[An excerpt of the European Association for the Study of the Liver's clinical practice guidelines on liver vascular diseases in 2025].” Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology (2026). PMID: 42209161 ↗
L1GUIDELINECited in: History and Evolution of Treatment
[436]
Tang Q, Zhou YH, Cai N et al.. “Sex Differences in Cirrhosis Incidence Among Untreated Chronic Hepatitis B Patients: A 10-year Chinese Cohort Study.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026). PMID: 42269997 ↗
L3COHORTCited in: History and Evolution of Treatment
[437]
Alkhouri N, Vuppalanchi R, Noureddin M et al.. “Assessment of Esophageal and Gastric Varices in Patients With Cirrhosis for Clinical Trials: A Centralized Blinded Evaluation System.” Gastro hep advances (2026). PMID: 42293772 ↗
L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment
[438]
Huang C, Li Z, Shen W et al.. “The bile acid-gut microbiota-vitamin D axis: new insights into biliary atresia.” Frontiers in cellular and infection microbiology (2026). PMID: 42416276 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[439]
Jovanović-Ćupić S, Krajnović M, Todorović L et al.. “HCV-Induced Hepatocarcinogenesis: Molecular Mechanisms, Persistent Cancer Risk, and Future Perspectives.” Biomedicines (2026). PMID: 42351723 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[440]
Ismaiel A, Almonajjed MB, Wardeh M et al.. “From dysbiosis to malignancy: decoding gut-driven pathways to clinical management in hepatocellular carcinoma.” Frontiers in cellular and infection microbiology (2026). PMID: 42345020 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[441]
Gish RG, Wong RJ, Di Tanna GL et al.. “Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis.” Hepatology (Baltimore, Md.) (2023). PMID: 37870278 ↗
L1SR_OBSCited in: Liver Transplantation & MELD-Based Candidacy
[442]
Guerrero A, Campo LD, Piscaglia F et al.. “Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis.” Journal of hepatology (2023). PMID: 36858157 ↗
L1SR_OBSCited in: Liver Transplantation & MELD-Based Candidacy
[443]
Chung SW, Moon HS, Shin H et al.. “Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study.” Hepatology (Baltimore, Md.) (2024). PMID: 38466796 ↗
L2COHORTCited in: Liver Transplantation & MELD-Based Candidacy
[444]
Belli LS, Duvoux C, Cortesi PA et al.. “COVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes - an ELITA/ELTR multicentre cohort study.” Gut (2021). PMID: 34281984 ↗
L2COHORTCited in: Liver Transplantation & MELD-Based Candidacy
[445]
Montano-Loza AJ, Bhanji RA, Wasilenko S et al.. “Systematic review: recurrent autoimmune liver diseases after liver transplantation.” Alimentary pharmacology & therapeutics (2016). PMID: 27957759 ↗
L2SR_OBSCited in: Liver Transplantation & MELD-Based Candidacy
[446]
Bowers SP, Brennan PN, Dillon JF. “Systematic review: the role of frailty in advanced chronic liver disease.” Alimentary pharmacology & therapeutics (2022). PMID: 36433627 ↗
L2SR_OBSCited in: Liver Transplantation & MELD-Based Candidacy
[447]
Ney M, Haykowsky MJ, Vandermeer B et al.. “Systematic review: pre- and post-operative prognostic value of cardiopulmonary exercise testing in liver transplant candidates.” Alimentary pharmacology & therapeutics (2016). PMID: 27539029 ↗
L2SR_OBSCited in: Liver Transplantation & MELD-Based Candidacy
[448]
Yong JN, Lim WH, Ng CH et al.. “Outcomes of Nonalcoholic Steatohepatitis After Liver Transplantation: An Updated Meta-Analysis and Systematic Review.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2021). PMID: 34801743 ↗
L1SR_OBSCited in: Liver Transplantation & MELD-Based Candidacy
[449]
Caussy C, Reeder SB, Sirlin CB et al.. “Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials.” Hepatology (Baltimore, Md.) (2018). PMID: 29356032 ↗
L5REVIEW_NARRATIVECited in: Liver Transplantation & MELD-Based Candidacy
[450]
Ghonem NS, Assis DN, Boyer JL. “Fibrates and cholestasis.” Hepatology (Baltimore, Md.) (2015). PMID: 25678132 ↗
L5REVIEW_NARRATIVECited in: Liver Transplantation & MELD-Based Candidacy
[451]
Lai JC, Covinsky KE, Dodge JL et al.. “Development of a novel frailty index to predict mortality in patients with end-stage liver disease.” Hepatology (Baltimore, Md.) (2017). PMID: 28422306 ↗
L2OTHERCited in: Liver Transplantation & MELD-Based Candidacy
[452]
Younossi ZM, Blissett D, Blissett R et al.. “The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.” Hepatology (Baltimore, Md.) (2016). PMID: 27543837 ↗
L2OTHERCited in: Liver Transplantation & MELD-Based Candidacy
[453]
Efe C, Lytvyak E, Eşkazan T et al.. “Efficacy and safety of infliximab in patients with autoimmune hepatitis.” Hepatology (Baltimore, Md.) (2024). PMID: 39250458 ↗
L3OTHERCited in: Liver Transplantation & MELD-Based Candidacy
[454]
Simonetto DA, Winder GS, Connor AA et al.. “Liver transplantation for alcohol-associated liver disease.” Hepatology (Baltimore, Md.) (2024). PMID: 38889100 ↗
L5REVIEW_NARRATIVECited in: Liver Transplantation & MELD-Based Candidacy
[455]
Chung BK, Jördens MS, Øgaard J et al.. “Multimodal transcriptomics identifies metallothionein as a novel pathway in primary sclerosing cholangitis.” Hepatology (Baltimore, Md.) (2025). PMID: 40560681 ↗
L3OTHERCited in: Liver Transplantation & MELD-Based Candidacy
[456]
Asrani SK, Devarbhavi H, Eaton J et al.. “Burden of liver diseases in the world.” Journal of hepatology (2018). PMID: 30266282 ↗
L5REVIEW_NARRATIVECited in: Liver Transplantation & MELD-Based Candidacy, Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae)
[457]
Younossi ZM. “Non-alcoholic fatty liver disease - A global public health perspective.” Journal of hepatology (2018). PMID: 30414863 ↗
L5REVIEW_NARRATIVECited in: Liver Transplantation & MELD-Based Candidacy
[458]
Bhushan S, Sohal A, Kowdley KV. “Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Therapy Landscape.” The American journal of gastroenterology (2024). PMID: 39480026 ↗
L5REVIEW_NARRATIVECited in: Liver Transplantation & MELD-Based Candidacy
[459]
Ahn JC, Attia ZI, Rattan P et al.. “Development of the AI-Cirrhosis-ECG Score: An Electrocardiogram-Based Deep Learning Model in Cirrhosis.” The American journal of gastroenterology (2022). PMID: 35029163 ↗
L3OTHERCited in: Liver Transplantation & MELD-Based Candidacy
[460]
Chapman B, Sinclair M, Majumdar A et al.. “Real-World Experience of Home Continuous Terlipressin Infusion for Complications of Portal Hypertension.” The American journal of gastroenterology (2025). PMID: 40498117 ↗
L4OTHERCited in: Liver Transplantation & MELD-Based Candidacy
[461]
Deutsch-Link S, Byers IS, Gu H et al.. “Addiction in Gastrointestinal and Liver Disorders.” The American journal of gastroenterology (2026). PMID: 41562474 ↗
L5OTHERCited in: Liver Transplantation & MELD-Based Candidacy
[462]
Kotlyar DS, Campbell MS, Reddy KR. “Recurrence of diseases following orthotopic liver transplantation.” The American journal of gastroenterology (2006). PMID: 16771963 ↗
L5REVIEW_NARRATIVECited in: Liver Transplantation & MELD-Based Candidacy
[463]
Ong J, Younossi ZM. “Non-alcoholic fatty liver disease after liver transplantation: a case of nurture and nature.” The American journal of gastroenterology (2010). PMID: 20203643 ↗
L5OTHERCited in: Liver Transplantation & MELD-Based Candidacy
[464]
Singal AK, Panneerselvam D, Arab JP et al.. “Delisting From Liver Transplant List for Improvement and Recompensation Among Decompensated Patients at One Year.” The American journal of gastroenterology (2024). PMID: 39714037 ↗
L3OTHERCited in: Liver Transplantation & MELD-Based Candidacy
[465]
Dufour JF, Marjot T, Becchetti C et al.. “COVID-19 and liver disease.” Gut (2022). PMID: 35701093 ↗
L5REVIEW_NARRATIVECited in: Liver Transplantation & MELD-Based Candidacy
[466]
Møller S, Henriksen JH. “Cardiovascular complications of cirrhosis.” Gut (2008). PMID: 18192456 ↗
L5REVIEW_NARRATIVECited in: Liver Transplantation & MELD-Based Candidacy
[467]
Bruix J, Gores GJ, Mazzaferro V. “Hepatocellular carcinoma: clinical frontiers and perspectives.” Gut (2014). PMID: 24531850 ↗
L5REVIEW_NARRATIVECited in: Liver Transplantation & MELD-Based Candidacy
[468]
Wester A, Shang Y, Toresson Grip E et al.. “Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes.” Gut (2024). PMID: 38253482 ↗
L3OTHERCited in: Liver Transplantation & MELD-Based Candidacy
[469]
O'Grady JG. “Liver transplantation alcohol related liver disease: (deliberately) stirring a hornet's nest!” Gut (2006). PMID: 17047102 ↗
L5REVIEW_NARRATIVECited in: Liver Transplantation & MELD-Based Candidacy
[470]
Cárdenas A, Ginès P. “Management of patients with cirrhosis awaiting liver transplantation.” Gut (2010). PMID: 21193458 ↗
L5REVIEW_NARRATIVECited in: Liver Transplantation & MELD-Based Candidacy
[471]
Avila MA, Dufour JF, Gerbes AL et al.. “Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting.” Gut (2019). PMID: 31879281 ↗
L5REVIEW_NARRATIVECited in: Liver Transplantation & MELD-Based Candidacy
[472]
Bajaj JS, Sikaroodi M, Shamsaddini A et al.. “Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.” Gut (2020). PMID: 32998876 ↗
L4OTHERCited in: Liver Transplantation & MELD-Based Candidacy
[473]
Piano S, Singh V, Caraceni P et al.. “Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide.” Gastroenterology (2018). PMID: 30552895 ↗
L2OTHERCited in: Liver Transplantation & MELD-Based Candidacy
[474]
Thursz M, Morgan TR. “Treatment of Severe Alcoholic Hepatitis.” Gastroenterology (2016). PMID: 26948886 ↗
L5REVIEW_NARRATIVECited in: Liver Transplantation & MELD-Based Candidacy
[475]
Crespo G, Mariño Z, Navasa M et al.. “Viral hepatitis in liver transplantation.” Gastroenterology (2012). PMID: 22537446 ↗
L5REVIEW_NARRATIVECited in: Liver Transplantation & MELD-Based Candidacy
[476]
Acharya C, Bajaj JS. “Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease.” Gastroenterology (2020). PMID: 33253686 ↗
L5REVIEW_NARRATIVECited in: Liver Transplantation & MELD-Based Candidacy
[477]
Elsaid MI, Li N, Firkins SA et al.. “Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes.” Alimentary pharmacology & therapeutics (2024). PMID: 38538967 ↗
L2OTHERCited in: Liver Transplantation & MELD-Based Candidacy
[478]
Ramirez-Cadiz C, Blaney H, Kubanek N et al.. “Review article: Current indications and selection criteria for early liver transplantation in severe alcohol-associated hepatitis.” Alimentary pharmacology & therapeutics (2024). PMID: 38475893 ↗
L5REVIEW_NARRATIVECited in: Liver Transplantation & MELD-Based Candidacy
[479]
Sinclair M, Gow PJ, Grossmann M et al.. “Review article: sarcopenia in cirrhosis--aetiology, implications and potential therapeutic interventions.” Alimentary pharmacology & therapeutics (2016). PMID: 26847265 ↗
L5REVIEW_NARRATIVECited in: Liver Transplantation & MELD-Based Candidacy
[480]
Kuo CC, Chuang MH, Li CH et al.. “Glucagon-Like Peptide-1 Receptor Agonists and Liver Outcomes in Patients With MASLD and Type 2 Diabetes.” Alimentary pharmacology & therapeutics (2025). PMID: 39791391 ↗
L2OTHERCited in: Liver Transplantation & MELD-Based Candidacy
[481]
Shen TD, Pyrsopoulos N, Rustgi VK. “Microbiota and the liver.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2018). PMID: 29316191 ↗
L5REVIEW_NARRATIVECited in: Liver Transplantation & MELD-Based Candidacy
[482]
Malleeswaran S, Sivajothi S, Reddy MS. “Viscoelastic Monitoring in Liver Transplantation.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2021). PMID: 34724319 ↗
L5REVIEW_NARRATIVECited in: Liver Transplantation & MELD-Based Candidacy
[483]
Blair JE. “Coccidioidomycosis in liver transplantation.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2006). PMID: 16382459 ↗
L5REVIEW_NARRATIVECited in: Liver Transplantation & MELD-Based Candidacy
[484]
Acidi B, Lim C, Hobeika C et al.. “AFP Model Predicts Outcomes After Liver Resection: A Multicenter Retrospective Cohort Study.” Annals of surgical oncology (2026). PMID: 42223775 ↗
L2COHORTCited in: Liver Transplantation & MELD-Based Candidacy
[485]
Bernal W, Bittermann T, Sheth R et al.. “Survival With and Without Liver Transplantation in Critically Ill Patients With Cirrhosis: A 20-Year Experience.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025). PMID: 40473089 ↗
L2OTHERCited in: Liver Transplantation & MELD-Based Candidacy
[486]
Ramia JM, Franco M, Alcázar C et al.. “Adrenal metastasis of hepatocellular carcinoma after liver transplantation: Case report and systematic review of literature.” World journal of transplantation (2026). PMID: 42281860 ↗
L4SR_OBSCited in: Liver Transplantation & MELD-Based Candidacy
[487]
Suo Y, Xu L, Zhao X et al.. “Occlusion of Paraspinal Vein Shunt Alleviated Post-TIPS Hepatic Myelopathy in a Patient with Cirrhosis.” Journal of clinical and translational hepatology (2026). PMID: 42273385 ↗
L4CASE_REPORTCited in: Liver Transplantation & MELD-Based Candidacy
[488]
Jamme P, Allgeier J, Koliogiannis D et al.. “Peak-MELD scores, a disease trajectory associated with reduced access to liver transplantation.” Frontiers in medicine (2026). PMID: 42433996 ↗
L2OTHERCited in: Liver Transplantation & MELD-Based Candidacy
[489]
Zeng RW, Yong JN, Tan DJH et al.. “Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin.” Alimentary pharmacology & therapeutics (2023). PMID: 36625733 ↗
L2SR_OBSCited in: Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prevention, Screening & Surveillance
[490]
Tang NSY, Gunalan S, Ong CEY et al.. “Meta-Analysis: Utilisation of Hepatocellular Carcinoma Surveillance.” Alimentary pharmacology & therapeutics (2025). PMID: 41077883 ↗
L2SR_OBSCited in: Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prognosis & Natural History, Prevention, Screening & Surveillance
[491]
Wang CC, Cheng PN, Kao JH. “Systematic review: chronic viral hepatitis and metabolic derangement.” Alimentary pharmacology & therapeutics (2019). PMID: 31746482 ↗
L2SR_OBSCited in: Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae)
[492]
Younossi Z, Tacke F, Arrese M et al.. “Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.” Hepatology (Baltimore, Md.) (2019). PMID: 30179269 ↗
L5REVIEW_NARRATIVECited in: Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prevention, Screening & Surveillance
[493]
Gu L, Zhu Y, Lin X et al.. “The IKKβ-USP30-ACLY Axis Controls Lipogenesis and Tumorigenesis.” Hepatology (Baltimore, Md.) (2020). PMID: 32221968 ↗
L5OTHERCited in: Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prevention, Screening & Surveillance
[494]
Allen KJ, Gurrin LC, Constantine CC et al.. “Iron-overload-related disease in HFE hereditary hemochromatosis.” The New England journal of medicine (2008). PMID: 18199861 ↗
L2OTHERCited in: Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae), Prevention, Screening & Surveillance
[495]
Jiménez-Zarazúa O, Tolentino-Pérez BI, Vélez-Ramírez LN et al.. “Prognostic value of C-reactive protein to albumin ratio (CAR) for mortality in older adults with sepsis: cohort study.” Clinical medicine (London, England) (2026). PMID: 42409282 ↗
L2COHORTCited in: Complications (Non-Portal-Hypertensive & Multi-Organ Sequelae)
[496]
Tandon P, Montano-Loza AJ, Lai JC et al.. “Sarcopenia and frailty in decompensated cirrhosis.” Journal of hepatology (2021). PMID: 34039486 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History
[497]
Rinella ME, Tacke F, Sanyal AJ et al.. “Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD.” Hepatology (Baltimore, Md.) (2019). PMID: 31287572 ↗
L5TRIAL_NONRANDOMCited in: Special Populations & Pregnancy
[498]
Jonas MM, Rhee S, Kelly DA et al.. “Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study.” Hepatology (Baltimore, Md.) (2021). PMID: 33811356 ↗
L4TRIAL_NONRANDOMCited in: Special Populations & Pregnancy
[499]
Rinella ME, Tacke F, Sanyal AJ et al.. “Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD.” Journal of hepatology (2019). PMID: 31300231 ↗
L5TRIAL_NONRANDOMCited in: Special Populations & Pregnancy
[500]
Borgia SM, Dearden J, Yoshida EM et al.. “Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.” Journal of hepatology (2019). PMID: 31195062 ↗
L4TRIAL_NONRANDOMCited in: Special Populations & Pregnancy
[501]
Gane EJ, Deray G, Liaw YF et al.. “Telbivudine improves renal function in patients with chronic hepatitis B.” Gastroenterology (2013). PMID: 24067879 ↗
L2RCTCited in: Special Populations & Pregnancy
[502]
Schwimmer JB, Thai NQN, Noon SL et al.. “Long-term mortality and extrahepatic outcomes in 1096 children with MASLD: A retrospective cohort study.” Hepatology (Baltimore, Md.) (2025). PMID: 40262118 ↗
L2COHORTCited in: Special Populations & Pregnancy
[503]
Ribrag V, Koscielny S, Bosq J et al.. “Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.” Lancet (London, England) (2016). PMID: 27080498 ↗
L1RCTCited in: Special Populations & Pregnancy
[504]
Pockros PJ, Reddy KR, Mantry PS et al.. “Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.” Gastroenterology (2016). PMID: 26976799 ↗
L4TRIAL_NONRANDOMCited in: Special Populations & Pregnancy
[505]
Gane E, Lawitz E, Pugatch D et al.. “Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.” The New England journal of medicine (2017). PMID: 29020583 ↗
L4TRIAL_NONRANDOMCited in: Special Populations & Pregnancy
[506]
Qureshi W, Hoang S, Frye J et al.. “AGA Clinical Practice Update on Diagnosis and Treatment of Hemorrhoids: Expert Review.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026). PMID: 42067175 ↗
L1GUIDELINECited in: Special Populations & Pregnancy
[507]
Søgaard KK, Horváth-Puhó E, Grønbaek H et al.. “Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study.” The American journal of gastroenterology (2009). PMID: 19098856 ↗
L3CASE_CONTROLCited in: Special Populations & Pregnancy
[508]
Aamann L, Dam G, Borre M et al.. “Resistance Training Increases Muscle Strength and Muscle Size in Patients With Liver Cirrhosis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2019). PMID: 31394282 ↗
L1RCTCited in: Special Populations & Pregnancy
[509]
Tapper EB, Martinez B, Jepsen P et al.. “Bisphosphonate effectiveness in patients with cirrhosis: An emulated clinical trial.” Alimentary pharmacology & therapeutics (2024). PMID: 38922994 ↗
L2TRIAL_NONRANDOMCited in: Special Populations & Pregnancy
[510]
Stättermayer AF, Halilbasic E, Wrba F et al.. “Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults.” Journal of hepatology (2020). PMID: 32376413 ↗
L5CASE_REPORTCited in: Special Populations & Pregnancy
[511]
Chen J, Eslick GD, Weltman M. “Systematic review with meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly.” Alimentary pharmacology & therapeutics (2013). PMID: 24261965 ↗
L1SR_OBSCited in: Special Populations & Pregnancy
[512]
Ji F, Wei B, Yeo YH et al.. “Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.” Alimentary pharmacology & therapeutics (2018). PMID: 29327780 ↗
L1SR_OBSCited in: Special Populations & Pregnancy
[513]
Lim WH, Tan C, Xiao J et al.. “De novo metabolic syndrome after liver transplantation: a meta-analysis on cumulative incidence, risk factors, and outcomes.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2023). PMID: 36724882 ↗
L1SR_OBSCited in: Special Populations & Pregnancy
[514]
Hagström H, Höijer J, Andreasson A et al.. “Body mass index in early pregnancy and future risk of severe liver disease: a population-based cohort study.” Alimentary pharmacology & therapeutics (2019). PMID: 30714185 ↗
L2COHORTCited in: Special Populations & Pregnancy
[515]
Aggarwal R, Jameel S. “Hepatitis E.” Hepatology (Baltimore, Md.) (2011). PMID: 21932388 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
[516]
Brunt EM, Kleiner DE, Carpenter DH et al.. “NAFLD: Reporting Histologic Findings in Clinical Practice.” Hepatology (Baltimore, Md.) (2021). PMID: 33111374 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
[517]
Albillos A, Krag A. “Beta-blockers in the era of precision medicine in patients with cirrhosis.” Journal of hepatology (2022). PMID: 36529293 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
[518]
Rimassa L, Personeni N, Czauderna C et al.. “Systemic treatment of HCC in special populations.” Journal of hepatology (2020). PMID: 33248171 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
[519]
Beuers U, Trauner M, Jansen P et al.. “New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond.” Journal of hepatology (2015). PMID: 25920087 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
[520]
Chang ML, Liaw YF. “Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management.” Journal of hepatology (2014). PMID: 25178562 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
[521]
Sharma R, Simon TG, Stephansson O et al.. “Pregnancy Outcomes in Women With Autoimmune Hepatitis - A Nationwide Population-based Cohort Study With Histopathology.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2021). PMID: 34954339 ↗
L2COHORTCited in: Special Populations & Pregnancy
[522]
Jutras G, Fenton C, Flemming JA et al.. “Epidemiologic Trends in Acute, Chronic, and Pregnancy-Specific Liver Diseases in Pregnancy.” The American journal of gastroenterology (2025). PMID: 40737002 ↗
L4OTHERCited in: Special Populations & Pregnancy
[523]
Huang AC, Grab J, Flemming JA et al.. “Pregnancies With Cirrhosis Are Rising and Associated With Adverse Maternal and Perinatal Outcomes.” The American journal of gastroenterology (2022). PMID: 34928866 ↗
L2OTHERCited in: Special Populations & Pregnancy
[524]
Tripathi PR, Sen Sarma M, Yachha SK et al.. “Relative Adrenal Insufficiency in Decompensated Cirrhotic Children: Does It Affect Outcome?” The American journal of gastroenterology (2022). PMID: 34506335 ↗
L2OTHERCited in: Special Populations & Pregnancy
[525]
Wright TL. “Introduction to chronic hepatitis B infection.” The American journal of gastroenterology (2006). PMID: 16448446 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
[526]
Kushner T, Sarkar M, Tran T. “Noninvasive Tests for Prognosticating Outcomes in Patients With Chronic Liver Disease in Pregnancy: Ready for Prime Time?” The American journal of gastroenterology (2019). PMID: 30730857 ↗
L5OTHERCited in: Special Populations & Pregnancy
[527]
Koff RS. “Editorial: Direct Antiviral Agents Eliminate the Age Barrier to Treatment of Chronic Hepatitis C.” The American journal of gastroenterology (2017). PMID: 28874853 ↗
L5OTHERCited in: Special Populations & Pregnancy
[528]
Lee JD, Gounko D, Lee JA et al.. “Assisted Reproductive Technology Treatment Outcomes in Women With Liver Disease.” The American journal of gastroenterology (2023). PMID: 36940434 ↗
L2OTHERCited in: Special Populations & Pregnancy
[529]
Mirici-Cappa F, Gramenzi A, Santi V et al.. “Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience.” Gut (2010). PMID: 20207642 ↗
L2OTHERCited in: Special Populations & Pregnancy
[530]
Yeh MM, Brunt EM. “Pathological features of fatty liver disease.” Gastroenterology (2014). PMID: 25109884 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
[531]
Goulet O, Ruemmele F. “Causes and management of intestinal failure in children.” Gastroenterology (2006). PMID: 16473066 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
[532]
Leonis MA, Balistreri WF. “Evaluation and management of end-stage liver disease in children.” Gastroenterology (2008). PMID: 18471551 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
[533]
Flemming JA, Mullin M, Lu J et al.. “Outcomes of Pregnant Women With Cirrhosis and Their Infants in a Population-Based Study.” Gastroenterology (2020). PMID: 32781083 ↗
L2OTHERCited in: Special Populations & Pregnancy
[534]
Bot KKIM, Heus R, Drenth JPH et al.. “Low-Dose vs. Standard Care Iv Human Albumin During Large-Volume Paracentesis in Patients With Liver Cirrhosis: A Systematic Review.” Liver international : official journal of the International Association for the Study of the Liver (2026). PMID: 41889150 ↗
L2SR_OBSCited in: Special Populations & Pregnancy
[535]
Smolders EJ, Burger DM, Feld JJ et al.. “Review article: clinical pharmacology of current and investigational hepatitis B virus therapies.” Alimentary pharmacology & therapeutics (2019). PMID: 31840863 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
[536]
Lampertico P, Chan HL, Janssen HL et al.. “Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients.” Alimentary pharmacology & therapeutics (2016). PMID: 27198929 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
[537]
Ritchie J, Seidman D, Srisengfa Y et al.. “Family Planning in Liver Transplant: Patient and Provider Knowledge and Practices.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2020). PMID: 32583555 ↗
L4OTHERCited in: Special Populations & Pregnancy
[538]
Junge N, Junge C, Schröder J et al.. “Pediatric cirrhotic cardiomyopathy: Impact on liver transplant outcomes.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2018). PMID: 29637720 ↗
L2OTHERCited in: Special Populations & Pregnancy
[539]
Hübscher S. “What does the long-term liver allograft look like for the pediatric recipient?” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2009). PMID: 19877293 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
[540]
Yan L, Wubuliaishan M, Kou X et al.. “Efficacy and Safety of 12-Week Coblopasvir/Sofosbuvir Regimen for Hepatitis C in Northwest China: A Multi-Center Prospective Study.” Journal of medical virology (2026). PMID: 42159424 ↗
L2COHORTCited in: Special Populations & Pregnancy
[541]
Griffin C, Agbim U, Ramani A et al.. “Underestimation of Cirrhosis-Related Mortality in the Medicare Eligible Population, 1999-2018.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2021). PMID: 34728405 ↗
L2OTHERCited in: Special Populations & Pregnancy
[542]
Zheng J, Zhou Z, Huang J et al.. “Sugar Rationing in the First 1000 Days After Conception and Long-term Risk of Metabolic Dysfunction-associated Steatotic Liver Disease and Major Adverse Liver Outcomes: A Natural Experiment Study.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025). PMID: 41284512 ↗
L2OTHERCited in: Special Populations & Pregnancy
[543]
Sarkar M, Djerboua M, Flemming JA. “NAFLD Cirrhosis Is Rising Among Childbearing Women and Is the Most Common Cause of Cirrhosis in Pregnancy.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2021). PMID: 33465483 ↗
L4OTHERCited in: Special Populations & Pregnancy
[544]
Yang L, Qiao Y, Zhao M et al.. “Resolving Metabolic Dysfunction-Associated Steatotic Liver Disease Reduces Subclinical Cardiovascular Damage in Chinese Youths.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025). PMID: 40058748 ↗
L2OTHERCited in: Special Populations & Pregnancy
[545]
He C, Liu P, Liu X et al.. “Changing etiological spectrum of cirrhosis in China: a systematic review and meta-analysis.” BMC gastroenterology (2026). PMID: 42286454 ↗
L2SR_OBSCited in: Special Populations & Pregnancy
[546]
Baboi ID, Nedelcu M, Bălăceanu LA et al.. “Impact of Ascites on Morbidity and Length of Hospital Stay: A Large Retrospective Study from a Tertiary Referral Center.” Medicina (Kaunas, Lithuania) (2026). PMID: 42075622 ↗
L2COHORTCited in: Special Populations & Pregnancy
[547]
Boulos M, Majdoub L, Basheer M et al.. “Renal Impairment as an Independent Predictor of Sepsis in Cirrhosis: A Retrospective Cohort Study.” Microorganisms (2026). PMID: 42075180 ↗
L2COHORTCited in: Special Populations & Pregnancy
[548]
Su R, Tao X, Yan L et al.. “Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in patients with chronic hepatitis B based on serum N-glycomics analysis: A cohort study.” Hepatology (Baltimore, Md.) (2025). PMID: 40117651 ↗
L2COHORTCited in: Prevention, Screening & Surveillance
[549]
Singal AG, Manjunath H, Yopp AC et al.. “The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis.” The American journal of gastroenterology (2014). PMID: 24445574 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance
[550]
Sulkowski M, Hezode C, Gerstoft J et al.. “Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.” Lancet (London, England) (2014). PMID: 25467560 ↗
L1RCTCited in: Prevention, Screening & Surveillance
[551]
Feng Z, Marrero JA, Khaderi S et al.. “Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study.” The American journal of gastroenterology (2019). PMID: 30699099 ↗
L2COHORTCited in: Prevention, Screening & Surveillance
[552]
Burton R, Leggio L, Louvet A et al.. “Prevention of Alcohol-Associated Liver Disease.” The American journal of gastroenterology (2025). PMID: 40135753 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[553]
Ghany MG, Saraswat VA. “Patients With Compensated Hepatitis B Virus-Related Cirrhosis and Low-Level Viremia: Treat or Not to Treat?” The American journal of gastroenterology (2023). PMID: 36940387 ↗
L5OTHERCited in: Prevention, Screening & Surveillance
[554]
Tapper EB, Parikh ND. “The Future of Quality Improvement for Cirrhosis.” Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2021). PMID: 33887806 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance

Quick Reference

Overview and Recommendations

Background

Evaluation

Management

Board Review — High Yield

Deep Dive — Evidence Details

Definition, Classification & Nomenclature

Synonyms

Staging and Clinical Phases

Etiologic Classification

Histologic Classification

Clinical Significance

Pathophysiology & Mechanism

Epidemiology, Etiology & Risk Factors

Etiologic Drivers

Risk Factors

Temporal Trends

Clinical Presentation

Silent Progression: Compensated Phase

The Transition to Decompensation

Acute-on-Chronic Liver Failure (ACLF)

Etiology-Specific Patterns

Urgent Presentations

Diagnosis & Workup

Non-invasive Liver Stiffness Measurement and Serum Biomarkers

Etiologic Workup

Liver Biopsy

Imaging for HCC Surveillance and Portal Hypertension

Diagnostic Algorithm

Severity, Staging & Risk Stratification

Child-Turcotte-Pugh (CTP) Score

MELD and MELD-Na

Beyond Conventional Scores

Staging Progression and Recompensation

Table: Prognostic Scores at a Glance

Acute Management & Decompensation Events

Variceal Hemorrhage

Spontaneous Bacterial Peritonitis (SBP)

Hepatic Encephalopathy (HE)

Hepatorenal Syndrome -AKI (HRS-AKI)

Controversies and Guideline Disagreement

Long-term & Definitive Management

Etiology-Directed Therapy

Disease Reversal and Recompensation

Surveillance and Preventive Care

Nutritional and Lifestyle Management

Liver Transplantation

Portal Hypertension & Decompensation Management

Step 1: Baseline Risk Stratification and Hemodynamic Modification

Step 2: Primary Prophylaxis of Variceal Bleeding

Step 3: Management of Ascites and Volume Overload

Step 4: Chronic Hepatic Encephalopathy Prophylaxis

Step 5: Prevention and Management of Hepatorenal Syndrome -Acute Kidney Injury

Step 6: Recompensation as a Therapeutic Goal

Controversies and Guideline Disagreement

History and Evolution of Treatment

The Era of Complication Control (1990s-2000s)

The Revolution of Etiologic Therapy (2000s-2020s)

Decompensation Prevention and Reversal (2010s-present)

Antifibrotic and Emerging Approaches

Controversies and Guideline Disagreement

Liver Transplantation & MELD-Based Candidacy

Indications for Liver Transplantation

MELD Score and Organ Allocation

Candidate Evaluation

Waitlist Management and Bridging

Post‑Transplant Outcomes

Controversies and Guideline Disagreement

Pearl

Non-Portal-Hypertensive Complications and Multi-Organ Sequelae

Hepatocellular Carcinoma

Cardiopulmonary Complications

Coagulopathy

Sarcopenia, Frailty, and Malnutrition

Immune Dysfunction and Infection

Metabolic and Bone Disease

Supportive Care in Hospitalized Patients

Prognosis & Natural History

Imaging for HCC Surveillance and Portal

MELD and

(SBP)

(HE)

-AKI (HRS-AKI)

Step 4: Chronic Prophylaxis

Step 5: Prevention and Management of -Acute Kidney Injury